Primed Uterine-Derived Regenerative Cell Compositions and Uses Thereof

Cell compositions derived from uterine tissue effectively treat inflammatory diseases in pets by reducing inflammation and improving disease symptoms, addressing the lack of effective non-invasive treatments.

JP2024543032APending Publication Date: 2024-11-19GALLANT PET INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024526559
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-04
Filing Date
2022-10-27
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current treatments for inflammatory and degenerative diseases in pets, such as chronic kidney disease and atopic dermatitis, are limited to symptomatic or invasive options, lacking effective and non-invasive alternatives.

Method used

Development of cell compositions derived from canine or feline uterine tissue, comprising mesenchymal and epithelial progenitor cells, co-cultured and primed with IFN-gamma, which are administered to treat conditions like chronic kidney disease, atopic dermatitis, and other inflammatory diseases.

Benefits of technology

The cell compositions demonstrate therapeutic efficacy by reducing pro-inflammatory environments and improving conditions in pets, as shown by clinical trials demonstrating improved GFR in cats with chronic kidney disease and reduced dermatitis scores in dogs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543032000001_ABST
    Figure 2024543032000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to heterogeneous cell compositions and / or primed heterogeneous cell compositions derived from dog or cat uterine tissue, as well as methods for producing and using the same. In some embodiments, the heterogeneous cell compositions are primed with IFN-gamma. In some embodiments, the heterogeneous cell compositions include a mixture of mesenchymal and epithelial progenitor cells. In some embodiments, the heterogeneous cell compositions are used as autologous or allogeneic therapeutic agents to treat diseases such as chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in dogs and cats.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Application No. 63 / 263550, filed November 4, 2021, and U.S. Provisional Application No. 63 / 263548, filed November 4, 2021.

[0002] The present disclosure relates to cell compositions derived from canine or feline uterine tissue, including primed cell compositions, as well as methods of producing and clinical use thereof. In some embodiments, the cell compositions derived from canine or feline uterine tissue are primed with IFN-gamma. In some embodiments, the heterogeneous cell compositions and / or primed heterogeneous cell compositions include a mixture of mesenchymal and epithelial progenitor cells. In further embodiments, cell compositions such as the heterogeneous cell compositions and / or primed heterogeneous cell compositions described above are used in autologous or allogeneic therapy for the treatment, inhibition, or amelioration of diseases in dogs and cats, including chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, wounds, or chronic gingivostomatitis. [Background technology]

[0003] Inflammation and age-related degenerative diseases can cause significant pain or discomfort to aging animals. If pet owners choose to pursue therapeutic or palliative interventions, this leads to emotional and potential financial burdens for the pet owners. However, for many degenerative diseases, only symptomatic treatment or overly invasive procedures are available. For example, chronic kidney disease (CKD) is the leading cause of death in domestic cats, but there is currently no effective treatment to restore the function of failing kidneys in these animals, except for costly kidney transplants. As another example, atopic dermatitis is one of the most common skin diseases affecting dogs, resulting in persistent itching. Thus, there is a persistent need for effective, inexpensive, and non-invasive treatments for CKD, atopic dermatitis, and other inflammatory and / or degenerative diseases in pets, such as dogs and cats, and other animals. Summary of the Invention

[0004] Disclosed herein, in some embodiments, are cell compositions and primed cell compositions. In some embodiments, these cell compositions and / or primed cell compositions comprise a mesenchymal progenitor cell population. In some embodiments, these cell compositions and / or primed cell compositions are heterogeneous and further comprise an epithelial progenitor cell population. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are obtained or derived from uterine tissue. In some embodiments, the uterine tissue is canine or feline uterine tissue. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are 1% vs. 99%, 2% vs. 98%, 3% vs. 97%, 4% vs. 96%, 5% vs. 95%, 10% vs. 90%, 20% vs. 80%, 30% vs. 70%, 40% vs. 60%, 50% vs. 50%, 60% vs. 40%, 70% vs. 30%, 80% vs. 20%, 90% vs. 10%, 95% vs. 5%, 96% vs. 4%, 97% vs. 3%, 98% vs. 2%, or 99% vs. 1%, or about 1% vs. 99%, about 2% vs. 98%, about 3% vs. 97%, or about 4% vs. 4%. %, about 4% to about 96%, about 5% to about 95%, about 10% to about 90%, about 20% to about 80%, about 30% to about 70%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 70% to about 30%, about 80% to about 20%, about 90% to about 10%, about 95% to about 5%, about 96% to about 4%, about 97% to about 3%, about 98% to about 2%, or about 99% to about 1%, or any ratio within a range defined by any two of the aforesaid percentages. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells in the composition are present in a ratio of 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or any ratio within a range defined by any two of the foregoing percentages.

[0005] In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with at least one biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, or hyaluronic acid, or any combination thereof. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured in at least one tissue culture vessel that has been pretreated with at least one biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, such as a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, or hyaluronic acid, or any combination thereof.

[0006] In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured in at least one tissue culture vessel for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 passages, days, or culture intervals, or for a range defined by any two of the foregoing passages, days, or culture intervals. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured in at least one tissue culture vessel for at least 4 passages, days, or culture intervals.

[0007] In some embodiments, the cell composition and / or primed cell composition (preferably a heterogeneous cell composition) is 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, 100 million, 20-30 million, 30-40 million, 40-50 million, 50-60 million, 60-70 million, 70-80 million, 80-90 million, or 90-100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about The present invention relates to a method for producing a cell-derived mesenchymal progenitor cell, comprising the steps of: 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 31 million cells, about 32 million cells, about 33 million cells, about 34 million cells, about 35 million cells, about 36 million cells, about 37 million cells, about 38 million cells, about 39 million cells, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, about 100 million, about 20-30 million, about 30-40 million, about 40-50 million, about 50-60 million, about 60-70 million, about 70-80 million, about 80-90 million, or about 90-100 million mesenchymal progenitor cells, or any number of mesenchymal progenitor cells within a range defined by any two of the aforesaid numbers.

[0008] In some embodiments, the cell composition and / or primed cell composition (preferably a heterogeneous cell composition) comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, 100 million, 20-30 million, 30-40 million, 40-50 million, 50-60 million, 60-70 million, 70-80 million, 80-90 million, or 90-100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 21 million, about 22 million, about 23 million, about 24 million, about 25 million, about 26 million, about 27 million, about 28 million, about 29 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 50 million, about 50 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, about 10 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, about 100 million, about 20-30 million, about 30-40 million, about 40-50 million, about 50-60 million, about 60-70 million, about 70-80 million, about 80-90 million, or about 90-100 million epithelial progenitor cells, or any number of epithelial progenitor cells within a range defined by any two of the aforesaid numbers.

[0009] In some embodiments, the cell compositions and / or primed cell compositions (preferably heterogeneous cell compositions) comprise a cell population that exhibits markers or characteristics of both mesenchymal and epithelial progenitor cells. In some embodiments, the cell compositions and / or primed cell compositions, preferably heterogeneous cell compositions, comprise a cell population, each cell of which exhibits markers or characteristics of both mesenchymal and epithelial progenitor cells.

[0010] In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are obtained from or derived from the same uterine tissue. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are obtained from or derived from the same canine or feline uterine tissue. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are obtained from or derived from different uterine tissues (e.g., from different felines or canines) or derived from different uterine tissues.

[0011] In some embodiments, the cell compositions and / or primed cell compositions (preferably heterogeneous cell compositions) comprise a vimentin positive (V+) / cytokeratin negative (C-) cell population. In some embodiments, these cell compositions and / or primed cell compositions (preferably heterogeneous cell compositions) further comprise a V+ / cytokeratin positive (C+) cell population. In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured. In some embodiments, the V+ / C- cells and the V+ / C+ cells are obtained or derived from uterine tissue. In some embodiments, the uterine tissue is canine or feline uterine tissue. In some embodiments, the V+ / C- cells and V+ / C+ cells are 1% to 99%, 2% to 98%, 3% to 97%, 4% to 96%, 5% to 95%, 10% to 90%, 20% to 80%, 30% to 70%, 40% to 60%, 50% to 50%, 60% to 40%, 70% to 30%, 80% to 20%, 90% to 10%, 95% to 5%, 96% to 4%, 97% to 3%, 98% to 2%, or 99% to 1%, or about 1% to about 99%, about 2% to about 98%, about 3% to about 97%, about It is present in the composition in a ratio of 4% to about 96%, about 5% to about 95%, about 10% to about 90%, about 20% to about 80%, about 30% to about 70%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 70% to about 30%, about 80% to about 20%, about 90% to about 10%, about 95% to about 5%, about 96% to about 4%, about 97% to about 3%, about 98% to about 2%, or about 99% to about 1%, or any ratio within a range defined by any two of the foregoing percentages. In some embodiments, the V+ / C- cells and V+ / C+ cells are present in the composition in a ratio of 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or any ratio within a range defined by any two of the foregoing percentages.

[0012] In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with at least one biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, or hyaluronic acid, or any combination thereof. In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel that has been pretreated with at least one biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, such as a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, or hyaluronic acid, or any combination thereof.

[0013] In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel for 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 passages, days, or culture intervals, or for a range defined by any two of the aforementioned passages, days, or culture intervals. In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel for at least 4 passages, days, or culture intervals.

[0014] In some embodiments, the cell composition and / or primed cell composition (preferably a heterogeneous cell composition) comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, 100 million, 20-30 million, 30-40 million, 40-50 million, 50-60 million, 60-70 million, 70-80 million, 80-90 million, or 90-100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 21 million, about 22 million, about 23 million, about 24 million, about 25 million, about 26 million, about 27 million, about 28 million, about 29 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 50 million, about 50 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, about 10 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, about 100 million, about 20-30 million, about 30-40 million, about 40-50 million, about 50-60 million, about 60-70 million, about 70-80 million, about 80-90 million, or about 90-100 million V+ / C- cells, or any number of V+ / C- cells within a range defined by any two of the aforesaid numbers.

[0015] In some embodiments, the cell composition and / or primed cell composition (preferably a heterogeneous cell composition) comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, 100 million, 20-30 million, 30-40 million, 40-50 million, 50-60 million, 60-70 million, 70-80 million, 80-90 million, or 90-100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 ... million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, about 100 million, about 20-30 million, about 30-40 million, about 40-50 million, about 50-60 million, about 60-70 million, about 70-80 million, about 80-90 million, or about 90-100 million V+ / C+ cells, or any number of V+ / C+ cells within a range defined by any two of the aforesaid numbers.

[0016] In some embodiments, the cell compositions and / or primed cell compositions (preferably heterogeneous cell compositions) include cell populations that exhibit markers or characteristics of both V+ / C- cells and V+ / C+ cells.

[0017] In some embodiments, the V+ / C- cells and the V+ / C+ cells are obtained from or derived from the same uterine tissue. In some embodiments, the V+ / C- cells and the V+ / C+ cells are obtained from or derived from the same canine or feline uterine tissue. In some embodiments, the V+ / C- cells and the V+ / C+ cells are obtained from or derived from different uterine tissues (e.g., from different felines or canines).

[0018] In some embodiments, the cell composition and / or the primed cell composition (preferably a heterogeneous cell composition) further comprises an amount of fibroblast growth factor (FGF). In some embodiments, the fibroblast growth factor is fibroblast growth factor 2 (FGF-2). In some embodiments, the FGF is recombinantly produced. In some embodiments, the FGF is human FGF. In some embodiments, the FGF is human FGF-2. In some embodiments, the FGF is recombinant human FGF-2. In some embodiments, the FGF, preferably human FGF-2, is present at a concentration of 0.01, 0.05, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 ng / mL, or at a concentration within a range defined by any two of the foregoing concentrations. In some embodiments, FGF is present at a concentration of 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ng / mL, or at a concentration within a range defined by any two of the foregoing concentrations, hi some embodiments, FGF is present at a concentration of 8 ng / mL.

[0019] In some embodiments, the uterine tissue is obtained by oophorectomy.

[0020] In some embodiments, the cell compositions and / or primed cell compositions (preferably heterogeneous cell compositions) further comprise at least one additive, including, but not limited to, trehalose, DMSO, or albumin, antibiotics, supplements, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, saccharides, polysaccharides, or carbohydrates, or any combination thereof.

[0021] In some embodiments, the cell composition and / or primed cell composition (preferably a heterogeneous cell composition) further comprises a cryopreservation medium, in some embodiments, the cryopreservation medium comprises CryoStor CS5, BioLife Solutions CS10, 98% Hespan and 2% DMSO, about 98% Hespan and about 2% DMSO, 2-10% DMSO and 2-20% FCS in growth medium, or about 2-10% DMSO and about 2-20% FCS in growth medium.

[0022] Disclosed herein in some embodiments are methods for preparing cell compositions and / or primed cell compositions, preferably heterogeneous cell compositions. Exemplary methods include contacting a single cell suspension or a heterogeneous cell suspension comprising mesenchymal and epithelial progenitor cells with FGF-2, and culturing the single cell suspension or the heterogeneous cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the single cell suspension or the heterogeneous cell suspension is cultured for at least 4 passages, days, or culture intervals. In some embodiments, the cells used to generate the single cell suspension or the heterogeneous cell suspension are obtained from or derived from uterine tissue. In some embodiments, the cells used to generate the single cell suspension or the heterogeneous cell suspension are obtained from or derived from canine or feline uterine tissue. In some embodiments, the cells used to generate the single cell suspension or the heterogeneous cell suspension are obtained or derived from the same canine or feline uterine tissue.

[0023] In some embodiments, at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the mesenchymal progenitor cells and epithelial progenitor cells are 1% vs. 99%, 2% vs. 98%, 3% vs. 97%, 4% vs. 96%, 5% vs. 95%, 10% vs. 90%, 20% vs. 80%, 30% vs. 70%, 40% vs. 60%, 50% vs. 50%, 60% vs. 40%, 70% vs. 30%, 80% vs. 20%, 90% vs. 10%, 95% vs. 5%, 96% vs. 4%, 97% vs. 3%, 98% vs. 2%, 99% vs. 1%, or about 1% vs. about 99%, about 2% about 98%, about 3% to about 97%, about 4% to about 96%, about 5% to about 95%, about 10% to about 90%, about 20% to about 80%, about 30% to about 70%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 70% to about 30%, about 80% to about 20%, about 90% to about 10%, about 95% to about 5%, about 96% to about 4%, about 97% to about 3%, about 98% to about 2%, or about 99% to about 1%, or in a ratio within a range defined by any two of the aforesaid percentages. In some embodiments, at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the mesenchymal progenitor cells and epithelial progenitor cells are present in a ratio of 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, or about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or in a ratio within a range defined by any two of the foregoing ratios.

[0024] Further embodiments relate to a method of preparing a cell composition and / or a primed cell composition, preferably a primed heterogeneous cell composition. In some embodiments, the method comprises contacting a single cell suspension comprising V+ / C- cells and V+ / C+ cells with FGF-2 and culturing the single cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the single cell suspension is cultured for at least 4 passages, days, or culture intervals. In some embodiments, the cells of the single cell suspension are obtained from or derived from uterine tissue. In some embodiments, the cells of the single cell suspension are obtained from or derived from canine or feline uterine tissue. In some embodiments, the cells of the single cell suspension are obtained from or derived from the same canine or feline uterine tissue. In some embodiments, the cells of the single cell suspension are obtained or derived from uterine tissue of different dogs or cats.

[0025] In some embodiments, at the end of 3, 4, 5, or 6 passages, days, or culture intervals, V+ / C- cells and V+ / C+ cells are 1% vs. 99%, 2% vs. 98%, 3% vs. 97%, 4% vs. 96%, 5% vs. 95%, 10% vs. 90%, 20% vs. 80%, 30% vs. 70%, 40% vs. 60%, 50% vs. 50%, 60% vs. 40%, 70% vs. 30%, 80% vs. 20%, 90% vs. 10%, 95% vs. 5%, 96% vs. 4%, 97% vs. 3%, 98% vs. 2%, or 99% vs. 1% or about 1% vs. about 99%. %, about 2% to about 98%, about 3% to about 97%, about 4% to about 96%, or about 5% to about 95%, about 10% to about 90%, about 20% to about 80%, about 30% to about 70%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 70% to about 30%, about 80% to about 20%, about 90% to about 10%, about 95% to about 5%, about 96% to about 4%, about 97% to about 3%, about 98% to about 2%, or about 99% to about 1%, or in a ratio within a range defined by any two of the aforesaid ratios. In some embodiments, at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the ratio of V+ / C- cells and V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, or 99% to 1%, or about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or any ratio within a range defined by any two of the foregoing ratios.

[0026] In some embodiments, the uterine tissue is enzymatically dissociated to form a single cell suspension. In some embodiments, the canine or feline uterine tissue is enzymatically dissociated to form a single cell suspension.

[0027] In some embodiments, FGF-2 is recombinantly produced. In some embodiments, FGF-2 is human FGF-2. In some embodiments, FGF-2 is recombinant human FGF-2. In some embodiments, FGF-2 is present at a concentration of 0.01, 0.05, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 ng / mL, or at any concentration within a range defined by any two of the aforementioned concentrations. In some embodiments, FGF-2 is present at a concentration of 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ng / mL, or at any concentration within a range defined by any two of the aforementioned concentrations. In some embodiments, FGF-2 is present at a concentration of 8 ng / mL.

[0028] In certain embodiments, interferon-γ (IFN-γ) is used to stimulate or enhance the immunomodulatory effects of the uterine-derived regenerative cells of the present invention. The uterine-derived regenerative cells of the present invention upregulate the activity of indoleamine-2,3-dioxygenase (IDO or IDO1) in response to IFN-γ.

[0029] In some embodiments, methods of treating, inhibiting, or ameliorating a disease or condition in a canine or feline subject are described herein. In some embodiments, the methods include providing at least one cell composition, preferably a heterogeneous cell composition comprising a mesenchymal progenitor cell population and an epithelial progenitor cell population, as described herein, and administering at least one cell composition, preferably a heterogeneous cell composition, to a canine or feline subject. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are obtained from or derived from canine or feline uterine tissue. In some embodiments, the canine or feline uterine tissue is autologous or allogeneic to the canine or feline subject. In some embodiments, the canine or feline uterine tissue is autologous to the canine or feline subject. In some embodiments, the canine or feline uterine tissue is allogeneic to the canine or feline subject. In some embodiments, the disease is chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-related polyarthritis, chronic gingivostomatitis or wounds. In some of these methods, the mesenchymal progenitor cells and epithelial progenitor cells are provided in the composition in a ratio of 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or in a ratio within a range defined by any two of the foregoing ratios.

[0030] Additional embodiments relate to methods of treating, inhibiting, or ameliorating a disease or condition in a canine or feline subject. Some of these methods include providing at least one cell composition and / or primed cell composition, preferably a heterogeneous cell composition comprising a V+ / C- cell population and a V+ / C+ cell population, and administering at least one heterogeneous cell composition to the canine or feline subject. In some embodiments, the V+ / C- and V+ / C+ cells are obtained from or derived from canine or feline uterine tissue. In some embodiments, the canine or feline uterine tissue is autologous or allogeneic to the canine or feline subject. In some embodiments, the disease is chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, or wound. In some of such methods, the V+ / C- cells and V+ / C+ cells are provided in the composition in a ratio of 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or in a ratio within a range defined by any two of the foregoing ratios.

[0031] In some embodiments, at least one cell composition and / or primed cell composition (preferably a heterogeneous cell composition) is administered to a feline or canine subject preferably identified or selected to receive progenitor cell therapy for chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds. Such selection or identification may be made by a clinician or veterinarian through clinical evaluation and / or diagnosis. The feline or canine subject preferably identified or selected is then given or administered one or more of the cell compositions provided herein enterally, parenterally, intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly, or intrarenally, or any combination thereof. In some embodiments, the at least one heterogeneous cell composition is administered after being thawed from a cryopreserved state. In some embodiments, the at least one heterogeneous cell composition is administered after being thawed from a cryopreserved state and transferred to a delivery device or container. In some embodiments, the delivery device or container is a syringe, an IV bag, a cannula, a pump, or a tube. In some embodiments, the delivery device or container comprises a suitable buffer, diluent, or fluid. In some embodiments, the suitable buffer, diluent, or fluid comprises saline, phosphate buffered saline, lactated Ringer's solution, acetated Ringer's solution, or dextrose solution. In some embodiments, thawing the at least one heterogeneous cell composition from a cryopreserved state comprises diluting the at least one heterogeneous cell composition to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x.Further embodiments relate to the use of any one or more of the cell compositions described herein as a pharmaceutical, preferably for the treatment, inhibition, or amelioration of chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, or wounds.

[0032] The embodiments provided herein preferably include the following numbered alternatives:

[0033] 1. A primed heterogeneous cell composition comprising: Mesenchymal progenitor cell populations, and Contains a population of epithelial progenitor cells, The mesenchymal progenitor cells and the epithelial progenitor cells are co-cultured, said mesenchymal precursor cells and said epithelial precursor cells are obtained or derived from canine or feline uterine tissue; the ratio of said mesenchymal progenitor cells to said epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to 20%, or a ratio within a range defined by any two of the foregoing percentages; The primed heterogeneous cell composition, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are primed with IFN-gamma.

[0034] 2. The composition of alternative 1, further comprising fibroblast growth factor 2 (FGF-2).

[0035] 3. The composition according to alternative 2, wherein said FGF-2 is recombinant human FGF-2.

[0036] 4. The composition according to alternative 2 or 3, wherein said FGF-2 is present at a concentration of 8 ng / mL.

[0037] 5. The composition of any of the preceding alternatives, wherein said mesenchymal progenitor cells and said epithelial progenitor cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

[0038] 6. The composition of any of the preceding alternatives, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals.

[0039] 7. The composition of any of the preceding alternatives, wherein said uterine tissue is obtained by oophorectomy.

[0040] 10. The composition of any of the preceding alternatives, comprising 8.5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million mesenchymal progenitor cells, or a number within a range defined by any two of the aforesaid numbers.

[0041] The composition of any of the preceding alternatives, comprising 9.5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million epithelial progenitor cells, or a number within a range defined by any two of the aforesaid numbers.

[0042] 10. The composition of any of the preceding alternatives, further comprising an additive, supplement, antibiotic, vitamin, growth factor, cryoprotectant, buffer, salt, protein, polypeptide, peptide, saccharide, polysaccharide, or carbohydrate, or any combination thereof, including but not limited to trehalose, DMSO, or albumin.

[0043] 11. The composition of any of the preceding alternatives, further comprising a population of cells, each cell exhibiting markers of both mesenchymal and epithelial progenitor cells.

[0044] 12. The composition of any of the preceding alternatives, wherein said mesenchymal precursor cells and said epithelial precursor cells are obtained or derived from the same canine or feline uterine tissue.

[0045] 13. The composition of any of the preceding alternatives, further comprising a cryopreservation medium.

[0046] 14. The cryopreservation medium comprises: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2–10% DMSO and 2–20% FCS in growth medium, or (e) The composition of alternative 13, comprising about 2-10% DMSO and about 2-20% FCS in growth medium.

[0047] 15. A method for preparing a heterogeneous cell composition, comprising: contacting a single cell suspension comprising mesenchymal progenitor cells and epithelial progenitor cells with FGF-2; culturing the single cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals; said single cell suspension being obtained from or derived from canine or feline uterine tissue; The method of preparing said method, wherein at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the ratio of said mesenchymal progenitor cells to said epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to 20%, or a ratio within a range defined by any two of the aforesaid percentages.

[0048] 16. The method of alternative 15, wherein the single cell suspension is obtained from or derived from uterine tissue of the same dog or cat.

[0049] 17. The method of alternative 15 or 16, wherein the canine or feline uterine tissue is enzymatically dissociated to form the single cell suspension.

[0050] 18. The method of any one of alternatives 15 to 17, wherein said FGF-2 is recombinant human FGF-2.

[0051] 19. The method of any one of alternatives 15-18, wherein the FGF-2 is at a concentration of 8 ng / mL.

[0052] 20. The method of any one of alternatives 15 to 19, wherein the single cell suspension is cultured for at least 4 passages, days, or culture intervals.

[0053] 21. A method for treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in a canine or feline subject in need thereof, comprising: providing at least one heterogeneous cell composition and / or primed heterogeneous cell composition comprising a population of mesenchymal progenitor cells and a population of epithelial progenitor cells, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are obtained or derived from canine or feline uterine tissue, the canine or feline uterine tissue being autologous or allogeneic to the canine or feline subject; administering to said canine or feline subject said at least one heterogeneous cell composition.

[0054] 22. The method of alternative 21, wherein the ratio of said mesenchymal progenitor cells to said epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, about 99% to about 1%, or a ratio within a range defined by any two of the aforesaid percentages.

[0055] 23. The method of any one of alternatives 15-22, wherein the at least one heterogeneous cell composition and / or primed heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

[0056] 24. A primed heterogeneous cell composition, comprising: Vimentin positive (V+) / cytokeratin negative (C-) cell population, and Contains the V+ / cytokeratin positive (C+) cell population, The V+ / C- cells and the V+ / C+ cells are co-cultured; the V+ / C- cells and the V+ / C+ cells are obtained from or derived from dog or cat uterine tissue; the ratio of V+ / C- cells and V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, or a ratio within a range defined by any two of the foregoing percentages;

[0057] The primed heterogeneous cell composition, wherein the V+ / C- cells and the V+ / C+ cells are primed with IFN-gamma. 25. The composition of alternative 24, further comprising fibroblast growth factor 2 (FGF-2).

[0058] 26. The composition according to alternative 25, wherein said FGF-2 is recombinant human FGF-2.

[0059] 27. The composition of alternative 25 or 26, wherein said FGF-2 is at a concentration of 8 ng / mL.

[0060] 28. The composition of any one of alternatives 24-26, wherein the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

[0061] 29. The composition of any one of alternatives 24 to 28, wherein the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals.

[0062] 30. The composition of any one of alternatives 24-29, wherein the uterine tissue is obtained by oophorectomy.

[0063] 31.5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million , about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C- cells, or any number of V+ / C- cells within a range defined by any two of the aforesaid numbers.

[0064] 32.5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million 32. The composition of any one of alternatives 24-31, comprising about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C+ cells, or any number of V+ / C+ cells within a range defined by any two of the aforesaid numbers.

[0065] 33. The composition of any one of alternatives 24-32, further comprising an additive, supplement, antibiotic, vitamin, growth factor, cryoprotectant, buffer, salt, protein, polypeptide, peptide, saccharide, polysaccharide, or carbohydrate, or any combination thereof, including but not limited to trehalose, DMSO, or albumin.

[0066] 34. The composition of any one of alternatives 24 to 33, wherein the V+ / C- cells and the V+ / C+ cells are obtained from or derived from the same canine or feline uterine tissue.

[0067] 35. The composition of any one of alternatives 24-34, further comprising a cryopreservation medium.

[0068] 36. The cryopreservation medium comprises: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2–10% DMSO and 2–20% FCS in growth medium, or (e) The composition of alternative 35, comprising about 2-10% DMSO and about 2-20% FCS in growth medium.

[0069] 37. A method for preparing a heterogeneous cell composition, comprising: contacting a single cell suspension comprising V+ / C- cells and V+ / C+ cells with FGF-2; culturing the single cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals; said single cell suspension being obtained from or derived from canine or feline uterine tissue; The method of preparation, wherein at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the ratio of V+ / C- cells to V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, or a ratio within a range defined by any two of the aforesaid percentages.

[0070] 38. The method of alternative 37, wherein the single cell suspension is obtained from or derived from uterine tissue of the same dog or cat.

[0071] 39. The method of alternative 37 or 38, wherein the dog or cat uterine tissue is enzymatically dissociated to form the single cell suspension.

[0072] 40. The method of any one of alternatives 37-39, wherein said FGF-2 is recombinant human FGF-2.

[0073] 41. The method of any one of alternatives 37 to 40, wherein the FGF-2 is at a concentration of 8 ng / mL.

[0074] 42. The method of any one of alternatives 37 to 41, wherein the single cell suspension is cultured for at least 4 passages, days, or culture intervals.

[0075] 43. A method for treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in a canine or feline subject in need thereof, comprising: providing at least one heterogeneous cell composition comprising a V+ / C- cell population and a V+ / C+ cell population, wherein the V+ / C- cells and the V+ / C+ cells are obtained from or derived from canine or feline uterine tissue, the canine or feline uterine tissue being autologous or allogeneic to the canine or feline subject; administering to said canine or feline subject said at least one heterogeneous cell composition; The method of treating, suppressing, or ameliorating, wherein the heterogeneous cell composition is primed with IFN-gamma.

[0076] 44. The method of alternative 43, wherein the ratio of V+ / C- cells and V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, about 99% to about 1%, or a ratio within a range defined by any two of the aforementioned percentages.

[0077] 45. A method for treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in a canine or feline subject in need thereof, comprising: Providing at least one heterogeneous cell composition according to any one of alternatives 1-14 or 24-36; administering to said canine or feline subject said at least one heterogeneous cell composition; The method of treating, suppressing, or ameliorating, wherein the heterogeneous cell composition is primed with IFN-gamma.

[0078] 46. ​​The method of any one of alternatives 37 to 45, wherein the at least one heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

[0079] 47. The method of any one of alternatives 37 to 46, wherein the at least one heterogeneous cell composition is administered after being thawed from frozen storage and transferred to a delivery device or container, such as a syringe, containing an appropriate buffer, diluent or fluid, such as phosphate buffered saline or lactated Ringer's solution.

[0080] 48. The composition according to any one of alternatives 1-14 or 24-36 for use in treating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

[0081] 49. A composition according to any one of alternative forms 1 to 14 or 24 to 36 for use as a medicament.

[0082] 50. A heterogeneous cell composition, comprising: (a) Vimentin-positive (V+) / cytokeratin-negative (C-) cell population; (b) Vimentin-negative (V-) / cytokeratin-positive (C+) cell population, and (c) comprising a V+ / C+ cell population; The populations (a) to (c) are co-cultured, The populations (a)-(c) are obtained from or derived from dog or cat uterine tissue; the V+ / C+ cell population is found in a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages; The heterogeneous cell composition is primed with IFN-gamma.

[0083] 51. The V+ / C- cell population is 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70% of the total number of cells in the heterogeneous cell composition. , 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or any percentage within a range defined by any two of the aforementioned percentages.

[0084] 52. The V- / C+ cell population is 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 108%, 109%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 52. The heterogeneous cell composition of alternative 50 or 51, wherein the heterogeneous cell composition is found in a percentage of 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, or any percentage within a range defined by any two of the aforesaid percentages.

[0085] 53. The heterogeneous cell composition of any one of alternatives 50-52, wherein the ratio of the V+ / C- cell population to the V- / C+ cell population is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, about 99% to about 1%, or a ratio within a range defined by any two of the aforementioned percentages.

[0086] 54. The heterogeneous cell composition of any one of alternatives 50-53, further comprising FGF-2.

[0087] 55. The heterogeneous cell composition of any one of alternatives 50 to 54, wherein said FGF-2 is recombinant human FGF-2.

[0088] 56. The heterogeneous cell composition of any one of alternatives 50 to 55, wherein the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL.

[0089] 57. The heterogeneous cell composition of any one of alternatives 50-56, wherein the populations (a)-(c) are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

[0090] 58. The heterogeneous cell composition of any one of alternatives 50-57, wherein the populations (a)-(c) are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals.

[0091] 59. The heterogeneous cell composition of any one of alternatives 50 to 58, wherein the uterine tissue is obtained by oophorectomy.

[0092] 60.5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 21 million, about 22 million, about 23 million, about 24 million, about 25 million, about 26 million, about 27 million, about 28 million, about 29 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 41 million, about 42 million, about 43 million, about 44 million, about 45 million, about 46 million, about 47 million, about 48 million, about 49 million, about 50 million, about 50 million, about 50 million, about 50 million, about 50 million, about 50 million, about 50 million, about 50 million, about 60 million, about 70 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 59. The heterogeneous cell composition of any one of alternatives 50-59, comprising about 4 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C- cells, or any number of V+ / C- cells within a range defined by any two of the aforesaid numbers.

[0093] 61.5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, or about 17 million. The heterogeneous cell composition of any one of alternatives 50-60, comprising about 4 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V- / C+ cells, or any number of V- / C+ cells within a range defined by any two of the aforesaid numbers.

[0094] 62.5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 21 million, about 22 million, about 23 million, about 24 million, about 25 million, about 26 million, about 27 million, about 28 million, about 29 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 41 million, about 42 million, about 43 million, about 44 million, about 45 million, about 46 million, about 47 million, about 48 million, about 49 million, about 50 ... 62. The heterogeneous cell composition of any one of alternatives 50-61, comprising about 4 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C+ cells, or any number of V+ / C+ cells within a range defined by any two of the aforesaid numbers.

[0095] 63. The heterogeneous cell composition of any one of alternatives 50 to 62, wherein the heterogeneous cell composition is further defined by a cell population that is positive for both CD44 and CD326.

[0096] 64. The population of cells that are positive for both CD44 and CD326 is 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32% of the total number of cells in the heterogeneous cell composition. , 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, or any percentage within a range defined by any two of the aforementioned percentages.

[0097] 65. The heterogeneous cell composition of any one of alternatives 50-64, further comprising an additive, supplement, antibiotic, vitamin, growth factor, cryoprotectant, buffer, salt, protein, polypeptide, peptide, saccharide, polysaccharide, or carbohydrate, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin.

[0098] 66. A heterogeneous cell composition described in any one of alternatives 50 to 65, wherein the populations (a) to (c) are obtained from or derived from the same canine or feline uterine tissue.

[0099] 67. The heterogeneous cell composition of any one of alternatives 50 to 66, further comprising a cryopreservation medium.

[0100] 68. The cryopreservation medium comprises: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2–10% DMSO and 2–20% FCS in growth medium, or (e) The heterogeneous cell composition of alternative 67, comprising about 2-10% DMSO and about 2-20% FCS in the growth medium.

[0101] 69. A method for preparing a heterogeneous cell composition, comprising: Dissociating dog or cat uterine tissue into a single cell suspension; Culturing the single cell suspension for 3, 4, 5, or 6 passages, days, or culture intervals, preparing the heterogeneous cell composition from the cultured single cell suspension; The method of the present invention, wherein at the end of the 3, 4, 5 or 6 passages, days or culture intervals, the heterogeneous cell composition comprises a cell population that is positive for both vimentin and cytokeratin-18.

[0102] 70. The cell population positive for both vimentin and cytokeratin-18 is 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, or less of the total number of cells in the heterogeneous cell composition. 69. The method of alternative 69, wherein the α-aminobutyric acid is present in a percentage of 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, or any percentage within a range defined by any two of the aforesaid percentages.

[0103] 71. The method of alternative 69 or 70, wherein the dissociation step comprises enzymatic dissociation.

[0104] 72. The method of alternative 71, wherein the enzymatic dissociation comprises contacting the canine or feline uterine tissue with trypsin, chymotrypsin, collagenase, papain, hyaluronidase, elastase, thermolysin, neutral protease, or any combination thereof.

[0105] 73. The method of any one of alternatives 69 to 72, wherein the single cell suspension is cultured with FGF-2.

[0106] 74. The method of alternative 73, wherein said FGF-2 is recombinant human FGF-2.

[0107] 75. The method of alternative 73 or 74, wherein the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL.

[0108] 76. The method of any one of alternatives 69 to 75, wherein the single cell suspension is cultured for at least 4 passages, days, or culture intervals.

[0109] 77. The method of any one of alternatives 69 to 76, wherein the heterogeneous cell composition is further defined by a cell population that is positive for both CD44 and CD326.

[0110] 78. The CD44 and CD326 positive cell population comprises 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, or less of the total number of cells in the heterogeneous cell composition. 78. The method of alternative 77, wherein the chromosome number is found in a percentage of 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, or any percentage within a range defined by any two of the aforementioned percentages.

[0111] 79. The method of any one of alternatives 69 to 78, wherein the heterogeneous cell composition is a heterogeneous cell composition described in any one of alternatives 50 to 68.

[0112] 80. A method for treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in a canine or feline subject in need thereof, comprising: administering to said canine or feline subject at least one heterogeneous cell composition; the at least one heterogeneous cell composition comprises a cell population that is positive for both vimentin and cytokeratin-18; The method of treating, suppressing, or ameliorating, wherein the heterogeneous cell composition is primed with IFN-gamma.

[0113] 81. The cell population positive for both vimentin and cytokeratin-18 is 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, or less of the total number of cells in the heterogeneous cell composition. 81. The method of alternative 80, wherein the α-amino acid is present in a percentage of 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, or any percentage within a range defined by any two of the aforesaid percentages.

[0114] 82. The method of alternative 80 or 81, wherein the heterogeneous cell composition is further defined by a cell population that is positive for both CD44 and CD326.

[0115] 83. The CD44 and CD326 positive cell population comprises 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, or less of the total number of cells in the heterogeneous cell composition. 83. The method of alternative 82, wherein the chromosome number is found in a percentage of 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, or any percentage within a range defined by any two of the aforesaid percentages.

[0116] 84. The method of any one of alternatives 80-83, wherein the heterogeneous cell composition is autologous or allogeneic to the canine or feline subject.

[0117] 85. The method according to any one of alternatives 80 to 84, wherein the at least one heterogeneous cell composition is a heterogeneous cell composition according to any one of alternatives 50 to 68 or is produced by a method according to any one of alternatives 69 to 79.

[0118] 86. The method of any one of alternatives 80 to 85, wherein the at least one heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

[0119] 87. The method of any one of alternatives 80 to 86, wherein the at least one heterogeneous cell composition is administered after being thawed from frozen storage and transferred to a delivery device or container, such as a syringe, containing an appropriate buffer, diluent or fluid, such as phosphate buffered saline or lactated Ringer's solution.

[0120] 88. The method of alternative 87, wherein thawing the at least one heterogeneous cell composition from the frozen storage state comprises diluting the at least one heterogeneous cell composition to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x.

[0121] 89. The heterogeneous cell composition according to any one of alternatives 50 to 68 for use in treating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

[0122] 90. The heterogeneous cell composition according to any one of alternatives 50-68 for use as a medicament, such as a medicament for the treatment or inhibition of chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

[0123] 91. A primed cell composition comprising dog or cat cells, preferably uterine cells, that are positive for both vimentin and cytokeratin-18.

[0124] 92. The cell composition of alternative 91, further comprising mesenchymal progenitor cells and / or epithelial progenitor cells.

[0125] 93. The cell composition of alternative 91 or 92, further comprising fibroblast growth factor 2 (FGF-2).

[0126] 94. The cell composition according to alternative 93, wherein the FGF-2 is recombinant human FGF-2.

[0127] 95. The cell composition of alternative 93 or 94, wherein the FGF-2 is present at a concentration of 8 ng / mL.

[0128] 96. The cell composition of any one of alternatives 91-95, wherein the cell composition is cultured in at least one tissue culture vessel that has not been pretreated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, an extracellular matrix, a basement membrane, Matrigel, a hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

[0129] 97. The cell composition of any one of alternatives 91 to 96, wherein the uterine tissue is obtained by oophorectomy.

[0130] 98. The cell composition of any one of alternatives 91-97, further comprising an additive, supplement, antibiotic, vitamin, growth factor, cryoprotectant, buffer, salt, protein, polypeptide, peptide, saccharide, polysaccharide, or carbohydrate, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin.

[0131] 99. The cell composition of any one of alternatives 91 to 98, further comprising a cryopreservation medium.

[0132] 100. The cryopreservation medium comprises: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2–10% DMSO and 2–20% FCS in growth medium, or (e) The cell composition of alternative form 99, comprising about 2-10% DMSO and about 2-20% FCS in the growth medium.

[0133] 101. A method for treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in a canine or feline subject in need thereof, comprising administering to said subject a therapeutically effective amount of the ... The method of treating, suppressing, or ameliorating, comprising administering to the canine or feline subject a primed cell composition of any one of alternatives 91-100.

[0134] 102. The method of alternative 101, wherein the cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

[0135] 103. The method of alternative 101 or 102, wherein the primed cell composition is administered after being thawed from frozen storage and transferred to a delivery device or container, such as a syringe, containing an appropriate buffer, diluent or fluid, such as phosphate buffered saline or lactated Ringer's solution.

[0136] 104. The method of alternative 103, wherein thawing the at least one primed heterogeneous cell composition from the frozen storage state comprises diluting the at least one heterogeneous cell composition to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x.

[0137] 105. The primed cell composition according to any one of alternatives 91 to 100 for use in treating or inhibiting chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

[0138] 106. A primed cell composition according to any one of alternatives 91 to 100 for use as a medicament.

[0139] In addition to the features described above, further features and variations will be readily apparent from the following description of the drawings and illustrative embodiments, which are to be understood as depicting exemplary embodiments and are not intended to be limiting in scope. [Brief description of the drawings]

[0140] [Figure 1] 1 shows forward scatter (FSC-A) and side scatter (SSC-A) flow cytometry dot plots and contour plots for the total cell population of PCF and day 4 samples of canine uterine-derived cells processed according to protocols A and B of Example 3. [Diagram 2] 1 shows FSC-A and Live / Dead assay flow cytometry dot plots and contour plots for PCF and intact cells of day 4 samples of canine uterine-derived cells processed according to protocols A and B of Example 3. [Diagram 3] 13 depicts contour plots of CD44 and CD90 staining flow cytometry for live cells of PCF and day 4 samples of canine uterine-derived cells processed according to protocols A and B of Example 3. [Figure 4] 13 depicts FSC-A and SSC-A flow cytometry contour plots for the total cell population of PCF and day 3 samples of canine uterine-derived cells processed according to protocols A and B of Example 4. [Diagram 5] 1 shows contour plots of FSC-A and Live / Dead assay flow cytometry for PCF and intact cells of day 3 samples of canine uterine-derived cells processed according to protocols A and B of Example 4. [Figure 6] 13 shows contour plots of CD44 and CD90 staining flow cytometry for viable cells of PCF, day 1, day 2, day 3, and day 4 samples of canine uterine-derived cells processed according to protocols A and B of Example 4. [Figure 7] 1 shows contour plots of vimentin and cytokeratin staining flow cytometry for live cells of PCF, day 1, day 2, day 3, and day 4 samples of canine uterine-derived cells processed according to protocols A and B of Example 4. [Figure 8] 1 shows flow cytometry dot plots of vimentin and cytokeratin staining for cells from a day 4 sample of feline uterine derived cells processed according to protocols A and B of Example 5. [Figure 9A] 1 shows a micrograph of feline uterine cells in phase contrast. [Figure 9B] 1 shows a micrograph of feline uterine cells with anti-vimentin / DAPI. [Figure 9C] 1 shows a micrograph of feline uterine cells with anti-cytokeratin-18 / DAPI. [Figure 9D] 1 shows a micrograph of feline uterine cells with anti-cytokeratin-18 / anti-vimentin. [Figure 10-1] 1 depicts individual animal iohexol clearance results, means, and statistics for Example 6. [Figure 10-2] Continued from Figure 10-1. [Figure 11-1] 1 depicts individual animal body weight results, averages, and statistics for Example 6. [Figure 11-2] Continued from Figure 11-1. [Figure 11-3] Continued from Figure 11-2. [Figure 12-1] 1 depicts individual animal urinalysis results, averages, and statistics for Example 6. [Figure 12-2] Continued from Figure 12-1. [Figure 12-3] Continued from Figure 12-2. [Figure 12-4] Continued from Figure 12-3. [Figure 12-5] Continued from Figure 12-4. [Figure 12-6] Continued from Figure 12-5. [Figure 13A] 1 depicts the composition of exemplary feline uterine-derived regenerative cells in a passage 4 cell culture. Both spindle-shaped and cuboidal-like cells are observed in the cell population. [Figure 13B] 1 depicts the composition of exemplary canine uterine-derived regenerative cells in passage 4 cell cultures, with spindle-shaped cells observed in the cell population. [Figure 14A] 1 depicts adipogenic staining of feline and canine URC populations following incubation in either control medium or adipogenic induction medium. [Figure 14B] 1 depicts chondrogenic staining of feline and canine URC populations following incubation in either control medium or chondrogenic induction medium. [Figure 14C] 1 depicts osteogenic staining of feline and canine URC populations following incubation in either control medium or osteogenic induction medium. [Figure 15] Figure 1 shows double staining of vimentin and cytokeratin-18 in a single cell of one exemplary feline URC preparation. A shows vimentin staining. B shows cytokeratin-18 staining. C shows merged vimentin and cytokeratin-18 staining. [Figure 16] 1 shows double staining of vimentin and cytokeratin-18 in single cells of a second exemplary feline URC preparation: A, vimentin staining; B, cytokeratin-18 staining; C, merged vimentin and cytokeratin-18 staining. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0141] Provided herein are cell compositions and / or primed cell compositions, preferably heterogeneous cell compositions and / or primed heterogeneous cell compositions, obtained from uterine tissue (such as from ovariectomy), which are referred to as uterine-derived regenerative cells (URCs). As shown herein, URCs can be classified as stem / progenitor cells based on several established characteristics of stem / progenitor cells. The canine and feline URCs disclosed herein have a CD marker profile that qualitatively matches that of human MSCs. Canine and feline URCs are also strongly positive for CD44, a known marker of stem / progenitor cells. Canine and feline URCs can also be induced to differentiate into adipogenic, chondrogenic, and osteogenic cell lineages, which is another requirement associated with multipotent human MSCs. Finally, canine and feline URCs adhere and grow in culture. Thus, the canine and feline URCs disclosed herein meet the requirement of being multipotent stem / progenitor cells.

[0142] However, canine and feline URCs display some unexpected characteristics for stem / progenitor cells. Both canine and feline URCs display the unexpected property of dual expression of progenitor-like and epithelial-like features in the same cell. This is believed to be the first report of dual expression of stem cell and epithelial cell markers in a single cell. Dual expression was observed in several ways. The physical presence of dual expressing cells in feline URCs was demonstrated by immunofluorescence, where some cells clearly expressed vimentin (a stem cell biomarker) and some cells expressed cytokeratin-18 (an epithelial biomarker), while a small population expressed both biomarkers simultaneously. By flow cytometry analysis, expression of vimentin and cytokeratin-18 was observed in both canine and feline URCs. In addition, both canine and feline URCs expressed CD44 and CD326, where CD44 is a stem cell biomarker and CD326 is an epithelial cell biomarker. Additionally, canine URCs were also observed to express CD44 and cytokeratin-18 by flow cytometry analysis. Thus, the URC preparations disclosed herein demonstrate the presence of cells expressing both progenitor-like and epithelial-like characteristics in the same cell. Dual-expressing cell populations were observed in cultures of both canine and feline URCs at higher passage numbers, supporting their unique potential as therapeutics. Thus, some embodiments include cell compositions and methods of use thereof, comprising cells expressing both vimentin and cytokeratin-18, which may be in purified or isolated form or may be present in a heterogeneous cell population, such as mixed with mesenchymal cells expressing vimentin and / or epithelial cells expressing cytokeratin-18.

[0143] Canine URC preparations have been evaluated in clinical trials to treat canine atopic dermatitis. After 30 days of treatment, the PVAS, CADESI-4 and CADLI (clinical measurement scale for assessing canine atopic dermatitis) assessment scores were reduced compared to pre-treatment scores, suggesting that the canine URC preparations used exhibited therapeutic effects.

[0144] Feline URC preparations have been evaluated in clinical trials for improving the condition of cats with chronic kidney disease. The study met one of the primary study outcomes, which was a 20% increase in GFR values ​​in more than 50% of treated cats over the 6-month study, along with improved food and water intake. This is the first study of seven published studies to achieve the primary endpoint, i.e., improved GFR.

[0145] Although not limited to a single mechanism of therapeutic effect, one of the common disease conditions of atopic dermatitis and chronic kidney disease is the presence of proinflammatory tissue reaction.Both canine and feline URCs described herein demonstrate the ability to downregulate proinflammatory environment as measured by MLR assay.Therefore, URCs disclosed herein provide therapeutic effect in part due to their ability to reduce proinflammatory tissue response.

[0146] In the following detailed description, reference is made to the accompanying drawings, which form a part of this specification. In the drawings, like numerals generally identify like elements unless the context dictates otherwise. The exemplary embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that aspects of the present disclosure, as generally described herein and illustrated in the figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are expressly contemplated herein.

[0147] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the subject matter belongs. The terms used in the description of the subject matter herein are for the purpose of describing particular embodiments only and are not intended to be limiting of the subject matter.

[0148] The articles "a" and "an" are used herein to refer to one or to more than one (e.g., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0149] As used herein, the term "about" or "approximately" refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by about 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% relative to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[0150] Throughout this specification, unless the context requires otherwise, the words "comprise", "comprises" and "comprising" will be understood to mean the inclusion of a recited step or element or group of steps or elements, but not the exclusion of any other step or element or group of steps or elements. With respect to "consisting of", it means inclusive and limited to whatever precedes the phrase "consisting of". Thus, the phrase "consisting of" indicates that the recited elements are necessary or mandatory, and that other elements may not be present. With respect to "consisting essentially of", it means the inclusion of any element recited before the phrase, and that other elements are limited to those that do not interfere with or contribute to the activity or action of the recited elements as set forth in this disclosure. Thus, the phrase "consisting essentially of" indicates that the recited elements are necessary or mandatory, but that other elements are optional, and that other elements may or may not be present depending on whether they substantially affect the activity or action of the recited elements.

[0151] As disclosed herein, the "individual", "patient" or "subject" to be treated is, in some embodiments, a mammal. As used herein, the term "mammal" includes, but is not limited to, humans, non-human animals, including primates, cows, sheep, goats, pigs, horses, cats, dogs, rabbits, rodents (e.g., rats or mice), monkeys, etc. In some embodiments, the individual, patient, or subject is a cat (feline) or a dog (canine). The subject may be a subject "in need" of the methods disclosed herein, or may be a subject experiencing and / or predicted to experience a disease state, and the methods and compositions of the present invention are used for therapeutic and / or prophylactic treatment. The subject may be a patient, which refers to a subject who meets with a health care provider for diagnosis or treatment of a disease. The subject may be suffering from or susceptible to a disease or disorder, but may or may not exhibit symptoms of the disease or disorder.

[0152] Some embodiments disclosed herein relate to the selection of subjects or patients in need. In some embodiments, subjects are selected who have a disease, who are in need of treatment or therapy for a disease, who are at risk of developing a disease, who previously had a disease, or who do not currently have a disease. In some embodiments, subjects who have not responded to other treatments in the past are selected. In some embodiments, the disease is chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds. In some embodiments, subjects are selected who may have any combination of the aforementioned selection criteria. Such subject or patient selection may be made by a clinician or veterinarian, or both, by clinical or diagnostic evaluation, or both.

[0153] As used herein, the term "priming" or "primed" refers to methods and compositions for modulating the pharmacokinetic properties and therapeutic activity of cells in an ex vivo environment to achieve a particular outcome in an in vivo environment when the primed cells are provided in the form of a therapeutic agent.

[0154] As used herein, the term "wound" refers to damage to the skin, epidermis, and / or dermis of a subject. A wound can be open or closed. Open wounds include, but are not limited to, cuts, lacerations, abrasions, avulsions, punctures, penetrations, or gunshot wounds. Closed wounds include, but are not limited to, hematomas or crush wounds. Wounds can be at risk of infection by pathogens such as bacteria, viruses, fungi, or protozoa.

[0155] As used herein, the term "chronic gingivitis" refers to wounds or lesions in the oral cavity of a subject. For example, cats diagnosed with feline chronic gingivostomatitis (FCGS) develop severe inflammation in the oral cavity, which affects the cat's appetite and water intake, resulting in a decrease in quality of life. Treatment is limited to removing most or all of the affected cat's teeth. However, even after such drastic medical procedures, a significant number of cats (approximately 30%) continue to suffer from severe oral inflammation, and their quality of life continues to decrease over time.

[0156] As used herein, the terms "atopic dermatitis" and "eczema" refer to a common inflammation-related disease that results in itchy skin. The disease can be caused by a wide range of factors, such as allergens in food, airborne allergens such as pollen and dust, or genetic predisposition. Atopic dermatitis affects humans as well as animals, including pets such as dogs and cats. Some cases of atopic dermatitis can be treated relatively easily, such as by discontinuing the use of certain foods. However, in many cases, there is no cure for atopic dermatitis, and the only treatments available are antihistamines or anti-inflammatory steroids. However, these treatments may cause other side effects, such as increased susceptibility to infection.

[0157] As used herein, the terms "osteoarthritis" and "OA" refer to a clinical condition in which one or more joints are disabled. Osteoarthritis (OA) is the most common form of arthritis in dogs, affecting approximately one-quarter of the total population. Osteoarthritis is a chronic joint disease characterized by loss of articular cartilage, thickening of the joint capsule, and new bone formation (osteophytosis) around the joint, ultimately resulting in pain and limb dysfunction. The majority of OA in dogs is secondary to progressive limb deformity diseases such as cranial cruciate ligament disease, hip dysplasia, elbow dysplasia, OCD, and patellar luxation. In a small proportion of dogs, OA develops without an obvious primary cause and may be genetic and age-related. Other factors that contribute to OA include weight, obesity, sex, exercise, and diet.

[0158] Symptoms include stiffness, lameness, shuffling gait, or difficulty getting up, lethargy, unwillingness to run, jump, or play, weight gain, irritability or behavioral changes, pain when petted or touched, difficulty positioning to urinate or defecate, or urinating in the house, and loss of muscle mass over the limbs and spine. For example, a dog that is owner-rated as having a Pain Severity Score (PSS) of 2 or more and a Pain Interference Score (PIS) of 2 or more on the Canine Brief Pain Inventory (CBPI) on day 0 may be a candidate for treatment with the cells of the present invention. Dogs may have a diagnosis of either newly diagnosed osteoarthritis or chronic / relapsing osteoarthritis. A diagnosis will usually consist of history, signs on physical exam, and radiographic evidence of osteoarthritis (by radiologist review). For example, a dog may have a lameness score of 2 or more. A dog may have a CBPI score of 10 or more. The dog may exhibit symptoms associated with OA for at least one month. As used herein, the term "effective amount" or "effective dosage" refers to the amount of the recited composition or compound that produces an observable effect. The actual dosage level of the active ingredient in the active composition of the presently disclosed subject matter may be altered so that an amount of the active composition or compound that is effective for achieving a desired response for a particular subject and / or application is administered. The selected dosage level will depend on a variety of factors, including, but not limited to, the activity of the composition, formulation, route of administration, combination with other drugs or therapeutics, the severity of the condition being treated, and the physical condition and medical history of the subject being treated. In some embodiments, a minimum dose is administered, and in the absence of dose-limiting toxicity, the dose is titrated up to the minimum effective amount. The determination and adjustment of the effective dosage, as well as the evaluation of when and how to make such adjustments, are contemplated herein.

[0159] As used herein, the terms "function" and "functional" refer to a biological function, an enzymatic function, or a therapeutic function.

[0160] As used herein, the term "isolated" refers to a substance and / or entity that is (1) separated from at least some of the components with which it was originally associated when produced (whether in nature and / or in an experimental environment) and / or (2) produced, prepared, and / or manufactured by the hand of man. Isolated substances and / or entities can be separated from or at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, about 99%, substantially 100%, or a value equivalent to 100% (or a range including and / or spanning the aforementioned values) of other components with which they were originally associated. In some embodiments, an isolated agent is greater than about 80%, greater than about 85%, greater than about 90%, greater than about 91%, greater than about 92%, greater than about 93%, greater than about 94%, greater than about 95%, greater than about 96%, greater than about 97%, greater than about 98%, greater than about 99%, substantially 100%, or 100% (or ranges including and / or spanning the aforementioned values) pure. As used herein, an "isolated" material can be "pure" (e.g., substantially free of other components). As used herein, the term "isolated cell" can refer to a cell that is not contained in a multicellular organism or tissue.

[0161] The term "primary cell fraction" or "PCF" refers to a cell population obtained from an isolation, dissociation, and / or purification step performed to prepare a viable single cell suspension from a target tissue prior to a culture step. A PCF population differs from a cell population obtained after one or more culture steps because the relative proportions of specific cell types in a heterogeneous population and the properties of those cell types change over one or more culture steps.

[0162] The term "mesenchymal progenitor cells" or "MPC" refers to a spindle-shaped, adherent cell population that exhibits the potential to differentiate into osteogenic, chondrogenic, and adipogenic lineages. MPCs may also be referred to as "mesenchymal stromal cells," "mesenchymal stem cells," "MSCs," or "stromal cells." MPCs have been primarily isolated from bone marrow, but are also present in other tissues, particularly umbilical cord tissue, umbilical cord blood, white adipose tissue, and placental tissue. When cultured, MPCs typically express CD105, CD73, and CD90, but generally do not express CD14, CD19, CD34, CD45, and HLA-DR (class II). In addition, the cytoskeletal intermediate filament vimentin (V) is a known MPC marker. The ability of MPCs to differentiate into multiple cell types, as well as the lack of MHC class II, has prompted research into their use in autologous or allogeneic regenerative cell therapy.

[0163] The term "epithelial progenitor cells" refers to a population of cuboidal adherent cells that are responsible for the production and regeneration of epithelia and extracellular matrix components that make up the surfaces of body tissues. These cells typically express CD44 and cell adhesion proteins (especially E-cadherin, epithelial cell adhesion molecule (EpCAM, CD326), etc.), but generally do not express CD45. In addition, keratin intermediate filament proteins (such as cytokeratin (C), e.g., cytokeratin-14, cytokeratin-18) are known epithelial cell and EPC markers.

[0164] The term "fibroblast growth factor" or "FGF" refers to a family of polypeptide growth factors that exert pleiotropic effects on cell proliferation, differentiation, and remodeling by binding to fibroblast growth factor receptor (FGFR) proteins on the cell surface. In humans, 22 FGFs are known. One of these is fibroblast growth factor 2 (FGF-2, basic fibroblast growth factor, bFGF, FGF-β), which has been shown to maintain the undifferentiated state of stem cells, among other functions. In some embodiments, FGF-2 is present in a growth medium for cell culture. In some embodiments, FGF-2 is present at a concentration of 0.01, 0.05, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 ng / mL, or any concentration within a range defined by any two of the aforementioned concentrations. In some embodiments, FGF-2 is present at a concentration of 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 ng / mL, or any concentration within a range defined by any two of the preceding concentrations. In some embodiments, FGF-2 is present at a concentration of 8 ng / mL. In some embodiments, FGF-2 is human FGF-2. In some embodiments, FGF-2 is canine or feline FGF-2. In some embodiments, FGF-2 is recombinantly produced. In some embodiments, FGF-2 is recombinantly produced in E. coli. In some embodiments, FGF-2 is produced according to research grade standards or current good manufacturing practice (cGMP).

[0165] The term "interferon-gamma" or "IFN-gamma" or "IFN-γ" is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoal infections. IFNγ is an important activator of macrophages and induces the expression of major histocompatibility complex class II molecules. Aberrant expression of IFN-γ is associated with several autoinflammatory and autoimmune diseases. The importance of IFN-γ in the immune system arises in part from its ability to directly inhibit viral replication, but most importantly from its immunostimulatory and immunomodulatory effects. IFN-γ is produced primarily by natural killer cells (NK) and natural killer T cells (NKT) as part of the innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocyte (CTL) effector T cells as part of the adaptive immune response, upon antigen-specific immunity. IFN-γ is also produced by non-cytotoxic innate lymphoid cells (ILCs), a family of immune cells first discovered in the early 2010s. In some embodiments, IFN-gamma is present at a concentration described herein. In some embodiments, IFN-gamma is human IFN-gamma. In some embodiments, IFN-gamma is canine or feline IFN-gamma. In some embodiments, IFN-gamma is recombinantly produced. In some embodiments, IFN-gamma is produced according to research grade standards or current good manufacturing practice (cGMP).

[0166] As used herein, the term "enzymatic dissociation" refers to the fragmentation or dissociation of cellular tissue using the catalytic activity of one or more enzymes. A process commonly known in the art, enzymatic dissociation typically requires the use of proteolytic enzymes (e.g., trypsin or collagenase) or enzymes specific for other molecules involved in surface adhesion or cell-cell junctions (e.g., hyaluronidase).

[0167] As used herein, "in vivo" has its ordinary meaning and refers to performing a method within a living organism (usually an animal, a mammal, including a human, and a plant), as opposed to a tissue extract or a dead organism.

[0168] As used herein, "ex vivo" has its ordinary meaning and refers to carrying out a method outside of a living organism with little alteration from natural conditions.

[0169] As used herein, "in vitro" has its ordinary meaning and refers to carrying out a method outside biological conditions (eg, in a petri dish or test tube).

[0170] As used herein, the term "purity" of any given substance, compound, or material refers to the actual abundance of the substance, compound, or material relative to the expected abundance. For example, the substance, compound, or material may be at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% pure (including all decimals therebetween). Purity may be affected by undesired impurities, including, but not limited to, nucleic acids, DNA, RNA, nucleotides, proteins, polypeptides, peptides, amino acids, lipids, cell membranes, cell debris, small molecules, degradation products, solvents, carriers, vehicles, or contaminants, or any combination thereof. In some embodiments, the substance, compound, or material is substantially free of host cell proteins, host cell nucleic acids, plasmid DNA, contaminating viruses, proteasomes, host cell culture components, process-related components, mycoplasma, pyrogens, bacterial endotoxins, and adventitious substances. Purity can be measured using techniques including, but not limited to, electrophoresis, SDS-PAGE, capillary electrophoresis, PCR, rtPCR, qPCR, chromatography, liquid chromatography, gas chromatography, thin layer chromatography, enzyme-linked immunosorbent assay (ELISA), spectroscopy, ultraviolet-visible spectroscopy, infrared spectroscopy, mass spectrometry, nuclear magnetic resonance, gravimetry, or titration, or any combination thereof.

[0171] As used herein, the term "yield" of any given substance, compound, or material refers to the actual total amount of the substance, compound, or material relative to the expected total amount. For example, the yield of a substance, compound, or material may be at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (including all decimal points in between) of the expected total amount. Yield may be affected by the efficiency of the reaction or process, undesired side reactions, decomposition, the quality of the input substances, compounds, or materials, or loss of the desired substance, compound, or material in any of the manufacturing steps.

[0172] As used herein, "pharmacologically acceptable" refers to a carrier, excipient, and / or stabilizer that is non-toxic or has an acceptable level of toxicity to cells or mammals exposed at the dosages and concentrations employed. As used herein, "pharmacologically acceptable" "diluent", "excipient" and / or "carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, that are compatible with administration to humans, felines, dogs, or other vertebrate hosts. Typically, pharmaceutically acceptable diluents, excipients, and / or carriers are those that are approved by federal, state, or other regulatory agencies or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, including humans and non-human mammals (such as cats and dogs). The terms diluent, excipient, and / or "carrier" may refer to a diluent, adjuvant, excipient, or vehicle that is administered with a pharmaceutical composition. Such pharmaceutical diluents, excipients, and / or carriers may be sterile liquids, such as water and oils (including those of petroleum, animal, vegetable, or synthetic origin). Water, saline, and aqueous dextrose and glycerol solutions may be employed as liquid diluents, excipients, and / or carriers, particularly for injectable solutions. Some examples of liquid diluents used for injectable solutions include, but are not limited to, saline, phosphate buffered saline, lactated Ringer's solution, acetated Ringer's solution, or dextrose solution. Suitable pharmaceutical diluents and / or excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, or ethanol, and the like. A non-limiting example of a physiologically acceptable carrier is an aqueous pH buffered solution.Physiologically acceptable carriers may also include one or more of the following: antioxidants (such as ascorbic acid), low molecular weight (less than about 10 residues) polypeptides, proteins (such as serum albumin, gelatin, immunoglobulins), hydrophilic polymers (polyvinylpyrrolidone), amino acids, carbohydrates (such as glucose, mannose, or dextrin), chelating agents (such as EDTA), sugar alcohols (such as mannitol or sorbitol), salt-forming counterions (such as sodium), and polyethylene glycol (PEG). The compositions may also contain minor amounts of wetting agents, bulking agents, emulsifying agents, or pH buffering agents, if desired. Such compositions may take the form of solutions, suspensions, emulsions, sustained-release formulations, and the like. The formulation should be appropriate for the mode of administration.

[0173] Cryoprotectants are cell composition additives to improve the efficiency and yield of cryopreservation by preventing the formation of large ice crystals. Cryoprotectants include, but are not limited to, DMSO, ethylene glycol, glycerol, propylene glycol, trehalose, formamide, methyl-formamide, dimethyl-formamide, glycerol 3-phosphate, proline, sorbitol, diethyl glycol, sucrose, triethylene glycol, polyvinyl alcohol, polyethylene glycol, or hydroxyethyl starch. Cryoprotectants may be used as part of a cryopreservation medium, which includes other components such as nutrients (e.g., albumin, serum, bovine serum, or fetal calf serum [FCS]) to enhance the post-thaw survival of cells. Some examples of cryopreservation media are CryoStor® CS5, BioLife Solutions CS10, Hespan® (6% hetastarch [hydroxyethyl starch] in 0.9% sodium chloride), as well as other compositions known in the art, including DMSO, FCS, and standard growth media. In such compositions, DMSO may be found at a concentration of 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%, or any percentage within the range defined by any two of the aforementioned numbers. In such compositions, FCS may be found at a concentration of 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30%, or any percentage within the range defined by any two of the aforementioned numbers. Such compositions may also include other cryoprotectants as described herein, such as trehalose.

[0174] Additional excipients with desirable properties include, but are not limited to, preservatives, adjuvants, stabilizers, solvents, buffers, diluents, chelating agents, antioxidants, alcohol, ethylenediaminetetraacetic acid (EDTA), citric acid, salts, sodium chloride, sodium bicarbonate, sodium phosphate, sodium borate, sodium citrate, potassium chloride, potassium phosphate, magnesium sulfate, sugars, dextrose, fructose, mannose, lactose, galactose, sucrose, sorbitol, cellulose, serum, amino acids, polysorbate 20, polysorbate 80, gelatin, esters, ethers, 2-phenoxyethanol, or vitamins, or any combination thereof. Some excipients may be in residuals or contaminants from the manufacturing process, including, but not limited to, serum, albumin, ovalbumin, antibiotics, inactivating agents, gelatin, cell debris, nucleic acids, peptides, amino acids, or growth media components, or any combination thereof. The amount of excipient may be found in the composition at a percentage of 0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% w / w, or any weight percentage in a range defined by any two of the foregoing numbers.

[0175] The term "pharmaceutically acceptable salts" includes, but is not limited to, relatively non-toxic inorganic and organic acid addition salts or inorganic and organic base addition salts of compositions or excipients, including analgesics, therapeutic agents, other ingredients, and the like. Examples of pharmaceutically acceptable salts include those derived from mineral acids, such as hydrochloric acid and sulfuric acid, and those derived from organic acids, such as ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like. Examples of inorganic bases suitable for forming salts include hydroxides, carbonates, and bicarbonates of ammonia, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc, and the like. Salts may also be formed with suitable organic bases, including those that are non-toxic and strong enough to form such salts. For example, such types of organic bases can include, but are not limited to, mono-, di-, and trialkylamines (including methylamine, dimethylamine, and triethylamine), mono-, di-, or trihydroxyalkylamines (including mono-, di-, and triethanolamine), amino acids (including glycine, arginine, and lysine), guanidine, N-methylglucosamine, N-methylglucamine, L-glutamine, N-methylpiperazine, morpholine, ethylenediamine, N-benzylphenethylamine, or trihydroxymethylaminoethane.

[0176] Depending on the selected administration route, formulation is appropriately made. The techniques for formulating and administering the compounds described herein are known to those skilled in the art. There are multiple techniques for administering compounds in the art, including but not limited to enteral, oral, rectal, topical, sublingual, buccal, ear drops, epidural, epicutaneous, aerosol, parenteral delivery (including intramuscular, subcutaneous, intraarterial, intravenous, intraportal, intraarticular, intradermal, intraperitoneal, intramedullary injection, intrathecal, direct intraventricular, intraperitoneal, intranasal or intraocular injection). Pharmaceutical compositions will generally be prepared for the specific intended administration route.

[0177] As used herein, a "carrier" refers to a compound, particle, solid, semi-solid, liquid, or diluent that facilitates the passage, delivery and / or uptake of a compound into cells, tissues and / or body organs.

[0178] As used herein, "diluent" refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharma- ceutically necessary or desirable. For example, a diluent may be used to increase the volume of a potent drug whose mass is too small to manufacture and / or administer. A diluent may also be a liquid for dissolving a drug to be administered by injection, ingestion, or inhalation. A common form of diluent in the art is a buffered aqueous solution, such as, but not limited to, phosphate buffered saline, which resembles the composition of human blood.

[0179] As used herein, the term "% w / w" or "% wt / wt" has its ordinary meaning as understood in the context of this specification and refers to the percentage of the weight of a component or agent relative to the total weight of the composition multiplied by 100. As used herein, the term "% v / v" or "% vol / vol" has its ordinary meaning as understood in the context of this specification and refers to the percentage of the liquid volume of a compound, substance, component, or agent relative to the total liquid volume of the composition multiplied by 100.

[0180] Uterus-derived regenerative cells (URC) The uterus periodically regenerates the outer endometrial structure (also known as the functional layer in humans). In humans, the cycle occurs approximately every 30 days, but in animals such as cats and dogs, the cycle occurs less frequently. Following shedding (in humans) or attachment (in mice), the outer endometrial layer is rapidly regenerated. For example, in humans, re-epithelialization occurs at the newly exposed surface within 24 hours after the functional layer is sloughed. Thus, a significant pool of stem and progenitor cells is found in the basal layer of the endometrium that supports the regeneration of the functional layer. Stem and progenitor cells present in the basal layer are both stromal (mesenchymal, pericytes, etc.) and epithelial (including epithelial stem cells). Epithelial stem cells have been identified as "founder" cells because they are associated with the extensive proliferation resulting from the "natural" endometrial insults of pregnancy and childbirth.

[0181] Another important cell type found in epithelial tissues is the "transiently proliferating" (TA) cell. TA cells are derived from epithelial stem cells, are incapable of "self-renewal" (a hallmark of true stem cells), and are destined to become adult cells required for homeostasis and repair of stratified epithelial tissues such as the endometrium. CD44+ epithelial cells are considered candidate uterine progenitor cells (epithelial progenitor cells). A variety of other cells are present in the endometrium, including stromal fibroblasts, vascular smooth muscle cells, endothelial cells, and leukocytes.

[0182] Epithelial tissues are frequently found at the interface between the external environment and internal structures, including the uterus, skin, intestine, airways, kidney, liver, breast, and prostate. An important aspect of epithelial stem cells is their plasticity, which is demonstrated when they are removed from their "niche" within the epithelial layer. When epithelial stem cells are removed from their niche and transplanted (either directly or after culture), they become more pluripotent, where unipotent or committed epithelial cells adopt a more "stem cell-like" state through a dedifferentiation mechanism.

[0183] Uterine tissue, processed according to protocols B, C, or D, or similar protocols, yields mainly two cell types after expansion in culture: 1) cells that are solely positive for vimentin (V+, an MSC marker), and 2) cells that are double positive for cytokeratin-18 and vimentin (C+ / V+) and / or double positive for CD44 and CD326 (CD44+ / CD326+). Cytokeratins are associated with epithelial cells. Cells obtained from dog uterus, processed according to the same protocol described herein, yield a roughly 1:1 frequency of V+ and C+ / V+ cells when examined on culture day 4 or at any subsequent passage, day, or culture interval. Furthermore, cells derived from dog uterine tissue were also double positive for CD90 / CD44 and solely positive for CD44. As mentioned above, the CD44 marker is thought to be associated with epithelial progenitor cells, whereas other markers are associated with progenitor cells and fibroblasts.

[0184] Herein, a stable culture environment in which "epithelial-like" cells coexist with "mesenchymal-like" cells is described all the way from the fourth passage onwards. It has been previously reported that the culture of single cell suspensions obtained after enzymatic digestion of human endometrial tissue results in two types of plastic-adherent cells: mesenchymal / fibroblastic and epithelial / small round cells. However, in appearance, the majority of adherent cells present in the third passage cultures were fibroblastic. Thus, in the protocol described herein, the presence of the two types of progenitor cells is rare up to the fourth passage. Furthermore, a clinical trial was conducted with a two-cell type preparation to treat feline chronic kidney disease (CKD). In the pilot study, therapeutic benefits were obtained in approximately 70% of the test subjects. This very positive result was in contrast to other clinical trials with cultured cell preparations, which were based on cell preparations containing only MSCs.

[0185] Chronic kidney disease is characterized by the damage of the epithelial layer of the nephron of the kidney. The long-term exposure to the proinflammatory environment that occurs when the epithelial layer is damaged promotes the progressive pathology associated with chronic kidney disease. Therefore, in the CKD clinical trial described herein, the two-cell type preparation could reverse the progression of CKD, possibly by suppressing inflammation, which is considered to be a major contributing factor to CKD.

[0186] One important property of progenitor cells such as MSCs is that they attenuate the pro-inflammatory environment through the secretion of various biochemicals (including cytokines such as IL-10) that act directly on various immune cells involved in promoting inflammatory responses. This ability is also associated with a wide range of immunomodulatory properties, such as promoting the transition of macrophages from a pro-inflammatory (M1) to an anti-inflammatory (M2) type. The presence of MSC-like cells in the preparations described herein should support attenuation of the pro-inflammatory environment associated with CKD and / or atopic dermatitis.

[0187] Apoptosis occurs when cells (adult tissue cells, neutrophils, chondrocytes, etc.) receive a "signal" to change their genome and undergo programmed cell death. For example, alveolar epithelial cells, when exposed to suboptimal levels of oxygen, produce hypoxia-inducible factors, which trigger apoptosis and cell death of alveolar epithelial cells. MSCs produce direct anti-apoptotic factors. The presence of MSC-like cells in the preparations described herein should support the rescue of tissue cells that have undergone apoptosis due to signals present at the site of pathology, such as pro-inflammatory nephrons.

[0188] In addition to apoptotic cell rescue, MSCs have been demonstrated to help restore the activity of alveolar type II epithelial cells when they are injured in a human lung injury model after MSCs are delivered intratracheally. In the case of feline CKD clinical trials and canine atopic dermatitis treatment, epithelial stem cell-like cells were injected together with mesenchymal-like stem cells. This combination may have enhanced the beneficial interactions between MSC-type cells and epithelial cells present in the affected nephron. In addition, epithelial stem cell-like cells may also respond to the epithelial niche by restoring the normal environment found in epithelial tissues, including the generation of TA cells, which may help repair and re-establish a functional epithelial barrier in the nephron.

[0189] Another manifestation of stem cell support for resident cells is the secretion of biochemical factors, such as fibroblast growth factor (FGF), known to promote the proliferation of a wide variety of resident tissue cells. For example, when chondrocytes are injured, as occurs in osteoarthritis, their proliferation is controlled in part by FGF. FGF-2 promotes colony formation and proliferation of stromal-derived "stem cells" in culture, but this factor does not promote the clonogenic activity of epithelial stem cells. In contrast, TGF-beta, EGF, and PDGF-BB all enhanced the clonogenic potential of both epithelial and stromal cells. Epithelial cells are critical for the regeneration of the "functional" layer of the endometrium (the outer layer of the endometrium that is shed during menstruation). Re-epithelialization of the functional layer occurs within 24 hours, and the epithelial cells are derived from epithelial progenitor cells.

[0190] The fact that two cell types are present at passage 4 in the therapeutic preparations used in the feline CKD and canine atopic dermatitis clinical trials described herein means that the two cell types have been co-cultured for extended periods, which may result in changes in the two cell types due to "crosstalk". For example, adipose-derived MSCs formed acinar-like structures when cultured in medium conditioned by the growth of a human breast epithelial cell line. The resulting modified MSCs upregulated epithelial genes, indicating that the MSCs are influenced by factors released by human breast epithelial cells. Whereas type II alveolar cells normally differentiate into type I cells when grown on plastic, alveolar cells in mixed co-culture experiments with bone marrow-derived MSCs and alveolar epithelial cells maintained type II morphology. Thus, it was demonstrated that MSCs and epithelial cells can influence each other in in vitro experiments.

[0191] When cells are co-cultured together, they can affect each other through the secretion of numerous biochemical factors. For example, in cell lines established from mouse kidney tubules, when epithelial cells were cultured in the presence of FGF-2 (a cytokine secreted by MSCs), they began to lose their reactivity to the epithelial cell marker cytokeratin and increased their reactivity to the mesenchymal stem cell marker vimentin. The authors point out that this may represent a known in vivo phenomenon called "epithelial-mesenchymal transition". Moreover, a typical pattern when initially culturing multiple cell types (including MSCs) is that over the course of several passages, the other cell types disappear and the culture becomes dominated by MSCs.

[0192] Therefore, the presence of cytokeratin-positive epithelial stem cell-like cells that are also CD44+ in the therapeutic preparation described herein suggests that the epithelial progenitor cells present at the beginning of the culture could influence the MSC-like progenitor cells through some kind of molecular crosstalk in a manner that allows them to survive until the fourth passage. The presence of epithelial progenitor cells in the therapeutic drug used in the feline CKD clinical trial described herein may have provided a therapeutic effect due to the critical role of epithelial stem cells in the regeneration of epithelial tissue, including the regeneration of the functional layer in the endometrium after shedding. The epithelial stem cell-like cells present in the therapeutic preparation may also help restore the TA cell-dependent repair mechanisms that are the basis for maintaining healthy epithelial tissue in the dysfunctional epithelial tissue of the nephron in CKD.

[0193] Finally, while potential crosstalk between cells in co-culture has been focused on the role of biochemicals such as IL-10, FGF and other cytokines, a crucial factor in the communication occurring between epithelial progenitor cells and MSC-like cells is the exosome. Exosomes are produced by all cells in the body and are released in vivo under very specific conditions. Depending on their source, exosomes are designed to contain a "cargo" consisting of proteins, lipids, proteoglycans, RNA species and DNA. Proteins carried as cargo in exosomes can include FGF or IL-10. As soon as an exosome binds to a cell that can be considered its "target" receptor, it releases its cargo. The mature protein can immediately affect the metabolism of the target cell. However, the RNA component will be incorporated into the genome, or protein synthesis machinery, of the target cell, and the production of a protein based on the exosomal cargo will begin. Another type of RNA component (miRNA) can inhibit the activation of target cell genes, which can lead to changes in the protein production of the cell. Therefore, the influence of the two cell types present in the therapeutic preparations described herein on each other may include the uptake of exosomes released into the culture, which may modify the functional behavior of the cells during the co-culture period and subsequently when injected into a test subject.

[0194] cell composition Some embodiments described herein relate to cell compositions comprising cells exhibiting specific characteristics. In some embodiments, the specific characteristics may include morphology (spindle and cuboidal shapes) or expression of cell markers associated with mesenchymal or epithelial cell types (e.g., vimentin, cytokeratin-18, CD44, or CD326). In some embodiments, the cell composition may comprise one or more cell populations exhibiting the specific characteristics. In some embodiments, the cell composition may be a heterogeneous cell composition comprising two or more cell populations. In some embodiments, some cell populations in a heterogeneous cell composition may exhibit characteristics of two or more cell types.

[0195] Disclosed herein are heterogeneous cell compositions. In some embodiments, the heterogeneous cell compositions comprise a mesenchymal progenitor cell population and an epithelial progenitor cell population. In some embodiments, the mesenchymal progenitor cells and the epithelial progenitor cells are co-cultured. In some embodiments, the mesenchymal progenitor cells and the epithelial progenitor cells are obtained or derived from canine or feline uterine tissue. In some embodiments, the ratio of mesenchymal progenitor cells to epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to 20%, about 90% to about 10%, or about 99% to about 1%, or a ratio within a range defined by any two of the foregoing percentages. In some embodiments, the mesenchymal precursor cells represent 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 109%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109 ... %, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percentages, or any percentage within a range defined by any two of the aforesaid percentages.In some embodiments, epithelial progenitor cells represent 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% of the total cells in the heterogeneous cell composition. , 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% percentage, or any percentage within a range defined by any two of the aforementioned percentages. In some embodiments, the heterogeneous cell composition further comprises fibroblast growth factor 2 (FGF-2). In some embodiments, the FGF-2 is recombinant human FGF-2. In some embodiments, the FGF2 is present at a concentration of 8 ng / mL or about 8 ng / mL. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof. In some embodiments, the mesenchymal progenitor cells and epithelial progenitor cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the uterine tissue is obtained by ovariectomy.In some embodiments, the heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million mesenchymal progenitor cells, or a number within a range defined by any two of the aforesaid numbers. In some embodiments, the heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million epithelial progenitor cells, or a number within a range defined by any two of the aforesaid numbers.In some embodiments, the heterogeneous cell composition comprises a total of 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, or about 10 million. In some embodiments, the heterogeneous cell composition comprises a total of 30-36 million or about 30-36 million cells. In some embodiments, the heterogeneous cell composition further comprises additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, sugars, polysaccharides, or carbohydrates, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin. In some embodiments, the heterogeneous cell composition further comprises a cell population, each cell exhibiting markers of both mesenchymal and epithelial progenitor cells. In some embodiments, the mesenchymal and epithelial progenitor cells are obtained or derived from the same canine or feline uterine tissue.In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells that are positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells that are positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, D, or a similar protocol. In some embodiments, the heterogeneous cell compositions further comprise a cryopreservation medium. In some embodiments, the cryopreservation medium comprises (a) CryoStor CS5 and / or BioLife Solutions CS10, (b) 98% Hespan and 2% DMSO, (c) about 98% Hespan and about 2% DMSO, (d) 2-10% DMSO and 2-20% FCS in the growth medium, or (e) about 2-10% DMSO and about 2-20% FCS in the growth medium. In some embodiments, the heterogeneous cell composition is further defined by a cell population that is both CD44 and CD326 positive. In some embodiments, cell populations that are positive for both CD44 and CD326 are found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the aforementioned percentages.

[0196] Also disclosed herein is a heterogeneous cell composition comprising a vimentin positive (V+) / cytokeratin negative (C-) cell population and a V+ / cytokeratin positive (C+) cell population. In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured. In some embodiments, the V+ / C- cells and the V+ / C+ cells are obtained or derived from canine or feline uterine tissue. In some embodiments, the ratio of V+ / C- cells and V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or a ratio within a range defined by any two of the foregoing percentages. In some embodiments, V+ / C- cells represent 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 109%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109 ... %, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percentages, or any percentage within a range defined by any two of the aforesaid percentages.In some embodiments, V- / C+ cells represent 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% of the total cells in the heterogeneous cell composition. , 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% percentage, or any percentage within a range defined by any two of the aforementioned percentages. In some embodiments, the heterogeneous cell composition further comprises FGF-2. In some embodiments, the FGF-2 is recombinant human FGF-2. In some embodiments, the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL. In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof. In some embodiments, the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the uterine tissue is obtained by ovariectomy.In some embodiments, the heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C- cells, or any number of V+ / C- cells within a range defined by any two of the aforesaid numbers. In some embodiments, the heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C+ cells, or any number of V+ / C+ cells within a range defined by any two of the aforesaid numbers.In some embodiments, the heterogeneous cell composition comprises a total of 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, or about 10 million. In some embodiments, the heterogeneous cell composition comprises a total of 30-36 million or about 30-36 million cells. In some embodiments, the heterogeneous cell composition further comprises additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, sugars, polysaccharides, or carbohydrates, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin. In some embodiments, the V+ / C- cells and the V+ / C+ cells are obtained or derived from the same canine or feline uterine tissue.In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells that are positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells that are positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol. In some embodiments, the heterogeneous cell compositions further comprise a cryopreservation medium. In some embodiments, the cryopreservation medium comprises (a) CryoStor CS5 and / or BioLife Solutions CS10, (b) 98% Hespan and 2% DMSO, (c) about 98% Hespan and about 2% DMSO, (d) 2-10% DMSO and 2-20% FCS in the growth medium, or (e) about 2-10% DMSO and about 2-20% FCS in the growth medium. In some embodiments, the heterogeneous cell composition is further defined by a cell population that is both CD44 and CD326 positive. In some embodiments, cell populations that are positive for both CD44 and CD326 are found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the aforementioned percentages.

[0197] Also disclosed herein are heterogeneous cell compositions. In some embodiments, the heterogeneous cell compositions include (a) a vimentin positive (V+) / cytokeratin negative (C-) cell population, (b) a vimentin negative (V-) / cytokeratin positive (C+) cell population, and (c) a V+ / C+ cell population. In some embodiments, populations (a)-(c) are co-cultured. In some embodiments, populations (a)-(c) are obtained or derived from canine or feline uterine tissue. In some embodiments, the V+ / C+ cell population is found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the aforementioned percentages. In some embodiments, the V+ / C- cell population represents 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 109%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109 ... %, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percentages, or any percentage within a range defined by any two of the aforesaid percentages.In some embodiments, the V- / C+ cell population represents 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 108%. %, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% percentages, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the ratio of the V+ / C- cell population to the V- / C+ cell population is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, about 99% to about 1%, or a ratio within a range defined by any two of the aforementioned percentages. In some embodiments, the heterogeneous cell composition further comprises FGF-2. In some embodiments, the FGF-2 is recombinant human FGF-2. In some embodiments, the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL. In some embodiments, populations (a)-(c) are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.In some embodiments, populations (a)-(c) are co-cultured in at least one tissue culture vessel for passages, days, or culture intervals of 3, 4, 5, or 6. In some embodiments, uterine tissue is obtained by ovariectomy. In some embodiments, the heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C- cells, or any number of V+ / C- cells within a range defined by any two of the aforesaid numbers. In some embodiments, the heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V- / C+ cells, or any number of V- / C+ cells within a range defined by any two of the aforesaid numbers.In some embodiments, the heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C+ cells, or any number of V+ / C+ cells within a range defined by any two of the aforesaid numbers. In some embodiments, the heterogeneous cell composition comprises a total of 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, or about 10 million. million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million cells, or a number of cells totaling within a range defined by any two of the foregoing numbers. In some embodiments, the heterogeneous cell composition comprises a total of 30-36 million or about 30-36 million cells. In some embodiments, the heterogeneous cell composition is further defined by a population of cells that are positive for both CD44 and CD326.In some embodiments, the population of cells that are positive for both CD44 and CD326 is found in a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the heterogeneous cell composition further comprises additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, saccharides, polysaccharides, or carbohydrates, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin. In some embodiments, populations (a)-(c) are obtained or derived from the same canine or feline uterine tissue. In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol. In some embodiments, the heterogeneous cell composition further comprises a cryopreservation medium. In some embodiments, the cryopreservation medium comprises: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2-10% DMSO and 2-20% FCS in growth medium; or (e) about 2-10% DMSO and about 2-20% FCS in growth medium.

[0198] Also disclosed herein are cell compositions. In some embodiments, the cell composition comprises canine or feline cells that are both vimentin and cytokeratin-18 positive. In some embodiments, the canine or feline cells are uterine cells. In some embodiments, the cell composition further comprises mesenchymal progenitor cells and / or epithelial progenitor cells. In some embodiments, the cell composition further comprises V+ / C- cells and / or V- / C+ cells. In some embodiments, the canine or feline cells are obtained from or derived from canine or feline uterine tissue. In some embodiments, the canine or feline cells are obtained from or derived from ovariectomy. In some embodiments, the cell composition further comprises FGF-2. In some embodiments, the FGF-2 is recombinant human FGF-2. In some embodiments, the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL. In some embodiments, the cell compositions are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof. In some embodiments, the cell compositions are cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals.In some embodiments, the cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million The composition may comprise about 10,000, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million canine or feline cells that are positive for both vimentin and cytokeratin-18, or any number of such cells within a range defined by any two of the aforementioned cell numbers. In some embodiments, the cell composition further comprises additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, saccharides, polysaccharides, or carbohydrates, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin. In some embodiments, the cell composition comprises a total of 30-36 million or about 30-36 million cells. In some embodiments, the cell composition is further defined by a population of cells that are positive for both CD44 and CD326. In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells that are positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells that are positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol. In some embodiments, the cell compositions further comprise a cryopreservation medium.In some embodiments, the cryopreservation medium comprises: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2-10% DMSO and 2-20% FCS in growth medium; or (e) about 2-10% DMSO and about 2-20% FCS in growth medium.

[0199] Some embodiments described herein relate to pharmaceutical compositions comprising, consisting essentially of, or consisting of an effective amount of a cell composition described herein and a pharma- ceutically acceptable carrier, excipient, or combination thereof. The pharmaceutical compositions described herein are suitable for human and / or veterinary use. Pharmaceutical compounds may also be administered locally rather than systemically (e.g., by injecting the compound directly into an organ, tissue, cancer, tumor, area of ​​infection, or other diseased area).

[0200] Manufacturing method Disclosed herein is a method for preparing a cell composition. In some embodiments, the method includes contacting a single cell suspension comprising mesenchymal and epithelial progenitor cells with FGF-2, and culturing the single cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the cell composition is any one of the cell compositions or heterogeneous cell compositions disclosed herein. In some embodiments, the single cell suspension is obtained from or derived from canine or feline tissue. In some embodiments, at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the ratio of mesenchymal progenitor cells to epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to 20%, about 90% to about 10%, or about 99% to about 1%, or a ratio within a range defined by any two of the foregoing percentages. In some embodiments, the mesenchymal precursor cells represent 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 109%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109 ... %, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percentages, or any percentage within a range defined by any two of the aforesaid percentages.In some embodiments, epithelial progenitor cells represent 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% of the total cells in the heterogeneous cell composition. , 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the single cell suspension is passaged when the cell culture reaches 70-80% confluence. In some embodiments, the single cell suspension is obtained from or derived from the same canine or feline uterine tissue. In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol. In some embodiments, the canine or feline uterine tissue is enzymatically dissociated to form a single cell suspension. In some embodiments, the FGF-2 is recombinant human FGF-2. In some embodiments, the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL. In some embodiments, the single cell suspension is cultured for at least 4 passages, days, or culture intervals. In some embodiments, the heterogeneous cell composition is further defined by a cell population positive for both CD44 and CD326.In some embodiments, cell populations that are positive for both CD44 and CD326 are found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the aforementioned percentages.

[0201] Also disclosed herein is a method of preparing a cell composition. In some embodiments, the method includes contacting a single cell suspension comprising V+ / C- cells and V+ / C+ cells with FGF-2, and culturing the single cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals. In some embodiments, the cell composition is any one of the cell compositions or heterogeneous cell compositions disclosed herein. In some embodiments, the single cell suspension is obtained from or derived from canine or feline tissue. In some embodiments, at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the ratio of V+ / C- cells and V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or a ratio within a range defined by any two of the foregoing percentages. In some embodiments, V+ / C- cells represent 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 109%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109 ... %, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percentages, or any percentage within a range defined by any two of the aforesaid percentages.In some embodiments, V- / C+ cells represent 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34% of the total cells in the heterogeneous cell composition. , 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the single cell suspension is passaged when the cell culture reaches 70-80% confluence. In some embodiments, the single cell suspension is obtained from or derived from the same canine or feline uterine tissue. In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol. In some embodiments, the canine or feline uterine tissue is enzymatically dissociated to form a single cell suspension. In some embodiments, the FGF-2 is recombinant human FGF-2. In some embodiments, the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL. In some embodiments, the single cell suspension is cultured for at least 4 passages, days, or culture intervals. In some embodiments, the heterogeneous cell composition is further defined by a cell population positive for both CD44 and CD326.In some embodiments, cell populations that are positive for both CD44 and CD326 are found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the aforementioned percentages.

[0202] Also disclosed herein are methods of preparing cell compositions, such as heterogeneous cell compositions. In some embodiments, cell compositions described herein, e.g., cell compositions comprising canine or feline cells positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol. In some embodiments, the method comprises dissociating canine or feline uterine tissue into a single cell suspension and culturing the single cell suspension for 3, 4, 5, or 6 passages, days, or culture intervals to prepare a heterogeneous cell composition from the cultured single cell suspension. In some embodiments, at the end of 3, 4, 5 or 6 passages, days or culture intervals, the heterogeneous cell composition comprises a cell population that is positive for both vimentin and cytokeratin-18. In some embodiments, the cell population that is positive for both vimentin and cytokeratin-18 is found in a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the single cell suspension is passaged when the cell culture reaches 70-80% confluence. In some embodiments, the heterogeneous cell composition is any one of the heterogeneous cell compositions disclosed herein. In some embodiments, the dissociation step comprises enzymatic dissociation.In some embodiments, the enzymatic dissociation comprises contacting the canine or feline uterine tissue with trypsin, chymotrypsin, collagenase, papain, hyaluronidase, elastase, thermolysin, neutral protease, or any combination thereof. In some embodiments, the single cell suspension is cultured with FGF-2. In some embodiments, the FGF-2 is recombinant human FGF-2. In some embodiments, the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL. In some embodiments, the single cell suspension is cultured for at least 4 passages, days, or culture intervals. In some embodiments, the heterogeneous cell composition is further defined by a cell population that is both CD44 and CD326 positive. In some embodiments, cell populations that are positive for both CD44 and CD326 are found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the aforementioned percentages.

[0203] How to use As used herein, the terms "treating", "treatment", "therapeutic" or "therapy" have their ordinary meaning as understood in light of the present specification and do not necessarily mean a complete cure or elimination of a disease or condition. As used herein (and as is well understood in the art), the terms "treating" or "treatment" also refer to an approach to obtain a beneficial or desired result in a subject's condition, including a clinical result. A beneficial or desired clinical result may include, but is not limited to, alleviation or remission of one or more symptoms or conditions, whether partial or total, detectable or undetectable, reduction in the extent of disease, stabilization (i.e., not worsening) of a disease state, prevention of disease spread or spread, delay or slowing of disease progression, remission or alleviation of a disease state, reduction in disease recurrence, and tendency to remission. As used herein, "treating" and "treatment" also include prophylactic treatment. The treatment method includes administering a therapeutically effective amount of an active agent to the subject. The administration step may consist of a single administration or may consist of a series of administrations. The composition is administered to the subject in an amount and for a period sufficient to treat the patient. The length of treatment period depends on various factors such as the severity of the condition, the age and genetic profile of the patient, the concentration of the active agent, the activity of the composition used for treatment, or a combination thereof. It will also be recognized that the effective dosage of the agent used for treatment or prevention may increase or decrease over the course of a particular treatment or prevention regime. Changes in dosage may be made and revealed as a result by standard diagnostic assays known in the art. In some cases, chronic administration may be required.

[0204] As used herein, the term "combination therapy" is intended to define a therapy that includes the use of a combination of two or more pharmaceutical compositions / agents or therapies. Thus, references in this application to "combination therapy," "combination," and "combined" use of compositions / agents may refer to compositions / agents that are administered as part of the same overall treatment plan. Thus, the dosage or timing of each of the two or more compositions / agents may be different. That is, each may be administered simultaneously or at different times. Thus, the combined compositions / agents may be administered sequentially (e.g., before or after) or simultaneously, either in the same pharmaceutical formulation (i.e., together) or in different pharmaceutical formulations (i.e., separately). Each of the two or more compositions / agents in the combination therapy may also differ with respect to the route of administration.

[0205] The subject (such as a canine or feline subject) may have a particular disease or condition. Alternatively, the subject may be developing a disease or condition, may be at risk of having a disease or condition, may have previously had a disease or condition, or may not have a disease or condition. The disease or condition may be idiopathic or may be associated with autoimmune disease or aging. The disease or condition may include, but is not limited to, chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds. At least one heterogeneous cell composition as described herein is administered to the subject. In some embodiments, at least one heterogeneous cell composition may be administered enterally or parenterally. In some embodiments, at least one heterogeneous cell composition may be administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.In some embodiments, at least one heterogeneous cell composition comprises 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 21 million, 22 million, 23 million, 24 million, 25 million, 26 million, 27 million, 28 million, 29 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 45 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million, or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, , about 10 million, about 11 million, about 12 million, about 13 million, about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 21 million, about 23 million, about 24 million, about 25 million, about 26 million, about 27 million, about 28 million, about 29 million, about 30 million, about 31 million, about 32 million, about 33 million, about 34 million, about 35 million, about 36 million, about 37 million, about 38 million, about 39 million, about 40 million, about 45 million, about 50 million cells, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million cells, or any number of cells in a range defined by any two of the aforesaid numbers. In some embodiments, the at least one heterogeneous cell composition comprises 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million cells, about 30 million cells, about 31 million cells, about 32 million cells, about 33 million cells, about 34 million cells, about 35 million cells, or about 36 million cells, or any number of cells within a range defined by any two of the foregoing cell numbers. In some embodiments, the at least one heterogeneous cell composition may be administered in 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 doses. In some embodiments, each dose can be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 days, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months, or 1, 2, 3, 4, 5 years after the previous dose.In some embodiments, the subject experiences a reduction in symptoms or complete or partial alleviation of the disease following administration of at least one heterogeneous cell composition.

[0206] Also disclosed herein are methods of treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, or wounds in a canine or feline subject in need thereof. In some embodiments, the methods include providing at least one heterogeneous cell composition comprising a mesenchymal progenitor cell population and an epithelial progenitor cell population, the mesenchymal progenitor cells and the epithelial progenitor cells being obtained from or derived from canine or feline uterine tissue, the canine or feline uterine tissue being autologous or allogeneic to the canine or feline subject, and administering the at least one heterogeneous cell composition to the canine or feline subject. In some embodiments, the ratio of mesenchymal progenitor cells to epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or a ratio within a range defined by any two of the foregoing percentages.In some embodiments, the mesenchymal precursor cells comprise at least 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109 ... %, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percentages, or any percentage within a range defined by any two of the aforesaid percentages. In some embodiments, epithelial progenitor cells comprise 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33% of the total cells of at least one heterogeneous cell composition. , 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% percentage, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the at least one heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly, or intrarenally, or any combination thereof. In some embodiments, at least one heterogeneous cell composition is thawed from frozen storage and transferred to a delivery device or container (such as a syringe containing an appropriate buffer, diluent or fluid, such as saline, acetated Ringer's solution, dextrose solution, phosphate buffered saline, or lactated Ringer's solution) prior to administration.In some embodiments, thawing the at least one heterogeneous cell composition from cryopreservation comprises diluting the at least one heterogeneous cell composition to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x. In some embodiments, the at least one heterogeneous cell composition is any one of the heterogeneous cell compositions disclosed herein. In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells that are positive for both vimentin and cytokeratin-18, preferably uterine cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells that are positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine cells), prepared according to Protocol B, C, or D, or a similar protocol.

[0207] Also disclosed herein are methods of treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, or wounds in a canine or feline subject in need thereof. In some embodiments, the methods include providing at least one heterogeneous cell composition comprising a V+ / C- cell population and a V+ / C+ cell population, the V+ / C- cells and the V+ / C+ cells being obtained from or derived from canine or feline uterine tissue, the canine or feline uterine tissue being autologous or allogeneic to the canine or feline subject, and administering the at least one heterogeneous cell composition to the canine or feline subject. In some embodiments, the ratio of V+ / C- cells and V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, or about 99% to about 1%, or a ratio within a range defined by any two of the foregoing percentages.In some embodiments, the V+ / C- cell population comprises 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109 ... 6%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the V- / C+ cell population comprises at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 109%, 109%, 108%. %, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% percentage, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, at least one heterogeneous cell composition is thawed from cryopreservation and transferred to a delivery device or container (such as a syringe containing an appropriate buffer, diluent or fluid, such as saline, acetated Ringer's solution, dextrose solution, phosphate buffered saline, or lactated Ringer's solution) prior to administration.In some embodiments, thawing the at least one heterogeneous cell composition from cryopreservation comprises diluting the at least one heterogeneous cell composition to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x. In some embodiments, the at least one heterogeneous cell composition is any one of the heterogeneous cell compositions disclosed herein. In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells that are positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells that are positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol.

[0208] Also disclosed herein are methods of treating, inhibiting, or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in a canine or feline subject in need thereof. In some embodiments, the method comprises administering at least one cell composition, preferably a heterogeneous cell composition, to the canine or feline subject. In some embodiments, the at least one cell composition (preferably a heterogeneous cell composition) comprises a cell population that is positive for both vimentin and cytokeratin-18. In some embodiments, the at least one heterogeneous cell composition is any one of the heterogeneous cell compositions disclosed herein. In some embodiments, the cell population that is positive for both vimentin and cytokeratin-18 is present at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the heterogeneous cell composition is further defined by a cell population that is positive for both CD44 and CD326. In some embodiments, the population of cells that are both CD44 and CD326 positive is found in a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages. In some embodiments, the heterogeneous cell composition is autologous or allogeneic to the canine or feline subject.In some embodiments, the at least one heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly, or intrarenally, or any combination thereof. In some embodiments, the at least one heterogeneous cell composition is administered after being thawed from cryopreservation and transferred to a delivery device or container (such as a syringe containing an appropriate buffer, diluent, or fluid, such as saline, acetate Ringer's solution, dextrose solution, phosphate buffered saline, or lactate Ringer's solution). In some embodiments, thawing the at least one heterogeneous cell composition from cryopreservation includes diluting the at least one heterogeneous cell composition to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x. In some embodiments, the cell compositions described herein, e.g., cell compositions comprising canine or feline cells that are positive for both vimentin and cytokeratin-18, preferably uterine-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., canine or feline cells that are positive for vimentin or cytokeratin-18 and / or both markers, preferably uterine-derived cells), are prepared according to Protocol B, C, or D, or a similar protocol.

[0209] Also disclosed herein is any of the heterogeneous cell compositions disclosed herein for use in treating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis, or wounds in dogs or cats.

[0210] Also disclosed herein is any of the heterogeneous cell compositions disclosed herein for use in the manufacture of a medicament.

[0211] chronic kidney disease In some embodiments, the disease affecting the animal patient is chronic kidney disease (CKD). Although more common in cats than dogs, CKD can potentially affect any animal, and thus any disclosure regarding CKD provided herein can be applied to cats, dogs, mice, rats, horses, cows, sheep, pigs, and other animals.

[0212] Feline CKD is a common inflammatory degenerative condition that usually occurs in older cats. The overall prevalence is approximately 4%, and the prevalence increases rapidly with age, reaching 30-40% in cats over 10 years of age and may reach as much as 80% after 15 years of age. CKD is the most common cause of death in cats over 5 years of age, with a median mortality rate of at least 13% at 15 years of age. Because the kidneys are responsible for a wide range of physiological processes, from the production of endocrine secretions to the excretion of waste products, the possible clinical symptoms are similarly diverse, but often involve weight loss and anorexia. The underlying cause of CKD varies from individual to individual and is usually unknown. Multiple processes have been proposed, including hypoxia, toxic injury, vaccination, chronic glomerulonephritis, chronic pyelonephritis, upper urinary tract obstruction, or viral infection, such as retrovirus or morbillivirus. Sometimes a cause can be identified, such as polycystic kidney disease, amyloidosis, renal lymphoma, congenital disease, hypercalcemic nephropathy, blunt abdominal trauma, acute kidney injury (e.g., ingestion of specific toxins), or a history of urethral obstruction. Besides age, several other risk factors are associated with CKD, including dehydration, dental disease, degenerative joint disease, or poor physical condition.

[0213] CKD is characterized by chronic renal inflammation and degeneration. Histologically, kidney specimens typically show inflammatory infiltrates, increased extracellular matrix, tubular loss, calcification, and fibrosis, all of which may be more simply described as tubulointerstitial nephritis and renal fibrosis. Macroscopically, the size of the kidney decreases over time.

[0214] The mechanisms of disease progression are multifactorial and poorly understood. Some experts speculate that glomerular filtration rate (GFR), the best measure of kidney function, decreases as a "normal" part of the kidney aging process due to structural changes, fewer functioning nephrons, and impaired tubular function. At the cellular level, these phenomena are associated with telomere shortening, mitochondrial injury, oxidative stress, pro-inflammatory and pro-fibrotic mediators, and a general imbalance between cell proliferation and regeneration and cell death and apoptosis. Some argue that these molecular processes are simply an aspect of natural aging, but others suggest that they may also result from chronic injury. Regardless of the exact etiology, kidneys in CKD patients become more susceptible to injury over time and recover less well after injury. The result is an imbalance toward chronic inflammation and degeneration.

[0215] At the cellular level, direct causes of injury can include hypoxia, proteinuria, angiotensin II, hyperglycemia, or oxidative stress. Injury stimulates changes in gene expression and recruitment of inflammatory cells such as T cells and macrophages, leading to increased levels of profibrotic and proinflammatory mediators. Myofibroblasts also arise from differentiation of fibrocytes, endothelial cells, and tubular epithelial cells, or through pericytes. This latter pathway contributes to the loss of the interstitial capillary network, promoting oxidative stress, hypoxia, fibrosis, and further injury. This creates a vicious cycle of disease progression.

[0216] The list of molecular abnormalities associated with feline CKD is long, but includes abnormal levels of growth factors, cytokines, and chemokines, including, but not limited to, interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), or reactive oxygen species.

[0217] According to the International Society of Feline Medicine, led by a panel of leading experts, the efficacy of treatments for CKD should be considered based on their ability to improve clinical signs that determine quality of life. Treatments can also prolong life by slowing the progression of the underlying disease, but this is generally considered a secondary measure of efficacy. Because of this paradigm, a fundamental understanding of the clinical signs of CKD will help interpret the studies.

[0218] As renal function declines, many physiological disturbances occur, including accumulation of toxins in the blood, decreased red blood cell production, electrolyte imbalance, dehydration, metabolic acidosis, gastrointestinal malabsorption, systemic inflammation, increased energy requirements, impaired immune function, hypertension, and protein loss. The effects of these abnormalities vary from animal to animal and can change over time.

[0219] Clinical signs associated with these changes include chronic weight loss, anorexia, nausea, vomiting, diarrhea, constipation, increased water intake and urination, lethargy, foul-smelling breath (bad breath), oral ulcers, and reduced hair coat. If the disease is severe enough to induce anemia, the gums may be pale pink or even white.

[0220] Hypertension can result in a variety of sequelae, including retinal hemorrhages that can cause permanent vision loss, cardiac abnormalities such as left ventricular hypertrophy (thickening of the heart), arrhythmias, heart murmurs, and epistaxis (nosebleeds), and neurological deficits such as mental abnormalities, seizures, behavioral changes, and vestibular signs (loss of balance).

[0221] CKD increases the risk of urinary tract infections (UTIs), possibly due to decreased urine concentration. UTIs that affect only the lower urinary tract may be asymptomatic or may cause a variety of clinical signs, including hematuria (blood in the urine), frequency (frequent urination), dysuria (painful urination), voiding (voiding in an inappropriate place), and / or painful dysuria (burdening). More seriously, UTIs can affect the kidneys themselves (pyelonephritis), as well as causing flank pain, fever, and extreme lethargy.

[0222] CKD is defined by a decline in renal function for at least 3 months. The gold standard for measuring renal function is the glomerular filtration rate (GFR), which is defined by the amount of plasma filtered by the glomerulus per minute and is a direct measure of kidney volume. The most accurate method of measuring GFR involves serial measurements of renally excreted substances. Ideally, such substances are non-toxic, minimally metabolized, minimally bound to plasma proteins, and excreted exclusively by the kidney. One example is the iodine-based contrast agent iohexol. To measure GFR, a single injection of iohexol is administered, followed by at least two post-injection serum samples taken at least 1 hour apart, although more samples taken over a longer period of time will give more accurate results. By measuring the amount of iohexol in these serial samples, the iohexol clearance rate can be determined, which is directly related to GFR. The clearance rate of iohexol, and therefore the GFR, can then be compared to the normal range to provide a reading of normal versus abnormal renal function. GFR can also be measured using injection of contrast agents and nuclear scintigraphy, although this technique is generally reserved for research use only.

[0223] Infusion with sequential measurements is the clinical gold standard for determining GFR, but is rare in clinical practice. Instead, most clinicians rely on a combination of serum creatinine and urine concentration, as recommended by the International Society of Feline Medicine (ISFM) and the International Renal Interest Society (IRIS). Creatinine is used for similar reasons as iohexol, with the notable exception that creatinine is naturally produced by the body (a by-product of muscle metabolism) and excreted via glomerular filtration, with minimal tubular secretion or reabsorption. In theory, a decrease in GFR will cause serum creatinine to rise above the normal range. Urine specific gravity (a measure of urine concentration) is used because it gives a rough indication of the kidney's ability to concentrate waste products. When that ability is diminished due to loss of function, urine becomes more dilute.

[0224] To complicate matters, both serum creatinine and urine specific gravity can be above the normal range for a variety of other reasons not related to the kidney. For example, creatinine can be increased by above-average muscle mass, and urine specific gravity can be low (i.e., urine is diluted) simply because the animal has recently drunk a large amount of water (among other reasons). Thus, both serum creatinine and urine specific gravity must be interpreted in light of other available data, which may include clinical signs, radiological findings, kidney biopsy, and other laboratory results, such as blood urea nitrogen (BUN) concentration and urine protein level, both of which may be elevated in CKD. CKD can also be substaged by proteinuria levels and systolic blood pressure levels.

[0225] The IRIS guidelines classify CKD into four stages based on serum creatinine and clinical signs, as shown in Table 1. (Azotemia refers to abnormally high levels of waste products in the blood, such as creatinine and BUN.) [Table 1]

[0226] It is worth reemphasizing that serum creatinine is a practical but imperfect measure of GFR, not only because it can be affected by nonrenal processes, but also because serum creatinine does not rise until at least 75% of the nephrons are lost, making creatinine an insensitive biomarker of kidney pathology. In other words, although IRIS stage 2 CKD is defined as "mild azotemia," the pathological reality of stage 2 disease is anything but mild, since three-quarters of kidney function has already been lost.

[0227] The insensitivity of creatinine and the impracticality of serial GFR measurements with agents such as iohexol have led to the consideration of alternative measures of GFR. A potential alternative (or supplement) to creatinine is symmetric dimethylarginine (SDMA), which may be more sensitive than creatinine but may also be affected by nonrenal processes. SDMA is now commercially available and is used by some practitioners, particularly as a means of improving early detection of disease.

[0228] Apart from dietary interventions, which have been shown to simultaneously improve quality of life (QOL) and life span, most treatments aim at managing clinical signs that impair QOL (such as antiemetic medications for gastrointestinal problems or fluids for dehydration).

[0229] A wide range of therapies are used to treat CKD, depending on the stage of the disease and the individual's clinical symptoms.

[0230] The mainstay of treatment is dietary modification, typically through prescription diets that are reduced in phosphorus, protein, and sodium and increased in caloric density, potassium, B vitamins, omega-3 fatty acids, and antioxidants. Notably, dietary therapy is the only existing treatment shown to improve both quality of life and life span.

[0231] For anorexia, nausea, and vomiting, many cats are also treated with antiemetic and antiemetic drugs, as well as appetite stimulants. Two commonly used drugs are maropitant (an antiemetic) and mirtazapine (an antiemetic, antiemetic, and appetite stimulant).

[0232] Dehydration is generally managed with subcutaneous saline-based fluids, often administered by the owner at home, with frequency and amount depending on the size of the animal and the severity of the disease, although intravenous fluids are used more frequently during acute episodes.

[0233] The remaining treatments depend on the specific disease symptoms. For example, anemic cats can be treated with darbepoetin, a synthetic form of the hormone erythropoietin, which stimulates red blood cell production in the bone marrow. Cats with high blood pressure are given antihypertensive drugs such as amlodipine, and cats with UTIs are given antibiotics, ideally based on urine cultures. Kidney transplants and hemodialysis are possible for cats in specialized facilities, but are rarely performed due to financial and ethical concerns.

[0234] As a chronic inflammatory condition, feline CKD may be a therapeutic target for mesenchymal stem cells (MSCs). MSCs have shown promise in veterinary therapy for other degenerative diseases, such as osteoarthritis and keratoconjunctivitis sicca in dogs. However, results on the efficacy of MSCs in cats with naturally occurring CKD are limited, and some preparations have caused acute fluid reactions.

[0235] In some embodiments, CKD may be treated with any one or more of the uterus-derived regenerative compositions or cell compositions disclosed herein. In some embodiments, the uterus-derived regenerative compositions or cell compositions, such as cell compositions comprising vimentin and cytokeratin-18 positive dog or cat cells, preferably uterus-derived cells, and / or cell compositions comprising any one or more of the heterogeneous cell populations described herein (e.g., vimentin or cytokeratin-18 and / or both marker positive dog or cat cells, preferably uterus-derived cells), may be prepared according to protocol B, C, or D, or a similar protocol. EXAMPLES

[0236] Certain aspects of the above-described embodiments are disclosed in further detail in the following examples, which are not intended to limit the scope of the disclosure in any way. Those skilled in the art will recognize that many other embodiments are within the scope of the present invention, as described herein above and as claimed.

[0237] Example 1. Uterine Tissue Processing Protocol A ("Protocol A") Uterine samples were obtained from mammals such as cats or dogs through a donor program. Adipose tissue was removed from the uterine tissue samples.

[0238] 1. The uterine body and horn tissue are opened along their longitudinal axis, cut into strips along their longitudinal axis, and the strips are finely minced into tissue pieces of approximately 2 mm x 2 mm.

[0239] 2. Transfer the minced tissue to a centrifuge-safe container, add DE 10 Collagenase Dissociation Reagent, and place the container in a dry incubator on a platform rocker at 37° C. for 40 minutes to digest the tissue.

[0240] 3. At the end of the incubation step, digestion is stopped by adding tissue culture medium containing 10% FBS.

[0241] 4. Fill the container with phosphate buffered saline (PBS) and centrifuge the container.

[0242] 5. Remove the supernatant, leaving the cell pellet.

[0243] 6. Add a small amount of PBS and resuspend the pellet.

[0244] 7. Pass the suspension through a series of cell strainers: 100 μm, 70 μm, and 40 μm strainers.

[0245] 8. Collect the cell suspension following the final cell strainer step, add PBS to bring the volume to 35-40 mL, and centrifuge.

[0246] 9. Remove the supernatant, leaving the cell pellet.

[0247] 10. Add a small amount of PBS and resuspend the pellet.

[0248] 11. Centrifuge again, remove the supernatant and resuspend the pellet in 3-4 mL PBS.

[0249] 12. Count the number of cells in the cell suspension.

[0250] 13. Add sufficient tissue culture medium and transfer the cell suspension to an appropriate number of tissue culture flasks depending on total cell number and seeding density.

[0251] 14. Place the flask in an incubator under standard conditions and grow the culture through 1, 2, 3, and 4 passages or days.

[0252] Cell preparation samples were taken and cryopreserved (A-PCF) prior to culture step 14 to assess composition at the end of processing protocol A. Adherent cells were cultured according to standard protocols and samples at each culture interval were taken and cryopreserved on days 1, 2, 3, and 4 (A-D1, A-D2, A-D3, and A-D4, respectively). Culture may continue and sampling may be further repeated to obtain additional cell compositions and samples on days 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and beyond.

[0253] Example 2. Uterine Tissue Processing Protocol B ("Protocol B") Uterine tissue samples were obtained from mammals such as cats or dogs through a donor program. Adipose tissue was removed from the uterine tissue samples.

[0254] 1. The uterine body and horn tissue are opened along their longitudinal axis, cut into strips along their longitudinal axis, and the strips are finely minced into tissue pieces of approximately 3 mm x 3 mm.

[0255] 2. Transfer the minced tissue to a container and add Defined Concentration (DE10) Collagenase (Vitacyte, #011-1110, a combination of collagenase and neutral protease) Dissociation Reagent and incubate for 60 minutes at 37°C to digest the tissue. Every 10 minutes, remove the container from the incubator, shake the container 40 times to disperse the solution, and return the container to the incubator.

[0256] 3. At the end of the incubation step, digestion is stopped by adding GIBCO DMEM tissue culture medium containing 10% fetal bovine serum (FBS).

[0257] 4. Add additional tissue culture medium to dilute the cell suspension.

[0258] 5. Transfer the contents of the digestion vessel into an appropriate number of T-225 culture flasks based on grams of tissue processed (eg, 0.1 g of tissue per T-225 culture flask).

[0259] 6. Add enough tissue culture medium to each flask and add human FGF-2 to a final concentration of 8 ng / mL (e.g., a total of 360 ng FGF-2 in 45 mL of medium in a T-225 flask) and place flasks in a 37° C., 5% CO2 incubator.

[0260] 7. Incubate under standard conditions to grow the cells through 1, 2, 3 and 4 passages or days.

[0261] Cell preparation samples were taken prior to culture step 7 and stored frozen (B-PCF) to assess composition at the end of processing protocol B.

[0262] Since samples prepared from tissues processed using this protocol contained undissociated tissue particles, cells were cultured in the following manner:

[0263] 1. One day after incubation from the processing in step 1 above (day 1, D1), non-adherent cells and tissue fragments were harvested by removing the culture medium while leaving the adherent cells behind.

[0264] 2. Adherent cells were detached from the plastic by standard protocols known in the art and cryopreserved (sample designated B-D1).

[0265] 3. The collected supernatant and tissue pieces were placed in a new flask and incubated overnight.

[0266] 4. Steps 1-3 were repeated to generate samples on days 2, 3, and 4 (B-D2, B-D3, and B-D4, respectively).

[0267] Another flask was established on day 0 (step 7) and harvested on day 4, but no harvest step was performed on the previous days (B-D4-1). Steps 1-3 can be further repeated to obtain additional cell compositions and samples on days 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, and beyond.

[0268] Example 3. Evaluation of Protocol A and Protocol B using canine uterine tissue Canine uterine tissue was obtained from donors and weighed. Half of the donor tissue was processed according to protocol A and the other half was processed according to protocol B. In this example, only the day 0 PCF (A-PCF and B-PCF) samples and the day 4 samples (A-D4 and B-D4-1) were analyzed.

[0269] Flow Cytometry Protocol (Example 3) All cell preparations were harvested from cryovials and stained with CD44 and CD90 reagents using standard protocols. Live / dead stain was added to all preparations.

[0270] Starting with the input cell population, the cell population, excluding swollen cells and debris, was determined based on side scatter. From this, a "Live / Dead vs Forward Scatter" plot was generated to determine the live cell population. Live cell population was examined by CD44 and CD90 staining.

[0271] Results (Example 3) Sample gates are shown in Figure 1. Gates were set based on side scatter to exclude debris and damaged cells. In the B-D4-1 panel, two cell populations were evident, whereas in the A-D4 panel, three cell populations were evident, with the third cell population located near the origin.

[0272] The distribution of live / dead cells is shown in Figure 2. The viability of cultured cells was reduced compared to that of PCF. This may reflect the mass death of cells that did not adhere to the plastic of the tissue culture flask or that may not have been supported by the culture medium used. As more easily visualized in the contour plots in Figure 2, there were two distinct live cell populations in both methods (i.e., there are two distinct contour regions within the live cell gate box). There was also a shift in the size and / or shape of cells obtained in the D4 cultures compared to the size / shape distribution evident in the PCF samples. This is seen by a shift to the right along the x-axis in the D4 plot relative to the cell distribution in the PCT plot, which was more tightly clustered near the origin.

[0273] Contour plots of CD90 / CD44 staining for PCF and D4 samples are shown in Figure 3. The percentages of cells in the upper right and lower right quadrants change significantly from PCF levels to D4 levels for both protocols.

[0274] As shown in Table 2, the number of viable cells in the PCF samples obtained with the protocols outlined above was 5.1 × 10 for Protocol A and 5.1 × 10 for Protocol B. 6 , 4.3 x 10 in Protocol B. 6 After 4 days of culture (D4 sample), the cell count was 0.45 × 10 6 , 5.3 x 10 in Protocol B. 6 The percentages shown in Table 2 reflect the values ​​after subtraction of the unstained signal (due to autofluorescence) for the CD44+ / CD90+ and CD44+ / CD90- stained populations in A-PCF, B-PCF, A-D4, and B-D4-1. However, the autofluorescence signal in the A-D4 sample was estimated due to the lack of control cells for this sample. [Table 2]

[0275] Table 3 shows the fold change in the percentage of cells positive for the indicated CD markers between D4 and PCF time points for each protocol. For example, the percentage of CD44+ / CD90+ cells was 3.9-fold higher in A-D4 versus A-PCF samples. A fold change of greater than 1 indicates enrichment of CD marker-positive cells as a result of the culture.

[0276] Table 4 shows the percentage frequency of cells reacting with the indicated CD marker sets in each process for PCF and D4 samples. For example, the percentage of CD44+ cells in A-PCF samples is 5.5-fold higher compared to the percentage of CD44+ / CD90+ cells in A-PCF samples. [Table 3] [Table 4]

[0277] Conclusion (Example 3) The cell distribution shown in Figure 1 appears similar in the PCF samples obtained with both protocols (Protocol A and Protocol B). However, the contour plot of B-D4-1 shows that two cell populations dominate, whereas the contour plot of A-D4 shows that in addition to the two cell populations, there is an additional region of different cell populations near the origin.

[0278] As can be seen in Figure 2, cells found in PCF samples generated by both Protocol A and Protocol B show tight clustering in the scatter plot. However, cells cultured to D4 in both protocols change in shape and size as evidenced by the shift of cells along the x-axis (forward scatter-A). These changes are likely due to the effects the cells are subjected to when cultured, indicating a shift in cell morphology from that present in PCF samples obtained by digesting uterine tissue.

[0279] Cells obtained from both protocols responded to CD90 and CD44 markers in a seemingly similar pattern for both PCF and D4, as shown in FIG.

[0280] As shown in Table 2, in PCF samples, protocol B resulted in a higher percentage of the indicated CD markers.

[0281] As shown in Table 2, culturing PCF samples until D4 revealed that the percentages of the indicated CD markers were not consistently higher with protocol B. In fact, the percentage of CD44+ / CD90- marker positive cells was higher with protocol A.

[0282] In general, D4 samples had a higher percentage of cells positive for the indicated CD markers compared to PCF samples, and the results are shown in Table 3 as fold increase in the percentage of cells positive for the indicated CD markers at D4 versus PCF for both Protocol A and Protocol B.

[0283] In this example, one CD marker set was used: CD44 / CD90. The percentage of cells expressing both markers (double positive - upper right quadrant of Figure 3) or only one marker (single positive - lower right quadrant of Figure 3) is shown in Table 2. The percentage change of single positive cells relative to double positive cells for each sample type is shown in Table 4. For example, the percentage of single positive cells (CD44+ / CD90-) in A-PCF is 5.5 times higher compared to the percentage of double positive cells (CD44+ / CD90+).

[0284] The percentage of CD44 single positive cells (CD44+ / CD90-) was higher in A-PCF and B-PCF compared to the percentage of double positive cells (CD44+ / CD90+) and was higher compared to the percentages in A-D4 and B-D4-1 samples (A-PCF 5.5-fold vs. A-D4 4.2-fold, B-PCF 6.2-fold vs. B-D4-1 2.1-fold). Furthermore, there was a 1.3-fold difference in the level of CD44 single positive cells between A-PCF (5.5-fold) and A-D4 (4.2-fold), and a 4.1-fold difference in the level of CD44 single positive cells between B-PCF (6.2-fold) and B-D4-1 (2.1-fold).

[0285] Example 4. Further evaluation of Protocol A and Protocol B using canine uterine tissue Canine uterine tissue was obtained from a donor (different from the donor in Example 3) and weighed. Half of the donor tissue was processed according to protocol A and the other half was processed according to protocol B. In this example, cells from days 0, 1, 2, 3 and 4 of both protocols (A-PCF, A-D1, A-D2, A-D3, A-D4 and B-PCF, B-D1, B-D2, B-D3, B-D4) were analyzed.

[0286] Flow Cytometry Protocol (Example 4) All cell preparations were harvested from cryovials and stained with CD44 and CD90 reagents using standard protocols. Live / dead stain was added to all preparations.

[0287] Starting with the input cell population, the cell population, excluding swollen cells and debris, was determined based on side scatter. From this, a "Live / Dead vs Forward Scatter" plot was generated to determine the live cell population. Live cell population was examined by CD44 and CD90 staining.

[0288] In addition, staining of cell preparations was performed to detect cytokeratin and vimentin, which required a separate cell aliquot. The protocol included fixing the cells with True-Nuclear Transcription Factor Buffer kit (BioLegend, #424401), followed by treatment of the cells with permeabilization buffer, and then incubation of the permeabilized cells with appropriate antibodies specific for cytokeratin or vimentin. CD90 / CD44 was also assessed on fixed cells.

[0289] Results (Example 4) Some preparations were not available for evaluation due to insufficient cell yield; these are indicated in the tables as "NA" or noted directly in the figures. This overview focuses on results from PCF and D1-4 samples from Protocol B, and A-PCF or A-D4 samples from Protocol A (fixed / permeabilized preparations only), when available.

[0290] Sample gates are shown in FIG. 4. Gates were set to exclude debris and damaged cells based on side scatter as shown in the A-PCF and B-PCF plots. There were insufficient samples to evaluate A-D3, A-D4, or B-D4. There is evidence of two major cell populations in the B-D3 plot, but a very small population at the higher side scatter levels. Donor-to-donor variability may be responsible for the presence of two populations with a "third" very small population in the B-PCF sample derived from processing of the donor samples in this example. In contrast, only two populations were prominently shown for B-D4-1 in the donor samples in Example 3.

[0291] The live / dead cell distribution is shown in FIG. 5. In both protocols, there were two distinct live cell populations (i.e., two distinct contour regions within the live cell gate box). There is also a shift in the size and / or shape of the cells obtained in the B-D3 sample compared to the size / shape distribution revealed in the B-PCF sample. This is seen by a shift to the right along the forward scatter axis (x-axis) in the B-D3 plot, relative to the cell distribution in B-PCF, which was more tightly clustered near the left axis. The patterns observed in A-PCF and B-PCF / B-D3 are similar to the Live / Dead results shown above in Example 3.

[0292] Contour plots of CD90 / CD44 staining for A-D4, B-PCF, B-D1, B-D2, B-D3, and B-D4 samples are shown in Figure 6. The percentages of cells in the upper right and lower right quadrants change significantly from levels in B-PCF to those in B-D3 and B-D4, a pattern previously observed in the Protocol B samples in Example 3.

[0293] Cytokeratin / vimentin (C / V) staining was obtained in A-D4, B-PCF, B-D1, B-D2, B-D3, and B-D4 samples, as shown in Figure 7. There were not enough A-PCF cells available to evaluate C / V staining.

[0294] As shown in Table 5, the protocol outlined above yielded very low numbers of viable cells in both A-PCF and B-PCF. Low cell numbers were also noted in B-D3. The percentages of CD44 / CD90 set were similar, but not identical, to the results observed in Example 3. [Table 5]

[0295] Since only A-PCF (due to poor yield), Table 6 shows the fold change in the percentage of cells positive for the indicated CD markers for B-PCF and B-D3. Table 7 shows the fold change in single positive CD marker levels versus double positive marker levels. [Table 6] [Table 7]

[0296] Flow cytometry results for B-PCF, -D1, -D2, -D3, and -D4, and A-D4 for reactivity with cytokeratin and vimentin (C / V) are shown in Table 8 for the percentage of single positive V+ cells (Figure 7, lower right quadrant) and double positive C+ / V+ cells (Figure 7, upper right quadrant) present in the preparations. The ratio of single positive (V+) to double positive (C+ / V+) cell levels varied from about 42-fold for B-PCF to 1.03-fold for B-D4. There are some C+ / V+ cells present in the A-D4 preparation, but the ratio of V+ to C+ / V+ cell percentages is 8.5-fold. [Table 8]

[0297] Conclusion (Example 4) The cell distribution shown in Figure 4 appears to be similar in the PCF samples obtained with both protocols. However, the contour plot of B-D3 shows that two cell populations dominate, with a very small population at the high side scatter value of B-D3. Comparison between A-PCF and A-D3 is not possible.

[0298] As can be seen in Figure 5, cells found in PCF samples generated by both protocols show tight clustering in the scatter plot. However, cells cultured to D3 in Protocol B change in shape and size as evidenced by the shift of cells along the x-axis (forward scatter-A). These changes are likely due to the effects the cells are subjected to while being cultured, indicating a shift in cell morphology from that present in PCFs obtained by digesting tissues.

[0299] Cells obtained with both protocols responded to CD90 and CD44 markers in a seemingly similar pattern for both PCF samples, as shown in FIG. 6 (CD90 / CD44).

[0300] As shown in Table 5, in contrast to the results of Example 3, the percentages of the indicated CD markers were higher in PCF samples by Protocol A compared to the values ​​in PCF samples by Protocol B. This is likely due to donor-to-donor variability.

[0301] As shown in Table 6, both fold change results revealed that the percentage of cells positive for the indicated CD markers was higher in the B-D3 sample compared to the B-PCF sample, which is similar to the results in Example 3.

[0302] In this example, one CD marker set was used: CD44 / CD90. The percentage of cells expressing both markers (double positive - upper quadrant in Figure 6) or only one marker (single positive - lower right quadrant in Figure 6) is shown in Table 5. The percentage change in single positive cells relative to double positive cells for each sample type is shown in Table 7. The fold shift in PCF was higher in Example 3 than D4, whereas in this example it was the opposite. Donor variability is likely the cause of the difference in patterns.

[0303] The reactivity for cytokeratin / vimentin (C / V) is shown in Figure 7 for material processed by protocol B from B-PCF to B-D1, -D2, -D3, and -D4. Among the cells present in B-PCF, there are low levels of C+ / V+ double positive cells (2.24%, upper right quadrant), and a significant portion is positive for vimentin only (93.1%, lower right quadrant). Within the vimentin only positive cell population (lower right quadrant), there are two populations, one of which can be considered C-deficient / V+, while the other shows a low signal for cytokeratin, but should also be considered negative. The decrease in the C-deficient / V+ population over time may suggest that these cells are nonviable or transform in culture. Also, there are virtually no cells in B-PCF that are positive for cytokeratin only (upper left quadrant), and this persists until B-D4.

[0304] The cellular pattern of Protocol B shifts during culture, as shown in Figure 7, with increasing levels of C+ / V+ cells, until at D4 the percentage of C+ / V+ cells is virtually identical to that of exclusively V+ cells. This progression is illustrated by the ratios shown in Table 8.

[0305] In contrast, in the A-D4 sample shown in Figure 7, there is a clear difference in the levels of vimentin-only positive and cytokeratin / vimentin double positive cells between cells processed by Protocol B and Protocol A after 4 days in culture, as the levels of V+ cells alone dominate over the levels of C+ / V+ cells, with a ratio of approximately 8.5.

[0306] The plots in Figure 7 for B-D1, -D2, -D3, and -D4 cultures were plated with tissue and cells on day 0 (D0), and therefore essentially reflect independent aspects of the cells present in the cultures on each day. The increase in C+ / V+ cell levels over time in culture may reflect the emergence of additional cytokeratin-positive epithelial progenitor cells from tissue fragments presented in the protocol B method. As shown in Table 8, C+ / V+ cells are present in the A-D4 cultures, but at a significantly different ratio compared to the V+-only cell levels.

[0307] Example 5. Characterization of feline uterine cell compositions Donor feline uterine tissue was processed according to protocol B. The resulting cell population was expanded for at least four passages. The cells were harvested, fixed, and permeabilized with Triton-X 100 buffer for 15 minutes according to standard procedures known in the art. Permeabilized cells were stained with anti-cytokeratin-18 antibody conjugated with FITC and anti-vimentin antibody conjugated with Alexa Fluor 647. Figure 8 shows the flow cytometry plot of these stained cells, showing the presence of C+ / V+ double positive cells (upper right quadrant), as well as V+ only single positive cells (upper left quadrant) and C+ only single positive cells (lower right quadrant). As shown in Figure 8, the ratio of V+ cells to C+ / V+ cells is 0.74.

[0308] The feline uterus-derived cell population at passage 4 includes cuboidal (i.e., epithelial progenitor cells) and spindle-like (i.e., mesenchymal progenitor cells) cells (Figure 9A). Feline uterus-derived cells at passage 4 were grown on cell culture slides, fixed, permeabilized, and incubated with (1) anti-vimentin-FITC and DAPI (Figure 9B), (2) anti-cytokeratin-18-FITC and DAPI (Figure 9C), and (3) anti-cytokeratin-18-FITC and anti-vimentin-Alexa Fluor 594 (Figure 9D). These images highlight the presence of heterogeneous cell populations when processed with Protocol B.

[0309] Example 6. Treatment of feline CKD with feline uterine-derived regenerative cells The use of allogeneic feline uterine-derived regenerative cells (URCs) as a treatment for chronic kidney disease (CKD) in cats was investigated. The efficacy of URCs in improving renal function in unilaterally nephrectomized cats with azotemia and reduced glomerular filtration rate associated with CKD was evaluated. As used herein, URCs includes heterogeneous cell compositions produced according to Protocol B, Protocol C, Protocol D, or similar protocols, which include both vimentin-only single positive cell populations and vimentin / cytokeratin double positive cell populations (e.g., mesenchymal progenitor cell populations and epithelial progenitor cell populations). In some embodiments, the ratio of vimentin-only single positive cells to vimentin / cytokeratin double positive cells is approximately 50%:50% or about 50%:50%, although this ratio may deviate by ±20% (e.g., about 40%:60% or about 60%:40%, or any ratio therebetween).

[0310] Study design The study included 18 nephrectomized cats (15 females and 3 males) with renal failure that met the inclusion criteria. All cats were dosed with allogeneic feline uterine-derived regenerative cells ("veterinary investigational product", "IVP") (30 million (M) cells) via a single intravenous (IV) infusion at a rate of one million cells per minute (1 mL / min) with an infusion rate of 0.5 mL / min for the first 5 minutes. The IVP was administered twice to all cats (days 0 / 1 and 14 / 15). As described above, the IVP comprises a heterogeneous cell composition prepared according to Protocol B, Protocol C, Protocol D, or a similar protocol, and is essentially comprised of a vimentin-only single positive cell population and a vimentin / cytokeratin double positive cell population.

[0311] The primary variables measured were plasma creatinine and glomerular filtration rate (GFR, as determined by iohexol clearance test). An individual cat was considered to have been efficacious on IVP if at least 50% of the cats experienced a 20% decrease in plasma creatinine levels or a 20% increase in GFR during the course of the study. Furthermore, to be considered successful, at least 50% of all cats had to demonstrate either an effective decrease in creatinine or an increase in GFR. Blood samples were taken on days -7, 7, 13, 29, 56, 97, 120, 149, and 181 to measure clinical pathology parameters. Blood samples taken for GFR measurements were obtained pre-dose and 2, 3, and 4 hours after iohexol administration on days -5, 13, and 28, and 2, 3, and 4 hours after iohexol administration on days 57, 99, 121, 150, and 182.

[0312] Secondary variables included urine specific gravity and total urinary protein analysis (samples taken on days -7, 7, 14, 28, 56, 97, 120, 149 and 181 were analyzed), as well as water and food intake (measured at weekly intervals).

[0313] An IVP was to be considered safe if no serious adverse events attributable to the IVP were observed for each cat. In addition, the product had to be well tolerated in cats with a low incidence of adverse events, in terms of the number of animals affected and the categories of events that occurred.

[0314] Results (Example 6) Key variables

[0315] Mean plasma creatinine was significantly decreased compared to baseline only on day 28 (P=0.0283). A 20% decrease in this parameter was observed in 4 animals on this day. Mean values ​​for GFR were significantly increased compared to baseline on days 13, 28, 57, 99, 121 and 182 (P<0.0001 for days 13 to 99 inclusive, P=0.0029 and P=0.0225 for days 121 and 182, respectively). More than 50% of cats showed a 20% increase in GFR on days 13, 28, 57 and 99.

[0316] Second variable

[0317] Statistical analysis showed that food intake was significantly increased on days 14, 42, 70, 84, 112, 126, 140 and 154 compared to baseline (P<0.05). Water intake was also significantly increased from days 42 to 168 (including days 42 and 168) compared to baseline (P<0.05). Urine analysis showed that, compared to baseline, urine specific gravity was significantly decreased only on day 13 (P<0.0001), urine protein was significantly increased only on day 181 (P=0.0221), urine creatinine was significantly decreased on days 7, 13, 28, 56, 97, 120 and 181 (P<0.05), and urine protein / creatinine ratio was significantly increased on days 120, 149 and 181 (P<0.05).

[0318] Preparation of test articles Test articles (enough for dosing on any given day) were removed from the dry shipper on the day of dosing. The CellSeal® vials containing the test articles were kept in a water bath maintained at 37°C (± 1°C) for 3-5 minutes until thawed. The cell suspension (10 x 10 6A 3 or 5 mL syringe and 18 gauge needle were used to remove 10 cells / mL. A sufficient amount of cells was placed into a syringe containing sufficient 3.3% trehalose in 0.9% saline to give 1 x 10 URC per mL. Immediately prior to dosing each cat, a quorum of the prepared test article suspension in a 60 mL syringe was mixed by inversion several times and then loaded into a syringe pump.

[0319] Test substance administration Cats were dosed with IVP via a single IV infusion. IVP dosing occurred on days 0 / 1 and 14 / 15.

[0320] Test articles were administered via IV infusion using a syringe pump. All cats received test articles (approximately 30M cells) at a rate of approximately one million cells per minute (approximately 1 mL / min). For the first 5 minutes of the infusion, cells were administered at half the rate (i.e., approximately 0.5 mL / min). Since there were no adverse events, cells were then infused at the normal rate (1 mL / min).

[0321] clinical chemistry Blood was drawn from each cat on the following schedule: once during acclimation on day -7, and on days 7, 13, 29, 56, 97, 120, 149 and 181.

[0322] On any given day, blood was collected in a fasting state. Blood was collected from the jugular vein by direct venipuncture using an appropriately sized needle and syringe. Approximately 2 mL of blood was collected and immediately transferred to an appropriately labeled blood collection tube.

[0323] Blood collection tubes used included the following:

[0324] 1x ethylenediaminetetraacetic acid (EDTA-0.7mL),

[0325] 1x lithium heparin (1.3 mL),

[0326] The EDTA and lithium heparin tubes were gently inverted to ensure proper mixing of the blood and anticoagulant. The lithium heparin tubes were centrifuged at 3000 rpm for 10 minutes and the plasma was removed for analysis.

[0327] Measurement of glomerular filtration rate using iohexol Glomerular filtration rates were measured using an iohexol clearance test on the following schedule: once during acclimation (day -5) and on days 13, 28, 57, 99, 121, 150 and 182.

[0328] Cats were fasted for at least 6 hours prior to the procedure. A dose of 300 mg iodine / kg (OMNIPAQUE®, iohexol injection, Nycomed Inc, Princeton, NJ) was administered via IV infusion over approximately 10 seconds. Blood samples were obtained prior to infusion and at 2, 3, and 4 hours (± 2 minutes) after iohexol administration on days -5, 13, and 28, and at 2, 3, and 4 hours (± 2 minutes) after iohexol administration on days 57, 99, 121, 150, and 182. Approximately 2.5 mL of blood was collected by jugular vein puncture into one standard serum tube. The standard serum tube was allowed to clot for at least 30 minutes and then centrifuged at 3000 rpm for 10 minutes. Serum was divided into two approximately equal aliquots and transferred to two labeled microtubes. Serum was transferred to a cryopreservation chamber (≦-70°C) within 90 minutes of collection. Samples were measured for iohexol clearance using a validated ICP / MS assay.

[0329] Urine specific gravity and protein / creatinine ratio Urine was collected from each cat on the following schedule: once during acclimation on day -7, and on days 7, 14, 28, 56, 97, 120, 149 and 181.

[0330] Approximately 1 mL of urine was collected by either free catch / catheterization / cystocentesis and transferred to a tube containing no additives. For urine collections performed by either catheterization or cystocentesis, cats were sedated with propofol to allow urine collection. Urine specific gravity was measured using a refractometer within 3 hours of urine collection. After specific gravity measurement, samples were analyzed for protein / creatinine ratio.

[0331] body weight Each cat's body weight was measured once during acclimation (day -7) and then every 4 weeks ± 1 day starting on day 5 using a calibrated weighing scale.

[0332] Feeding Programs and Schedules Cats were fed standard commercial cat food at the recommended rates, i.e., approximately 300 g / cat / day from Study Day -7 to Study Day 9, and approximately 400 g / cat / day from Study Day 10 to Study Termination. For blood collection (clinical pathology) days, feeding was discontinued the evening before sample collection.

[0333] The amount of food offered was weighed and recorded during the following time periods: days -3-3, 10-17, 24-31, 38-45, 52-59, 66-73, 80-87, 94-101, 108-115, 122-129, 136-143, 150-157, and 164-171. The amount of food not consumed from the previous day was removed from each cat's enclosure, weighed, and recorded. Diets met or exceeded the current National Research Council requirements for energy, protein, vitamins, and minerals for the species and age class.

[0334] Water Supply and Water Programmes Cats had free access to water via stainless steel bowls throughout the study. The amount of water provided (approximately 300 ml per day) was weighed and recorded during the following periods: days -3-3, 10-17, 24-31, 38-45, 52-59, 66-73, 80-87, 94-101, 108-115, 122-129, 136-143, 150-157, and 164-171. The amount of water remaining from the previous day was removed from each cat's enclosure, weighed, and recorded.

[0335] Serum collection for biomarker analysis For potential serum biomarker analysis, blood was collected from each cat as follows: once during acclimation on day 7, and on days 7, 13, 29, 56, 97, 120, 149, and 181. For potential urinary biomarker analysis, urine was collected from each cat as follows: once during acclimation on day 7, and on days 7, 14, 28, 56, 97, 120, 149, and 181.

[0336] Approximately 2 mL of blood was collected using an appropriately sized needle and syringe and transferred to an appropriately labeled serum separator tube (SST). The serum separator tube was allowed to clot for at least 30 minutes and then centrifuged at 3000 rpm for 10 minutes at room temperature. Serum was divided into approximately 150 μL aliquots into two appropriately labeled polypropylene microtubes and frozen at ≦−70° C. within 90 minutes of collection. Serum samples were analyzed for biomarkers.

[0337] Approximately 1 mL of urine was collected by cystocentesis / catheterization or free catch and transferred to chilled tubes containing no additives. Tubes were labeled with study number, animal ID, date, and collection time point. Tubes were placed on wet ice until transferred to a cryostat. Samples were frozen at ≦-70°C within 90 minutes of collection. Because urine sample availability was unpredictable (i.e., the bladder was palpated to collect urine samples), efforts were made to collect samples as close to the desired time point as possible.

[0338] How to analyze efficacy To determine efficacy, the following primary outcomes were analyzed:

[0339] 1) A decrease in serum creatinine levels over the course of the study.

[0340] 2) An increase in GFR over the course of the study.

[0341] Repeated measurement analyses were performed to estimate the mean relative change in both serum creatinine levels and GFR for each sample during the study compared to baseline using linear mixed models. In addition, mean changes in serum creatinine and GFR compared to both baseline and final samples were calculated.

[0342] Descriptive statistics for weight change were calculated.

[0343] For each cat, the IVP was considered effective if there was a 20% decrease in plasma creatinine levels over the course of the study. The success criterion was that 50% of the cats should demonstrate efficacy of the IVP; or

[0344] For each cat, the IVP was considered effective if a 20% increase in GFR was achieved in the cat during the course of the study. The success criterion was that 50% of the cats should demonstrate efficacy of the IVP.

[0345] An IVP was to be considered safe if no serious adverse events attributable to the IVP were observed for each cat. In addition, the product had to be tolerated by cats with a low incidence of adverse events, in terms of the number of animals affected and the categories of events that occurred.

[0346] Results and Discussion (Example 6) Eighteen animals met the inclusion criteria. All procedures (i.e., dosing, general health observations, clinical observations, veterinary examinations, weight measurements, food intake measurements, water intake measurements, blood sampling, and urine collection) were performed at the designated time points.

[0347] Plasma creatinine level

[0348] The results of the statistical analysis show that plasma creatinine was significantly decreased compared to baseline only on day 28 (P=0.0283), on which day a 20% decrease in this parameter was observed in 4 animals.

[0349] GFR level Statistical analysis showed that GFR was significantly increased compared to baseline on days 13, 28, 57, 99, 121 and 182 (P<0.0001 for days 13 to 99 (inclusive), P=0.0029 and P=0.0225 for days 121 and 182, respectively). Over 50% of cats showed a 20% increase in GFR on days 13, 28, 57 and 99. Iohexol clearance results, means and statistics for individual animals are shown in FIG. 10.

[0350] body weight

[0351] Over the course of the study (i.e., from day -7 to day 168), nine cats gained weight, three cats maintained their weight, and five cats lost weight (weight loss ranged from 0.1 kg to 0.8 kg). The animal that died on day 120 gained weight from day -7 to day 112. Statistical analysis showed that there were no significant differences (P>0.05) in weight compared to baseline at any time during the study. Weight values, means, and statistics for individual animals are shown in Figure 11.

[0352] Dietary intake

[0353] Statistical analysis showed that food intake was significantly increased on days 14, 42, 70, 84, 112, 126, 140 and 154 compared to baseline (P<0.05).

[0354] Water intake

[0355] Statistical analysis showed that water intake from days 42 to 168 (inclusive) was significantly increased compared to baseline (P<0.05).

[0356] Urine tests

[0357] Urinalysis results, means, and statistics for individual animals are shown in Figure 12. Results of statistical analysis compared to baseline show the following:

[0358] 1) Urine specific gravity was significantly decreased only on the 13th day (P<0.0001).

[0359] 2) Urinary protein increased significantly only on day 181 (P=0.0221).

[0360] 3) Urinary creatinine was significantly decreased on days 7, 13, 28, 56, 97, 120 and 181 (P<0.05).

[0361] 4) The urinary protein / creatinine ratio was significantly increased on days 120, 149, and 181 (P<0.05).

[0362] Conclusion (Example 6) IVP (allogeneic feline uterine-derived regenerative cells) is effective as a treatment for chronic kidney disease in cats, as a 20% increase in iohexol clearance was observed in at least 50% of nephrectomized cats on days 13, 28, 57, and 99, based on glomerular filtration rate. Statistical improvements in GFR were observed throughout the 6-month evaluation period, except for day 150.

[0363] Based on the plasma creatinine results, a decrease in plasma creatinine was observed only on day 28. On this day, 22% of cats achieved a 20% decrease in this parameter.

[0364] IVP was well tolerated at two doses of 30M cells administered two weeks apart during the study.

[0365] Example 7. Treatment of canine CKD with canine uterus-derived regenerative cells It is contemplated that CKD in dogs (canines) may be treated with canine uterine-derived regenerative cells in a manner similar to that disclosed in Example 6.

[0366] Donor canine uterine tissue is prepared according to Protocol B, Protocol C, or a similar protocol to obtain a heterogeneous cell population that includes both vimentin only single positive and vimentin / cytokeratin double positive cell populations (e.g., mesenchymal progenitor cell populations and epithelial progenitor cell populations). In some embodiments, the ratio of vimentin only single positive cells to vimentin / cytokeratin double positive cells is approximately 50%:50% or about 50%:50%, although this ratio can deviate as much as 80%:20% or 20%:80% (V+ / C-:V+ / C+).

[0367] As in Example 6, canine subjects with CKD can be treated with the heterogeneous cell population in at least one IV administration for a total of 30 million cells. However, this amount can be optimized depending on the size and weight of the dog, such as a total of 1 million, 5 million, 10 million, 20 million, 25 million, 30 million, 31 million, 32 million, 33 million, 34 million, 35 million, 36 million, 37 million, 38 million, 39 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million cells, or any number of cells within a range defined by any two of the aforementioned amounts. After administration of the heterogeneous cell composition, a positive effect on kidney function has been observed in the canine subject.

[0368] Example 8. Treatment of canine or feline diseases with autologous or allogeneic uterine-derived regenerative cells The canine or feline patient presents with a disease. The disease may be idiopathic or may be associated with autoimmune disease or aging. The disease may be chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disc disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, or wound. An autologous or allogeneic heterogeneous cell composition prepared from uterine tissue and containing both a vimentin-only single positive cell population and a vimentin / cytokeratin double positive cell population is administered to the canine or feline patient. The heterogeneous cell composition may be prepared according to Protocol B, Protocol C, Protocol D, or a similar protocol. In some embodiments, the ratio of vimentin / cytokeratin double positive cells to vimentin single positive cells in the heterogeneous cell composition is approximately 50%:50% or about 50%:50%, but this ratio can deviate to 80%:20% or 20%:80% (V+ / C-:V+ / C+). The heterogeneous cell composition can be administered intravenously or by another enteral or parenteral route.

[0369] With respect to atopic dermatitis, the canine or feline patient experiences relief from discomfort and itching symptoms following administration of the heterogeneous cell composition. In some embodiments, the heterogeneous cell composition is administered in conjunction with another therapeutic agent for atopic dermatitis, such as steroids, glucocorticoids, hydrocortisone, cyclosporine, oclacitinib, lokivetomab, antihistamines, hydroxyzine, chlorpheniramine, or topical ointments and shampoos. In other embodiments, the heterogeneous cell composition is administered in place of another therapeutic agent, for example, because the other therapeutic agent does not have a significant effect in treating atopic dermatitis, the other therapeutic agent is short-lived and requires multiple applications, or the other therapeutic agent causes adverse side effects in the canine or feline patient.

[0370] With respect to osteoarthritis or other immune-mediated arthritis, the canine or feline patient experiences reduced joint pain and inflammation following administration of the heterogeneous cell composition. The composition can be administered systemically or intra-articularly. In some embodiments, the heterogeneous cell composition is administered in conjunction with another therapeutic agent for osteoarthritis or other immune-mediated arthritis, such as a steroid, a corticosteroid, a nonsteroidal anti-inflammatory drug, platelet-rich plasma (PRP), glucosamine, PSGAG, hyaluronic acid, or an opiate. In other embodiments, the heterogeneous cell composition is administered in place of another therapeutic agent, for example, because the other therapeutic agent does not have a significant effect in treating osteoarthritis or other immune-mediated arthritis, the other therapeutic agent is short-lived and requires multiple applications, or the other therapeutic agent causes adverse side effects in the canine or feline patient.

[0371] With respect to keratoconjunctivitis sicca, the canine or feline patient experiences a complete or partial restoration of tear production and / or reduced inflammation of the lacrimal gland, conjunctiva, and cornea following administration of the heterogeneous cell composition. In some embodiments, the heterogeneous cell composition is administered in conjunction with another therapeutic agent for keratoconjunctivitis sicca, such as artificial tears, corticosteroids, cyclosporine, pimecrolimus, or tacrolimus. In other embodiments, the heterogeneous cell composition is administered in place of another therapeutic agent, for example, because the other therapeutic agent does not have a significant effect in treating keratoconjunctivitis sicca, the other therapeutic agent is short-lived and requires multiple applications, or the other therapeutic agent causes adverse side effects in the canine or feline patient.

[0372] With respect to wounds, the canine or feline patient experiences faster wound healing, reduced risk of infection, and / or less pain or discomfort resulting from the wound following administration of the heterogeneous cell composition. In some embodiments, the heterogeneous cell composition is administered in conjunction with another therapeutic agent for wound healing, such as a topical antimicrobial agent. In other embodiments, the heterogeneous cell composition is administered in place of another therapeutic agent, for example, because the other therapeutic agent does not have a significant effect in treating the wound, the other therapeutic agent is short-lived and requires multiple applications, or the other therapeutic agent causes adverse side effects in the canine or feline patient.

[0373] With regard to hepatitis and other liver diseases, canine or feline patients experience reduced liver inflammation and scarring, as well as improved liver function, following administration of the heterogeneous cell composition.

[0374] With respect to inflammatory bowel disease, canine or feline patients experience reduced intestinal inflammation, increased appetite, and reduced vomiting following administration of the heterogeneous cell composition.

[0375] With respect to intervertebral disc disease, the canine or feline patient experiences reduced spinal inflammation and pain following administration of the heterogeneous cell composition.

[0376] With respect to pancreatitis, canine or feline patients experience reduced inflammation of the pancreas, increased appetite, and reduced vomiting following administration of the heterogeneous cell composition.

[0377] With respect to fibrosis, the canine or feline patient experiences a reduction in fibrotic scarring of organs, such as the liver, lungs, heart, kidneys, or other organs, following administration of the heterogeneous cell composition.

[0378] With respect to sclerosis, the canine or feline patient experiences improved vision and reduced cataract-like symptoms following administration of the heterogeneous cell composition, hi some embodiments, the heterogeneous cell composition is administered intraocularly.

[0379] With respect to amyloidosis, the canine or feline patient experiences a reduction in amyloid deposits throughout the body, such as in the kidney, liver, or heart, following administration of the heterogeneous cell composition.

[0380] Example 9. Autologous Uterine-Derived Regenerative Cells All the preceding examples can be applied with autologous cells. The uterine tissue used to obtain the heterogeneous cell composition from the present specification can be obtained from a dog or cat patient who has a disease and needs the heterogeneous cell composition, or can be derived from the dog or cat patient. In some embodiments, the uterine tissue is obtained from the dog or cat patient when the patient is young. In some embodiments, the uterine tissue is obtained from the dog or cat patient during a spay / neuter operation (ovariohysterectomy or hysterectomy), which is usually performed at an early age, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months of age. In some embodiments, the uterine tissue is cryopreserved. For example, the uterine tissue is stored in a cryopreservation medium at low temperature (i.e., liquid nitrogen temperature). When the dog or cat patient needs the heterogeneous cell composition described herein, the uterine tissue is thawed and processed according to the protocol described herein or a similar protocol to produce the heterogeneous cell composition. The heterogeneous cell composition can then be administered to a dog or cat patient as an autologous composition that causes little or no immune-related negative effects.In some embodiments, uterine tissue is processed according to the protocol described herein or a similar protocol, and the resulting heterogeneous cell composition is cryopreserved.When a dog or cat patient needs the heterogeneous cell composition, the heterogeneous cell composition is thawed and administered to the dog or cat patient as an autologous composition that causes little or no immune-related negative effects.Optionally, the heterogeneous cell composition is expanded in cell culture to obtain a large number of cells for cryopreservation, so that the autologous composition can be administered to a dog or cat patient more than once from a single uterine tissue donation.

[0381] Example 10. Clinical Doses Prepared Using an Enzymatic Digestion and Cultivation Process of Canine and Feline Uterine Tissue (Protocol C) Uterine tissue obtained from ovariectomy of dog and cat donors was processed within 24 hours after surgery. At ovariectomy, the uterus was isolated by dissection from other tissues present. Uterine tissue was minced into 2 mm x 2 mm pieces and digested with collagenase and thermolysin (both from VitaCyte, Inc., 13 mg collagenase and 0.2 mg thermolysin per gram of uterine tissue). Digestion was performed in 4.5 mL DPBS at 37°C for 1 hour with periodic manual shaking. The reaction was quenched by adding Corning DMEM (HG, high glucose, Dulbecco's modified Eagle's medium) culture medium containing 10% fetal bovine serum (FBS). The digestion, consisting of free cells and explanted tissue pieces, was plated in T225 flasks (0.1 g tissue / flask) and incubated at 37°C, 5% CO2, and 100% humidity. The medium was supplemented with 8ng / mL recombinant human fibroblast growth factor-basal activity protein (rhFGF-2, CellGenix, Inc.), 6mM L-glutamine and 10% FBS. T225 flasks were processed on day 3 to remove tissue debris or explants and spent medium, and fresh medium was added. Once flasks reached 70-80% confluence, cells were released by treatment with TrypLE™ (Gibco), washed, counted on a NucleoCounter NC-200, and cryopreserved in 1mL cryopreservation medium (CS10, BioLife Solutions). Cryovials (CellSeal, Sexton Biotechnologies) were transferred to a cooling chamber dedicated to CellSeal vials and placed in a -80°C freezer overnight, after which the vials were transferred to a monitorable liquid nitrogen (LN2) vapor storage. Each vial contained 5x10 6Each vial contained 4000–10000 cells / cm. These vials were designated as passage 1 (P1). Cell culture continued in DMEM (HG) containing 10% FBS, 6 mM L-glutamine, and 8 ng / mL FGF-2 in T225 flasks and were passaged when the cells reached nearly 70–80% confluence. At each passage, cells were released by TrypLE treatment, washed, counted, and plated at 4000–10000 cells / cm in appropriate culture flasks. 2 At the end of the culture cycle (e.g., passage 4 or 5), uterine tissue-derived regenerative cells (URCs) were cryopreserved in CS10 (BioLife Solutions), transferred to a -80°C freezer overnight, and placed in a liquid nitrogen vapor storage vessel.

[0382] Example 11. Adherent cells from feline uterine tissue in culture When cells derived from feline uterine tissue were cultured in DMEM containing 10% FBS and FGF-2 (8 ng / mL) according to protocol C (Example 10), they showed adherent cells as shown in FIG. 13A (ID: S-001, 4th passage).

[0383] The clear presence of two cell types in Figure 13A (S-001) indicates that both spindle-shaped and cuboid-shaped cells continue to proliferate up to the fourth passage. Subculture requires treatment of the adherent cells with an enzymatic agent (e.g., TrypLE, Gibco) to release the adherent cells that are attached to the plastic vessel. The detached cells are then seeded into fresh culture vessels. Thus, in the example depicted in Figure 13A, the cells have been detached and reseeded four times. Feline URC preparations consist of detached cells cryopreserved in an appropriate cryopreservation medium (e.g., CS10, or CS5 BioLife Solutions).

[0384] Example 12. Adherent cells from canine uterine tissue in culture Canine uterine tissue-derived cells, when cultured according to protocol B in DMEM containing 10% FBS and FGF-2 (8 ng / mL), show adherent cells as shown in FIG. 13B (S-002, passage 4). Spindle-shaped cells are present throughout the culture process up to passage 4. Subculture requires treatment of the adherent cells with an enzymatic agent (TrypLE, Gibco) to release the adherent cells that are stuck to the plastic vessel. The detached cells are seeded into fresh culture vessels. Thus, in the example depicted in FIG. 13B, the cells have been detached and reseeded four times. Canine URC preparations consist of detached cells cryopreserved in an appropriate cryopreservation medium (e.g., CS10, BioLife Solutions).

[0385] Example 13. Trilineage differentiation of canine and feline URC preparations Both canine and feline URC preparations from Protocol B or Protocol C differentiated into adipogenic, chondrogenic, and osteogenic cell lineages when cultured in the appropriate induction medium. Table 9 shows the tri-lineage differentiation conditions. [Table 9]

[0386] Each donor URC preparation was assessed for tri-lineage differentiation in response to induction medium and paired with cells maintained in culture as a control. After staining was completed, wells were imaged with a phase contrast microscope equipped with an Amscope MD camera. The specific assay conditions for tri-lineage differentiation in both dogs and cats were as follows:

[0387] Adipogenesis: Precursor cells undergoing adipocyte differentiation give rise to lipid-containing vacuoles in the cytoplasm of the cells, similar to how adult adipocytes store lipids. After 14 days in culture, wells on 6-well plates for adipocyte differentiation assays were examined for evidence of lipid vacuole formation within the cells. Wells were fixed after a 21-day seeding period. The fixation process used Oil Red O as a stain, which is preferentially retained in lipid-containing vacuoles (droplets) that form within the cytoplasm of the cells. It is important not to allow the cells to dry for more than 30 seconds during the staining procedure. Cells were considered to be undergoing adipocyte differentiation if they had red-stained lipid "droplets" or vacuoles within the cytoplasm of the cells.

[0388] Chondrogenic differentiation: Cell-enriched droplets were seeded into 6-well plates and incubated in induction medium for 3 weeks. Precursor cells that underwent chondrogenic differentiation typically grew in "nodules" that contained a variety of extracellular proteins, including collagen. Alcian blue was used to stain collagen present in the extracellular matrix.

[0389] Osteogenic Differentiation: Cells were seeded in 6-well plates and incubated overnight before switching the medium in the test wells to induction medium. Incubation continued for 3 weeks. Cells that responded to osteogenic induction medium showed extensive deposition of mineralized extracellular matrix synthesized by cells differentiating along the osteogenic lineage. Calcium present in the mineralized extracellular matrix secreted by osteoblasts was stained using Alizarin Red.

[0390] Each set of images presented in Figures 14A-C shows a positive response in both feline and canine URC preparations upon treatment with induction medium to establish trilineage differentiation.

[0391] Example 14. Monochromatic positive frequency of canine and feline URC preparations Cells were analyzed with commercially available directly conjugated antibodies reactive to CD34, CD45, CD90 (dog and cat, ThermoFisher), CD44 (dog and cat, BioLegend), CD105 (cat, ThermoFisher), MHCII (dog, ThermoFisher) and Live / Dead (dog and cat, 7-AAD, Invitrogen). Cells were incubated in pre-optimized reagents for 30 min in the dark on ice before reactivity was assessed. All events were first assessed by Live / Dead staining and only viable single-cell events were analyzed for reactivity with the surface-reactive CD marker panel. Samples were evaluated on an Attune Flow Cytometer. Data were analyzed on a FloJo (BD Life Sciences).

[0392] Multiple unrelated feline and canine URC preparations were prepared using Protocol B and Protocol C, respectively, and evaluated for reactivity with various CD marker reagents known to be reactive with canine or feline cells. Table 10 shows the monochromatic positivity frequencies for feline URC preparations, and Table 11 shows the monochromatic positivity frequencies for canine URC preparations. [Table 10] [Table 11]

[0393] The CD marker profiles shown in Tables 10 and 11 are generally based on the conventional consensus on how to characterize progenitor cells. The first requirement for a cell to be considered a stromal cell is that it is plastic-adherent and can be induced to differentiate in vitro into chondrogenic, osteogenic and adipogenic cell lineages. Furthermore, the CD marker single positivity frequency of cultured human "mesenchymal stem cells" (MSCs) is as follows: 1) positive reactivity (e.g., >95%) with CD73, CD90 and CD105, and 2) negative reactivity (e.g., <2%), especially with CD34 and CD45. There is also a requirement for human MSCs to be "negative" for HLA-DR, which would mean that non-human MSCs are negative for MHCII.

[0394] As shown in Figures 13A-B, feline and canine URCs readily expand as adherent cells. As shown in Figures 14A-C, representative donors of both feline and canine URCs have been shown to differentiate into chondrogenic, osteogenic, and adipogenic cell lineages. As can be seen in Tables 10 and 11, cultured feline and canine URCs are clearly negative for CD34 and CD45, with some evidence that canine URCs are MHCII negative. CD44 is associated with progenitor cells. However, while CD44 is clearly positive, CD90 and CD105, although positive in canine and / or feline URCs, do not reach the levels of >95% commonly accepted for cells to be considered MSCs. Thus, the uterine tissue-derived URCs disclosed herein do not resemble classical human-derived MSCs. Nevertheless, the feline and canine URCs disclosed herein grow plastic-adherently, differentiate into the three adult cell lineages (adipogenic, chondrogenic, and osteogenic), and display the traditional CD marker profile associated with stem / progenitor cells, supporting their status as uterine tissue-derived progenitor cells in dogs and cats.

[0395] As established in the Examples below, further characterization of the canine and feline URC preparations further indicates that the URC preparations herein are unique progenitor cells.

[0396] Example 15. Dual expression of vimentin and cytokeratin-18 in feline uterine tissue-derived adherent cells by immunofluorescence As shown in Figure 13A, two distinct cell types were persistently present in feline URC preparations over successive passaging and reseeding cycles, but it was surprising to find that some of the cells present in the feline uterine tissue-derived cell cultures displayed cellular characteristics related to progenitor cells as well as epithelial cells within the same subpopulation: vimentin is associated with cells considered to be progenitor cells, whereas cytokeratin-18 is associated with epithelial-like cells and cells that would not normally be expected to express vimentin.

[0397] Using the technique of immunofluorescence (IF), the presence or absence of vimentin and cytokeratin-18 in adherent URC cultures was visualized through a staining and visualization process. Cells were obtained from growth culture vessels or from cryopreserved cell vials and seeded in a dedicated culture chamber (Lab Tech II CC2 Chamber Slide) and incubated overnight at 37°C / 5% CO2. During overnight incubation in DMEM containing 10% FBS and 8ng / mL FGF-2, cells adhered to the vessel surface. After overnight culture, the medium was removed and the chamber was washed with PBS to remove the medium. Cells were fixed for 15 minutes at room temperature (Invitrogen, Image-iT Fixative / Permeabilization Kit: Fixative, Wash Buffer, Permeabilization Solution, Blocking Solution), after which the fixative was removed and the chamber was washed three times with Wash Buffer. The cells were permeabilized by adding a permeabilization reagent (Image-iT Permeabilization Solution) and incubated for 15 minutes at room temperature. Both vimentin and cytokeratin are cytoskeletal proteins within the cells, and therefore permeabilization is necessary. After removing the permeabilization solution and washing with Wash Buffer, the treated cell layer was blocked overnight using Blocking Solution. After washing the blocked cells with PBS, anti-vimentin reagent labeled with AlexaFluor 647 dye (abcam) and anti-cytokeratin-18 reagent labeled with FITC (abcam) were added to the chamber. This results in structures stained red if vimentin is present and green if cytokeratin-18 is present. After staining, the chamber(s) were imaged with an eVOS instrument (ThermoFisher). The staining patterns of two unrelated feline uterine tissue-derived preparations using Protocol C are depicted in Figures 15A-C and 16A-C.

[0398] In each image set of feline URC preparations shown in Figures 15A-C and 16A-C, the top images (Figures 15A and 16A) show a large number of vimentin-positive cells. The middle images (Figures 15B and 16B) show a small number of cytokeratin-positive cells. The bottom merged images (Figures 15C and 16C) identify cells that are positive for both vimentin and cytokeratin. Not all vimentin-positive cells are also positive for cytokeratin, and not all cytokeratin-positive cells are also positive for vimentin. However, it is clear that a population of double-stained cells is unexpectedly present in multiple unrelated feline donor URC preparations. Thus, the double-stained cells identify a smaller population of cells with both epithelial-like (cytokeratin-positive) and progenitor-like (vimentin-positive) characteristics that persist in stable cultures of progenitor-like and epithelial-like cells.

[0399] Example 16. Evaluation of CD marker positivity frequency demonstrates the presence of cells multiply expressing vimentin, cytokeratin, CD44, and CD326 In the surface marker detection assay, cells have been evaluated for their single-color positive frequency (Tables 10 and 11). However, as indicated in Example 15, it is possible to detect vimentin and cytokeratin in fixed and permeabilized cells. For flow cytometry analysis, a modified staining assay was performed in which CD44 and CD326 reagents were incubated with the cells, and after washing off only the excess reagents, the cells were fixed, permeabilized and blocked (Invitrogen, Image-iT Fixative-Permeabilization Kit) and reacted with labeled anti-vimentin (dog and cat, abcam) and anti-cytokeratin-18 (dog and cat, abcam) reagents as described in Example 15. Samples were evaluated on an Attune Flow Cytometer. Data were analyzed on a FloJo (BD Life Sciences).

[0400] Cells from cultured cell preparations from multiple unrelated feline and canine donor uterine tissues using Protocol C and Protocol B, respectively, were examined by flow cytometry assay for co-expression of CD44, CD326, vimentin, and cytokeratin-18. CD44 is a progenitor cell marker and CD326 is an epithelial cell marker. The frequency of double staining positivity for vimentin / cytokeratin and CD44 / CD326 for the three donor feline URC preparations evaluated is shown in Table 12. Multiple canine donor URC preparations were evaluated for the frequency of double positivity for CD44 / CD326, CD44 / cytokeratin, CD44 / vimentin, and vimentin / cytokeratin, as shown in Table 13. [Table 12] [Table 13]

[0401] As shown in Table 12, each feline donor cell preparation demonstrated the unexpected presence of cells co-expressing progenitor-like or epithelial-like characteristics with respect to both vimentin / cytokeratin or CD44 / CD326 combinations.

[0402] In evaluating cell cultures derived from canine donor uterine tissue, the presence of cells dually expressing several marker combinations, as shown in Table 13, was examined.

[0403] The expression profiles of both CD marker pairs support the identification of cells that simultaneously express both progenitor- and epithelial-like characteristics.

[0404] Although there is donor variability, each donor URC preparation in Tables 12 and 13 shows the unexpected presence of both progenitor-like markers (vimentin and CD44) and epithelial-like markers (CD326 and cytokeratin-18) in the same cells for canine and feline URC preparations. As shown in Table 13, the high percentage of CD44 and vimentin double expression for canine URC preparations suggests that the vimentin marker in canine URC is associated with progenitor-like cells. Thus, the combined vimentin and cytokeratin double positive cells identify a cell population in URC that exhibits both progenitor-like and epithelial-like characteristics. This further supports the interpretation in Example 15 that the presence of feline URCs that co-express vimentin and cytokeratin in the same cells indicates that individual cells co-express both progenitor-like and epithelial-like characteristics. Corroborating these findings, there are measurable percentages of both canine and feline URCs that express both CD44 and CD326, as well as canine cells that co-express CD44 and cytokeratin. This combination of reagents detects feline and canine URCs that are both progenitor- and epithelial-like.

[0405] The presence of cells expressing both progenitor- and epithelial-like markers in feline and canine URC cultures demonstrates the existence of a unique progenitor cell type derived from uterine tissue that can be cultured to high passages and is therefore of therapeutic interest.

[0406] Example 17. Outcome of a clinical dose of canine donor uterine tissue in atopic dermatitis The clinical dose was obtained from canine donor S-011. Uterine tissue from S-011 was processed as described in protocol B for enzymatic digestion of the tissue and culturing of the resulting digest. Cells were expanded in culture and cryopreserved at passage 4 in CS10 (BioLife Solutions) at 36 million cells / cryovial. After thawing and diluting with PBS, doses were administered by IV infusion to eligible canine patients with atopic dermatitis. Two clinical doses were infused with a 2-week dosing interval, after which each canine patient was monitored for clinical symptoms. Canine patients were evaluated by several clinical metrics, including the Pruritus Visual Analog Score (PVAS, an index of the severity of pruritus (itch)), the Canine Atopic Dermatitis Extent and Severity Index-4 (CADESI-4), and the Canine Atopic Dermatitis Lesion Index (CADLI) before and at intervals after treatment. Available clinical data are shown in Table 14. [Table 14]

[0407] Clinical benefit of treating canine patients with established atopic dermatitis was demonstrated by trends in clinical metrics, with the mean values ​​of the three metrics decreasing compared to pretreatment baseline values ​​for the four treated canine patients. Reductions in clinical metrics suggested improvement in the clinical condition of the patients.

[0408] The PVAS is a validated scale for assessing the severity of pruritus in patients. The scale ranges from "healthy dog ​​- no itch problems" to "very severe itch / almost constant (itch needs to be physically controlled)". The same owner performs this assessment at each study visit based on observations of the itch levels seen at home. The CADESI-4 is a validated assessment tool for assessing canine skin conditions. The CADESI-4 focuses on specific areas of the dog, such as the front and back paws, flanks, and groin area, and measures the severity of erythema (redness), lichenification (skin thickening and excoriation (skin trauma)) and / or alopecia (hair loss). The assessment is performed by the same veterinarian at each study visit. The CADLI is a validated assessment tool for assessing canine skin conditions. The CADLI is similar to the CADESI-4 assessment tool and works in a similar manner with only minor technical differences. The CADLI focuses on more general areas of the dog's skin but still assesses the same severity criteria, including hyperpigmentation (skin pigmentation levels), and is also performed by the same veterinarian at each study visit.

[0409] Example 18. Cytokine profile of canine and feline URCs Cytokines are key molecules secreted by progenitor cells and constitute a well-known paracrine mechanism to regulate both adult and immune cells in tissues. Cytokine profiles of canine and feline URCs were obtained in culture supernatants of these cell preparations. For specificity, canine and feline supernatants were analyzed separately by commercial assays. In the absence of background levels of cytokines in the culture medium, two unrelated canine URCs (S-016 and S-002) were found to constitutively secrete galectin-3 (involved in cell-cell adhesion, macrophage activation), MCP-1 (monocyte chemotactic protein-1, attracts monocytes, memory T cells and dendritic cells to sites of inflammation), IGFBP-2 (insulin-like growth factor binding protein, involved in maintenance of stemness, cell migration [chemotaxis]), and VEGF (vascular endothelial growth factor - angiogenesis). The feline donor (S-001) was found to secrete MIP-1, VEGF, PDGF (platelet-derived growth factor, which supports angiogenesis and cell proliferation in tissues), and IL-10 (interleukin-10, which acts to suppress the pro-inflammatory response of immune cells).

[0410] Example 19. Mixed lymphocyte reaction and IDO activity and PGE2 levels The precursor cells were evaluated in a mixed lymphocyte reaction (MLR) assay for their ability to suppress the proliferation of donor-derived monocytes. The assay was based on using isolated donor peripheral blood monocytes (PBMCs) stimulated (usually with a mitogen such as concanavalin A (Con A)) to grow (control condition) compared to the same conditions but with the inclusion of a precursor cell preparation (test condition). The addition of URC reduced the proliferation levels in the PBMC / Con A condition, providing evidence that the URC preparation can modulate immunity in proinflammatory conditions. In addition, the supernatants of the PBMC / Con A / URC reactions were analyzed for indoleamine-2,3-dioxygenase activity (IDO, assessed by levels of kynurenine, the main metabolite of IDO action on tryptophan) and prostaglandin E2 (PGE2, measured by a commercial ELISA) levels. Both IDO activity and PGE2 have been identified as biomarkers / effector molecules that suppress inflammation by downregulating T cell-mediated immune responses.

[0411] Table 15 shows proliferation inhibition by feline URC formulations as assessed by feline PBMC MLR assay, along with IDO activity and PGE2 levels obtained in the supernatant. Table 16 shows proliferation inhibition by canine URC formulations as assessed by canine PBMC MLR assay, along with IDO activity and PGE2 levels obtained in the supernatant. Note: Fold increase was determined by comparing IDO activity and PGE2 levels to donor PBMC+Con A values. [Table 15] [Table 16]

[0412] Both canine and feline URC preparations demonstrated down-regulated proliferation in the MLR, suggesting that URCs possess important immunomodulatory properties commonly associated with stem / progenitor cells. Additionally, both canine and feline URC preparations produced IDO and PGE2, which are known to be involved in the immunomodulatory actions of stem / progenitor cells on activated immune cells.

[0413] Example 20. Differential in vitro proliferation behavior of URCs derived from unrelated feline donor uterine tissue Several unrelated feline donor tissues were digested with Protocol C (Example 10). Equal portions of each digest were divided and cultured in either Lonza® DMEM or Corning® DMEM formulations, both containing 10% FBS and 8 ng / mL FGF-2. Each culture preparation was treated in an identical manner, and cells were passaged when the cultures exhibited approximately 70-80% confluence in the culture flasks.

[0414] The cultures were passaged by detaching the adherent cells with an enzymatic agent, counting the cells, and reseeding the cells in a new culture flask containing fresh medium. Thus, the cultures required an increase in cell number during the culture interval to obtain enough cells to be reseeded next for passage. As shown in Table 17, the culture status was evaluated as growth-arrested / differentiated (SG / D) or proliferating (G) for each passage number for each feline URC preparation. Note that "NA" in Table 17 refers to cultures that had either growth-arrested or differentiated (i.e., converted to adult cells) in the previous passage and therefore had no cells to seed for the current passage. "L" refers to Lonza® DMEM and "C" refers to Corning® DMEM. [Table 17]

[0415] Two of the feline URC preparations (S-004 and S-007) stopped growing or differentiated (differentiated slowly into adult cells, if they expanded at all) in Lonza® DMEM at passage 3. Two of the feline URC preparations (S-004 and S-023) stopped growing or differentiated (differentiated slowly into adult cells, if they expanded at all) in Corning® DMEM at passage 4. Only one URC preparation (S-005) expanded in Lonza® DMEM at passage 4, but failed to expand at passage 5. Thus, 5 / 6 of the URC preparations were unable to expand in Lonza® DMEM before passage 5, and only 1 / 6 was seeded at passage 5 but failed to expand. In contrast, 4 / 6 of the URC preparations grown in Corning® DMEM were seeded and expanded at passage 5. The remaining 2 / 6 of the URC preparations either stopped growing or differentiated into adult cells and were not plated at passage 5.

[0416] As seen in Table 17, six unrelated feline donor URC preparations cultured in parallel from a common digest did not grow well in Lonza® DMEM, and only one of the URCs failed to grow when seeded at passage 5. In contrast, four of the URCs grew robustly in Corning® DMEM to the end of passage 5 without differentiation, and only two URCs failed to grow well (or differentiated) at passage 4.

[0417] The compositional differences between Lonza® DMEM and Corning® DMEM are shown in Table 18. [Table 18]

[0418] Effects of different compositions:

[0419] Inositol: Inositol is an important in vivo cofactor involved in neurotransmission and steroid hormone binding. Inositol has been shown to be involved in cell membrane metabolism and is affected by glucose levels. Since cells can synthesize inositol, the effect of a 2.8% difference in exogenous inositol is unknown.

[0420] Phenol red: Phenol red is used as a pH indicator and can act as an indicator of culture health and metabolic activity. Phenol red has been identified as having weak estrogenic activity, can be a target for redox reactions, and has been shown to affect the differentiation activity of MSCs. None of these effects appear to have a direct bearing on the culture efficiency of the medium for uterine tissue-derived cells.

[0421] Osmolality / monobasic sodium phosphate: Monobasic sodium phosphate is one of the inorganic salts that contribute to the osmolality of the culture medium and is part of the buffering capacity of the medium. The impact of the 15% higher level of this species in Corning® medium can be seen in the higher osmolality of the exemplary lot of Corning® DMEM, which is at the upper limit of the osmolality of Lonza® DMEM.

[0422] Glutamine: Glutamine is a key amino acid required for protein synthesis. Lonza® DMEM lacks glutamine. However, whenever a complete medium was required, glutamine was added to the basal medium as a supplement. The glutamine level was adjusted to reach 5.5 mM. Corning® medium contains 4 mM glutamine, which is approximately 73% of the level in Lonza® DMEM supplemented with glutamine.

[0423] Overall, URC preparations cultured in Corning® DMEM showed robust growth until the end of the fifth passage, compared to growth in Lonza® DMEM, which was relatively poor. As shown in Table 18, the difference between the two media was limited, but Corning® DMEM had significantly less glutamine by 27%. Without being bound to any theory or mechanism, it is possible that low levels of glutamine create an unfavorable environment for the differentiation of adherent cells into adult cells.

[0424] Example 21. Effect of decontamination of feline uterine tissue on the proliferation of cells obtained by enzymatic digestion. Although uterine tissue is obtained from dogs and cats during aseptic ovariectomy, the risk of microbial contamination remains. Therefore, an alternative protocol for creating a clinical dose was evaluated (Protocol D). Protocol D is one of the protocols that minimizes the possibility of microbial contamination of cells placed in culture after enzymatic digestion of the uterine tissue, and requires an initial decontamination step followed by further processing. Additional aspects of Protocol D are described in Table 20. The decontamination step of Protocol D uses a 1% (poly)vinylpyrrolidone (PVP) solution and a 0.1% sodium thiosulfate solution, followed by a PBS rinse. A different decontamination condition from Protocol D was also evaluated that included washing and rinsing the uterine tissue four times with PBS. The evaluation of the two decontamination methods was performed by harvesting tissue from three cats by ovariectomy, dissecting out the non-uterine tissue, and then dividing the uterine tissue of each donor into two halves. One of the halves was processed as follows:

[0425] 1. Place the uterine tissue into a 50 mL conical tube containing 10 mL of PBS and mix gently to expose the tissue to the PBS.

[0426] 2. Clean the forceps used to transfer the tissue by wiping with 70% isopropyl alcohol.

[0427] 3. Transfer the uterine tissue from the first PBS tube to a second 50 mL conical tube containing 10 mL of PBS and mix gently to expose the tissue to the PBS.

[0428] 4. Transfer the uterine tissue to a 50 mL conical tube containing 5 mL of 1% PVP. Mix gently and allow incubation to continue for 2 minutes.

[0429] 5. After the 2 minute incubation in the PVP solution is complete, remove the tissue from the PVP conical tube and place the uterine tissue in a 50 mL conical tube containing 5 mL of 0.1% sodium thiosulfate. Allow the uterine tissue to incubate in the 0.1% sodium thiosulfate solution for 1 minute.

[0430] 6. After the 1 minute incubation in the sodium thiosulfate solution, remove the tissue from the sodium thiosulfate conical tube and place the uterine tissue in a 50 mL conical tube containing 10 mL of PBS. Gently mix the tube to expose the tissue to the PBS.

[0431] 7. Transfer the uterine tissue from the PBS tube to another 50 mL conical tube containing 10 mL of PBS. Gently mix the tube to expose the tissue to the PBS.

[0432] The other half of the uterine tissue was decontaminated by placing the tissue into four separate 50 mL conical tubes each containing 10 mL of PBS.

[0433] Each tissue piece was minced and digested under identical conditions (collagenase and thermolysin, digestion for 30 min with manual shaking of the tube at 10 min intervals). The digests were placed in flasks and incubated at 37°C / 5% CO2 / 100% humidity in complete medium (DMEM, high glucose, containing 10% FBS and 8 ng / mL FGF-2, 0.44 μg / mL amphotericin B and 0.05 mg / mL gentamicin). Cultures were checked daily for contamination and harvested on day 4 to determine total cell counts for each decontamination treatment from each donor. The cell yield for cultures of PBS-decontaminated tissue was divided by the corresponding cell yield for cultures of PVP / thiosulfate-decontaminated tissue from each donor and multiplied by 100 to obtain % proliferation values ​​(cell counts) for PBS-treated cell cultures compared to PVP / thiosulfate (control)-treated cell cultures from each donor, as shown in Table 19. [Table 19]

[0434] No contamination was observed in cultures of the three donor tissues under any condition, but the use of PBS significantly increased the average cell yield over the four-day culture period.The current protocol C uses PBS as a means to decontaminate the uterine tissue during the enzymatic digestion process to generate the clinical dose.

[0435] Example 22. Comparison of Protocol C and Protocol D There are several further differences that distinguish Protocol C from Protocol D. These are listed in Table 20. [Table 20-1] [Table 20-2]

[0436] There are some important differences between Protocol C and Protocol D.

[0437] 1. Tissue Processing:

[0438] A) Protocol C uses benign PBS for decontamination, whereas Protocol D exposes tissue to harsh chemicals for decontamination. The decontamination solution in Protocol D has been shown to reduce cell yields in the first culture interval due to its effect on tissue cells.

[0439] B) The time to digest the tissue is only 30 minutes in protocol D versus 60 minutes in protocol C. The increased digestion time has been shown to result in a cellular composition in the digest that can reach 70-80% confluence more quickly (3 days) compared to the corresponding tissue digest produced with only 30 minutes of digestion time (which took 5 days to reach 70-80% confluence).

[0440] 2. Digestion and cell culture:

[0441] A) In protocol C, the cells and explants are left in the medium until day 3, whereas in protocol D, the medium and tissue fragments are removed on day 1 and the tissue fragments are replaced in the culture flask with fresh medium. In both protocols, the medium is replaced on day 3. The effect of removing the medium on day 1 is difficult to assess, but clearly any biomolecules that diffuse out of the tissue or are secreted by the cells into the surrounding fluid will be lost in protocol D. From the experimental results shown in the key differences section 1B above, it was observed that tissue fragments digested for 30 min took approximately 2 days longer to reach confluence compared to those digested for 60 min. The longer exposure to the digestive enzymes may have caused more disruption of the tissue matrix compared to the shorter incubation time, which allowed the cells and biomolecules to more easily detach from the tissue matrix and enter the medium environment, resulting in a faster time to reach confluence.

[0442] B) Another potentially significant difference is the use of amphotericin B and gentamicin in the culture medium of Protocol D. Both of these antibiotics are known to be harsh on cells. For example, amphotericin B has been reported to reduce the viability of cells in culture. Penicillin and streptomycin also transiently reduce the viability of cells in culture. This type of behavior suggests that amphotericin B, and other antibiotics, may be negatively affecting cells in some manner. Therefore, since Protocol C does not use amphotericin B or gentamicin, it is possible that the culture environment of Protocol D, which contains amphotericin B and gentamicin, may be affecting cultured cells in a way that does not occur in the culture environment of Protocol C.

[0443] C) Protocol C uses Corning® DMEM for cell culture, whereas Protocol D uses Lonza® DMEM. The compositional differences between these two DMEM formulations are shown in Table 18. The glutamine level in Corning® DMEM is approximately 27% lower than that in Lonza® DMEM, which may explain the higher number of donor preparations that reached passage 5 (n=4 out of 6) when grown in the medium used in Protocol C, as indicated by the culture responses of six unrelated feline donor URC preparations (Table 17), compared to only one out of six preparations that reached passage 5 in the medium used in Protocol D.

[0444] 3. Cell expansion to generate clinical dose:

[0445] A) As shown in Table 20, the manufacturing process used in Protocol D to obtain a clinical dose requires four culture intervals after generating the Master Cell Bank (MCB) stage of cryopreserved cells. Three culture intervals are employed after generating the MCB stage of cryopreserved cells. In light of the data shown in Table 17, which revealed poor growth patterns of URCs grown in the Lonza® DMEM formulation in Protocol D, the superior growth patterns of the Corning® DMEM formulation in Protocol C would more likely result in a useful dose.

[0446] B) Table 20 shows the major differences in the techniques used for cell growth prior to cryopreservation of clinical doses. Protocol D relied on the use of microcarrier particles kept in suspension by an impeller, called spinner flask technology. Cells attach to the microcarrier particles and are kept in suspension by the rotation of the impeller during the culture interval. The bioreactor, a much larger scale example than the spinner flask technology, provides a very high degree of control over the composition of the gas phase by actively monitoring CO2 and oxygen (nitrogen can be introduced as needed). Protocol C does not use spinner flask or impeller-based bioreactor technology for cell growth to create clinical doses, but instead relies on specialized high density multiplate bioreactor technology designed specifically for cell types that may be adversely affected by the shear forces generated in impeller-based bioreactors. Protocol C avoids the shear-inducing impeller-based bioreactor environment and employs static culture, resulting in more stable growth of URC preparations.

[0447] 4. Cryopreserved preparations:

[0448] A) Protocol D uses two formulations in the process of creating clinical doses of URC preparations. The first cryoprotectant formulation is based on the use of culture medium containing 10% FBS, which is mixed with DMSO to obtain a final cryoprotectant containing 10% DMSO / 5% FBS. This formulation was used for cryopreservation of all cultured cells prior to generating clinical doses. Protocol D clinical doses were cryopreserved in a solution consisting of 2% DMSO (final) and a commercially available preparation (HESPAN, B. Braun Medical) of 6% hydroxyethyl starch (HES) in 0.9% saline.

[0449] B) Protocol C uses a commercially available cryoprotectant called CS10 (BioLife Solutions) for cryopreservation of all cells, including clinical doses.

[0450] In summary, there are significant differences between Protocol C, which was developed to obtain more optimal cultures and yields for clinical doses of canine and feline URC, and Protocol D. These differences include digestion times, culture medium antibiotics, composition of culture medium components (e.g., glutamine levels), and bioreactor technology used to grow cells to generate clinical doses. As shown in Table 17, it is clear that the Protocol C processing and culture approach allows more donor tissue to be processed to clinical doses compared to performance with the Protocol D approach.

[0451] Example 23. Administration of URC URC doses are provided as cryopreserved doses that require thawing at the clinic or as thawed doses that are ready to be administered to patients upon arrival at the clinic. If cryopreserved doses are provided to the clinic, the cryopreserved dose is shipped in an appropriate temperature-controlled container that maintains it at a temperature below -120°C. If thawed doses are provided to the clinic, the thawed dose is shipped in an appropriate temperature-controlled container that maintains a temperature of 1°C to 8°C. URC cryopreserved doses are stored by cryopreserving the URC in an appropriate cryoprotectant (e.g., CS10, BioLife Solutions) and packaged in a sterile, cryo-stable vial (e.g., CellSeal vial, Sexton Biotechnologies). URC thawed doses are packaged in a sterile syringe or similar sealed, sterile container with no headspace or voids. URC thawed doses are thawed prior to shipment and suspended in a compatible liquid such as PBS, lactated Ringer's solution, normal saline, or other liquid compatible with the maintenance of viable nucleated cells.

[0452] The URC cryopreserved dose is thawed by one of several means, including the use of dry heat (e.g., a heating pad) or a device designed to apply controlled dry heat (ZipThaw, FreMon Scientific) or a 37° C. water bath, or by leaving at room temperature until no ice is visible. The URC cryopreserved dose is removed from the cryovial and placed in a suitable container for administration to the patient, such as a syringe. The syringe can be pre-filled with an appropriate diluent, such as PBS, lactated Ringer's solution, normal saline, or other liquid compatible with the maintenance of viable nucleated cells, prior to loading the cryovial's URC. The URC can be administered to the patient undiluted or diluted to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x prior to administration to the patient. URC thawed doses are typically diluted to 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x before shipping to the clinic. URC can be administered via a variety of routes, including intravenous (IV), intraarterial (IA), intrathecal (IT), intraparenchymal (IP), intralesional, topical (skin wound), intradermal (ID), subcutaneous (SC), and intramuscular (IM) injection. Dedicated medical components, including syringes, needles, cannulated IV sets, extension sets, T-connector sets, and other components, may be utilized to administer URC via the mentioned routes. Administration of URC can be done manually or dispensed using a syringe pump.

[0453] The target pathology and patient condition will influence the method of administration of the URC, which may affect the number of injections, the time between injections, the use of a single route for injection or a mixed route set, and the number of URC injected. A URC dose will typically contain a minimum of 20 million cells and a maximum of 40 million cells, with a preferred number of cells per dose being 30 to 36 million cells.

[0454] Example 24: Outcome of a clinical dose of canine donor uterine tissue in atopic dermatitis The clinical dose was obtained from canine donor S-011. Uterine tissue from S-011 was processed as described in protocol B to obtain digesta for enzymatic digestion and culture. Cells were expanded in culture and cryopreserved at passage 4 in CS5 at 36 million cells / cryovial. After thawing and diluting with PBS, doses were administered by IV infusion to eligible canine patients with atopic dermatitis. Two clinical doses were infused with a 2-week dosing interval, after which each canine patient was monitored for clinical symptoms. Seven canine patients were evaluated with several clinical metrics, including Pruritus Visual Analog Score (PVAS, an index of the severity of pruritus (itch)), Canine Atopic Dermatitis Extent and Severity Index-4 (CADESI-4), and Canine Atopic Dermatitis Lesion Index (CADLI) before and at intervals after treatment. Available clinical data are shown in Table 21. [Table 21]

[0455] The clinical benefit of treating canine patients with confirmed atopic dermatitis is demonstrated by trends in clinical metrics, with the mean values ​​of the three metrics decreasing compared to pretreatment baseline values ​​for the seven treated canine patients. Reductions in clinical metrics suggest an improvement in the clinical condition of the patient. Five of the six patients demonstrated significant improvement in the three metrics evaluated from pretreatment to the D90 evaluation.

[0456] The PVAS is a validated scale for assessing the severity of pruritus in patients. The scale ranges from "healthy dog ​​- no itch problems" to "very severe itch / almost constant (itch needs to be physically controlled)." The same owner completes this assessment at each study visit, based on observations of itch levels observed at home.

[0457] The CADESI-4 is a validated assessment tool for assessing dog skin conditions. It focuses on specific areas of the dog, such as the front and back paws, flanks, and groin area, and measures the severity of erythema (redness), lichenification (thickening of the skin and excoriation (skin trauma)), and / or alopecia (hair loss). This assessment is performed by the same veterinarian at each study visit. The CADLI is a validated assessment tool for assessing dog skin conditions. The CADLI is similar to the CADESI-4 assessment tool and works in a similar manner, with only minor technical differences. The CADLI focuses on more general areas of the dog's skin, but also assesses the same severity criteria, including hyperpigmentation (skin pigmentation levels). This assessment is also performed by the same veterinarian at each study visit.

[0458] Example 25: Outcome of a clinical dose of canine donor uterine tissue in osteoarthritis The clinical dose was obtained from canine donor S-011. Uterine tissue from S-011 was processed as described in protocol B to obtain digesta for enzymatic digestion and culture. Cells were expanded in culture and cryopreserved at passage 4 in CS5 at 36 million cells / cryovial. After thawing and diluting with PBS, doses were administered by IV infusion to eligible canine patients with naturally occurring osteoarthritis. Two clinical doses were infused with a 2-week dosing interval, after which each canine patient was monitored for clinical symptoms. Six patients were evaluated at D30. Patient outcomes Canine Brief Pain Inventory (CBPI) and Client-Specific Outcome Measures (CSOM) were assessed by owners at each clinic visit along with lameness assessment by veterinarians. Pre-treatment and D30 data values ​​are shown in Table 22. [Table 22]

[0459] In 11 of 12 owner evaluations, the pet's condition at D30 was assessed as improved by the owner. This improvement was also shown in the mean CBPI and CSOM, with the mean D30 scores well below the mean pre-treatment scores for both CBPI and CSOM. The attending veterinarian determined that lameness improved in 4 of 6 treated patients, with the mean lameness score at D30 being below the mean pre-treatment lameness score. The early therapeutic effect shown in Table 22 was achieved by delivering two treatment doses by IV infusion, 2 weeks apart. The standard therapeutic approach for treating osteoarthritis in either human or veterinary patients is cell infusion via intra-articular (i.e., intracapsular) injection.

[0460] Example 26: Outcome of a clinical dose of feline donor uterine tissue in refractory feline chronic gingivostomatitis Cats diagnosed with feline chronic gingivostomatitis (FCGS) develop severe inflammation in the oral cavity, which affects the cat's appetite and water intake, resulting in a reduced quality of life. Treatment is limited to removing most or all of the affected cat's teeth. However, even after such drastic medical procedures, a significant number of cats (approximately 30%) continue to suffer from severe oral inflammation, and their quality of life continues to decline over time.

[0461] Clinical trials were initiated in enrolled cats with continued poor outcomes after tooth extraction. The doses used to treat FCGS patients were obtained from donor S-025 (processed according to protocol C). Each patient was treated twice with 36 million cells delivered intravenously over 30 minutes. Each cat was assessed with the Stomatitis Disease Activity Index (SDAI) before and periodically after treatment. This index consists of a semiquantitative scoring system performed by the attending veterinarian to assess disease severity (reflecting oral inflammation parameters) combined with owner assessment of parameters related to the patient's quality of life.

[0462] After the second dose was injected, three patients reached D14, and two had a slight decrease in SDAI scores at D14 compared to before treatment. It has been reported that improvement in cats with refractory FCGS requires several months due to resolution of the inflammatory state. However, patients with refractory FCGS tolerated the cell therapy without any adverse events and showed a slight decrease (improvement) in SDAI scores early by D14.

[0463] Example 27: Yield, viability and phenotypic evaluation of cultured cells using tissue explants Studies were performed using multiple unrelated canine uterine tissue donors to evaluate the results of cultures of tissue alone, cells alone, and tissue with cells during the initial culture interval after enzymatic digestion.

[0464] Tissue digestion conditions and cryopreservation

[0465] The uterus of each canine donor was dissected free from other tissues and minced into small pieces in a BSC. After mincing, the tissue was digested with collagenase and thermolysin for 60 min at 37°C with manual shaking every 10 min. In each case, the digested tissue and cells (T-PCF) were placed in cryovials and cryopreserved in a commercial cryoprotectant solution (BioLife Solutions, CryoStore CS10) containing 10% DMSO or in a solution of 20% DMSO in culture medium mixed 1:1 (v:v) with culture medium (containing 10% FBS).

[0466] Cultivation of T-PCFs

[0467] Each cryovial of T-PCF was retrieved from the LN2 vapor storage and thawed in a 37°C water bath until only small pieces of ice remained. The thawed cryovial processed for the combination of explanted tissue and cells (T-PCF) was immediately diluted in tissue culture medium (DMEM, high glucose, 10% FBS, 8ng / mL FGF-2 and 4mM glutamine), placed in a culture flask and incubated at 37°C in a 5% CO2 incubator (100% humidity). Another cryovial from the digestion of the same donor tissue was processed through a 40μm cell strainer and rinsed with culture medium to obtain the cells only (PCF) condition. The explanted tissue was retrieved by turning the cell strainer upside down and rinsing with culture medium to obtain the explanted tissue only (Tissue) condition. Both PCF and Tissue preparations were placed in a culture flask and incubated as described for the T-PCF condition.

[0468] PCF and Tissue Flasks were fed with fresh medium every 3 days until harvest. T-PCF flasks were fed with the explanted tissue on D3.

[0469] Flasks of all three conditions were incubated for 5 or 7 days. On the day of harvest, spent medium was removed from PCF and T-PCF flasks and Dulbecco's Phosphate Buffered Saline (DPBS) was added to rinse the flasks, followed by the addition of TrypLE™ (Gibco) to detach the cells. Harvested cells were washed with DPBS and counted on a NucleoCounter NC-200 (Chemometec, Denmark). Spent medium and explanted tissue pieces were removed from Tissue flasks and then handled as described for PCF and T-PCF flasks.

[0470] Immunophenotyping

[0471] Cells were analyzed with commercially available directly conjugated antibodies reacting with CD34-PE (Thermo Fisher, Clone 1H6), CD45-PE (Thermo Fisher, Clone YKIX716.13), CD90-APC (Thermo Fisher, Clone Thy-1), CD326-PE (Thermo Fisher, ...

Claims

1. 1. A primed heterogeneous cell composition comprising: Mesenchymal progenitor cell populations, and Contains a population of epithelial progenitor cells, The mesenchymal progenitor cells and the epithelial progenitor cells are co-cultured, said mesenchymal precursor cells and said epithelial precursor cells are obtained or derived from canine or feline uterine tissue; the ratio of said mesenchymal progenitor cells to said epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to 20%, or a ratio within a range defined by any two of the foregoing percentages; The primed heterogeneous cell composition, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are primed with IFN-gamma.

2. The composition of claim 1, further comprising fibroblast growth factor 2 (FGF-2).

3. The composition of claim 2, wherein the FGF-2 is recombinant human FGF-2.

4. The composition of claim 2 or 3, wherein the FGF-2 is present at a concentration of 8 ng / mL.

5. 10. The composition of any of the preceding claims, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

6. 2. The composition of any preceding claim, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals.

7. 2. The composition of any preceding claim, wherein the uterine tissue is obtained by oophorectomy.

8. 10. The composition of any of the preceding claims comprising at least about 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million mesenchymal precursor cells, or a number within a range defined by any two of the aforesaid numbers.

9. 10. The composition of any of the preceding claims, comprising at or about 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million epithelial progenitor cells, or a number within a range defined by any two of the aforesaid numbers.

10. 13. The composition of any preceding claim, further comprising additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, sugars, polysaccharides, or carbohydrates, or any combination thereof, including but not limited to trehalose, DMSO, or albumin.

11. 10. The composition of any preceding claim, further comprising a population of cells, each cell exhibiting markers of both mesenchymal and epithelial progenitor cells.

12. 10. The composition of any preceding claim, wherein the mesenchymal precursor cells and the epithelial precursor cells are obtained or derived from the same canine or feline uterine tissue.

13. 13. The composition of any of the preceding claims, further comprising a cryopreservation medium.

14. The cryopreservation medium may contain: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2-10% DMSO and 2-20% FCS in growth medium, or The composition of claim 13, comprising: (e) about 2-10% DMSO and about 2-20% FCS in the growth medium.

15. 1. A method for preparing a primed heterogeneous cell composition, comprising: contacting a single cell suspension comprising mesenchymal progenitor cells and epithelial progenitor cells with FGF-2; culturing the single cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals; said single cell suspension being obtained from or derived from canine or feline uterine tissue; at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the ratio of said mesenchymal progenitor cells to said epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to 20%, or a ratio within a range defined by any two of the aforesaid percentages; The preparation method, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are primed with IFN-gamma.

16. 16. The method of claim 15, wherein the single cell suspension is obtained or derived from uterine tissue of the same dog or cat.

17. 17. The method of claim 15 or 16, wherein the canine or feline uterine tissue is enzymatically dissociated to form the single cell suspension.

18. The method according to any one of claims 15 to 17, wherein the FGF-2 is recombinant human FGF-2.

19. The method of any one of claims 15 to 18, wherein the FGF-2 is at a concentration of 8 ng / mL.

20. The method of any one of claims 15 to 19, wherein the single cell suspension is cultured for at least 4 passages, days, or culture intervals.

21. 1. A method of treating, inhibiting or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis or wounds in a canine or feline subject in need thereof, comprising: providing at least one heterogeneous cell composition comprising a population of mesenchymal progenitor cells and a population of epithelial progenitor cells, wherein the mesenchymal progenitor cells and the epithelial progenitor cells are obtained or derived from canine or feline uterine tissue, the canine or feline uterine tissue being autologous or allogeneic to the canine or feline subject; administering to said canine or feline subject said at least one heterogeneous cell composition; The method of treating, suppressing, or ameliorating, wherein the heterogeneous cell composition is primed with IFN-gamma.

22. 22. The method of claim 21, wherein the ratio of said mesenchymal progenitor cells to said epithelial progenitor cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, or a ratio within a range defined by any two of the foregoing percentages.

23. 23. The method of any one of claims 15 to 22, wherein the at least one heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

24. 1. A primed heterogeneous cell composition comprising: Vimentin positive (V+) / cytokeratin negative (C-) cell population, and V+ / cytokeratin positive (C+) cell population, The V+ / C- cells and the V+ / C+ cells are co-cultured; said V+ / C- cells and said V+ / C+ cells are obtained or derived from dog or cat uterine tissue; the ratio of said V+ / C- cells to said V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, or a ratio within a range defined by any two of the foregoing percentages; The primed heterogeneous cell composition, wherein the V+ / C- cells and the V+ / C+ cells are primed with IFN-gamma.

25. 25. The composition of claim 24, further comprising fibroblast growth factor 2 (FGF-2).

26. The composition of claim 25, wherein the FGF-2 is recombinant human FGF-2.

27. The composition of claim 25 or 26, wherein the FGF-2 is at a concentration of 8 ng / mL.

28. 27. The composition of any one of claims 24 to 26, wherein the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

29. 29. The composition of any one of claims 24 to 28, wherein the V+ / C- cells and the V+ / C+ cells are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals.

30. The composition of any one of claims 24 to 29, wherein the uterine tissue is obtained by oophorectomy.

31. 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, 31. The composition of any one of claims 24-30, comprising about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C- cells, or any number of V+ / C- cells within a range defined by any two of the foregoing numbers.

32. 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, 32. The composition of any one of claims 24-31, comprising about 14 million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C+ cells, or any number of V+ / C+ cells within a range defined by any two of the foregoing numbers.

33. 33. The composition of any one of claims 24-32, further comprising additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, sugars, polysaccharides, or carbohydrates, or any combination thereof, including but not limited to trehalose, DMSO, or albumin.

34. The composition of any one of claims 24 to 33, wherein the V+ / C- cells and the V+ / C+ cells are obtained or derived from the same canine or feline uterine tissue.

35. The composition of any one of claims 24 to 34, further comprising a cryopreservation medium.

36. The cryopreservation medium may contain: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2-10% DMSO and 2-20% FCS in growth medium, or 36. The composition of claim 35, comprising: (e) about 2-10% DMSO and about 2-20% FCS in the growth medium.

37. 1. A method for preparing a primed heterogeneous cell composition, comprising: contacting a single cell suspension comprising V+ / C- cells and V+ / C+ cells with FGF-2; culturing the single cell suspension with FGF-2 for 3, 4, 5, or 6 passages, days, or culture intervals; said single cell suspension being obtained from or derived from canine or feline uterine tissue; at the end of 3, 4, 5, or 6 passages, days, or culture intervals, the ratio of said V+ / C- cells to said V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, or a ratio within a range defined by any two of the foregoing percentages; The preparation method, wherein the V+ / C- cells and the V+ / C+ cells are primed with IFN-gamma.

38. 38. The method of claim 37, wherein the single cell suspension is obtained or derived from uterine tissue of the same dog or cat.

39. 39. The method of claim 37 or 38, wherein the canine or feline uterine tissue is enzymatically dissociated to form the single cell suspension.

40. The method of any one of claims 37 to 39, wherein the FGF-2 is recombinant human FGF-2.

41. The method of any one of claims 37 to 40, wherein the FGF-2 is at a concentration of 8 ng / mL.

42. 42. The method of any one of claims 37 to 41, wherein the single cell suspension is cultured for at least 4 passages, days, or culture intervals.

43. 1. A method of treating, inhibiting or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis or wounds in a canine or feline subject in need thereof, comprising: providing at least one heterogeneous cell composition comprising a V+ / C- cell population and a V+ / C+ cell population, wherein the V+ / C- cells and the V+ / C+ cells are obtained or derived from canine or feline uterine tissue, the canine or feline uterine tissue being autologous or allogeneic to the canine or feline subject; administering to said canine or feline subject said at least one heterogeneous cell composition; The method of treating, suppressing, or ameliorating, wherein the heterogeneous cell composition is primed with IFN-gamma.

44. 44. The method of claim 43, wherein the ratio of the V+ / C- cells and the V+ / C+ cells is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, or about 80% to about 20%, or a ratio within a range defined by any two of the foregoing percentages.

45. 1. A method of treating, inhibiting or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis or wounds in a canine or feline subject in need thereof, comprising: Providing at least one heterogeneous cell composition according to any one of claims 1 to 14 or 24 to 36; administering to said canine or feline subject said at least one heterogeneous cell composition; The method of treating, suppressing, or ameliorating, wherein the heterogeneous cell composition is primed with IFN-gamma.

46. 46. ​​The method of any one of claims 37-45, wherein the at least one heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

47. 47. The method of any one of claims 37-46, wherein the at least one heterogeneous cell composition is administered after being thawed from cryopreservation and transferred into a delivery device or container, such as a syringe, containing an appropriate buffer, diluent or fluid, such as phosphate buffered saline or lactated Ringer's solution.

48. 37. A composition according to any one of claims 1 to 14 or 24 to 36 for use in the treatment of chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

49. A composition according to any one of claims 1 to 14 or 24 to 36 for use as a medicament.

50. 1. A heterogeneous cell composition comprising: (a) Vimentin positive (V+) / cytokeratin negative (C-) cell population; (b) a vimentin-negative (V-) / cytokeratin-positive (C+) cell population, and (c) a V+ / C+ cell population; The populations (a) to (c) are co-cultured; said populations (a)-(c) being obtained from or derived from canine or feline uterine tissue; the V+ / C+ cell population is found in a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages; The heterogeneous cell composition, wherein the V+ / C+ cell population is primed with IFN-gamma.

51. The V+ / C- cell population represents 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, or 71% of the total number of cells in the heterogeneous cell composition.

51. The heterogeneous cell composition of claim 50, wherein the heterogeneous cell composition is found in a percentage of 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, or any percentage within a range defined by any two of the foregoing percentages.

52. The V- / C+ cell population comprises 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38% or less of the total number of cells in the heterogeneous cell composition. 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60% or any percentage within a range defined by any two of the foregoing percentages.

53. 53. The heterogeneous cell composition of any one of claims 50-52, wherein the ratio of the V+ / C- cell population to the V- / C+ cell population is 20% to 80%, 40% to 60%, 50% to 50%, 60% to 40%, 80% to 20%, 90% to 10%, 99% to 1%, about 20% to about 80%, about 40% to about 60%, about 50% to about 50%, about 60% to about 40%, about 80% to about 20%, about 90% to about 10%, about 99% to about 1%, or a ratio within a range defined by any two of the aforesaid percentages.

54. The heterogeneous cell composition of any one of claims 50 to 53, further comprising FGF-2.

55. The heterogeneous cell composition of any one of claims 50 to 54, wherein said FGF-2 is recombinant human FGF-2.

56. 56. The heterogeneous cell composition of any one of claims 50 to 55, wherein the FGF-2 is at a concentration of at or about 8 ng / mL.

57. 57. The heterogeneous cell composition of any one of claims 50-56, wherein said populations (a)-(c) are co-cultured in at least one tissue culture vessel that has not been pre-treated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

58. 58. The heterogeneous cell composition of any one of claims 50-57, wherein the populations (a)-(c) are co-cultured in at least one tissue culture vessel for 3, 4, 5, or 6 passages, days, or culture intervals.

59. 59. The heterogeneous cell composition of any one of claims 50 to 58, wherein the uterine tissue is obtained by ovariectomy.

60. 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 60. The heterogeneous cell composition of any one of claims 50-59, comprising about one million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C- cells, or any number of V+ / C- cells within a range defined by any two of the aforesaid numbers.

61. 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 61. The heterogeneous cell composition of any one of claims 50-60, comprising about one million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V- / C+ cells, or any number of V- / C+ cells within a range defined by any two of the aforesaid numbers.

62. 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 11 million, 12 million, 13 million, 14 million, 15 million, 16 million, 17 million, 18 million, 19 million, 20 million, 30 million, 40 million, 50 million, 60 million, 70 million, 80 million, 90 million, or 100 million or about 5 million, about 6 million, about 7 million, about 8 million, about 9 million, about 10 million, about 11 million, about 12 million, about 13 million, about 14 62. The heterogeneous cell composition of any one of claims 50-61, comprising about one million, about 15 million, about 16 million, about 17 million, about 18 million, about 19 million, about 20 million, about 30 million, about 40 million, about 50 million, about 60 million, about 70 million, about 80 million, about 90 million, or about 100 million V+ / C+ cells, or any number of V+ / C+ cells within a range defined by any two of the aforesaid numbers.

63. The heterogeneous cell composition of any one of claims 50 to 62, wherein the heterogeneous cell composition is further defined by a cell population that is both CD44 and CD326 positive.

64. 64. The heterogeneous cell composition of claim 63, wherein the population of cells that are positive for both CD44 and CD326 is found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages.

65. 65. The heterogeneous cell composition of any one of claims 50-64, further comprising additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, sugars, polysaccharides, or carbohydrates, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin.

66. 66. The heterogeneous cell composition of any one of claims 50-65, wherein said populations (a)-(c) are obtained or derived from the same canine or feline uterine tissue.

67. 67. The heterogeneous cell composition of any one of claims 50 to 66, further comprising a cryopreservation medium.

68. The cryopreservation medium may contain: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2-10% DMSO and 2-20% FCS in growth medium, or 68. The heterogeneous cell composition of claim 67, comprising: (e) about 2-10% DMSO and about 2-20% FCS in the growth medium.

69. 1. A method for preparing a heterogeneous cell composition, comprising: Dissociating dog or cat uterine tissue into a single cell suspension; Culturing the single cell suspension for 3, 4, 5, or 6 passages, days, or culture intervals, preparing the heterogeneous cell composition from the cultured single cell suspension; The method of the invention, wherein at the end of the 3, 4, 5 or 6 passages, days or culture intervals, the heterogeneous cell composition comprises a cell population that is positive for both vimentin and cytokeratin-18.

70. 70. The method of claim 69, wherein the cell population that is positive for both vimentin and cytokeratin-18 is present at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages.

71. 71. The method of claim 69 or 70, wherein the dissociation step comprises enzymatic dissociation.

72. 72. The method of claim 71, wherein the enzymatic dissociation comprises contacting the canine or feline uterine tissue with trypsin, chymotrypsin, collagenase, papain, hyaluronidase, elastase, thermolysin, neutral protease, or any combination thereof.

73. 73. The method of any one of claims 69 to 72, wherein the single cell suspension is cultured with FGF-2.

74. 74. The method of claim 73, wherein said FGF-2 is recombinant human FGF-2.

75. 75. The method of claim 73 or 74, wherein the FGF-2 is at a concentration of 8 ng / mL or about 8 ng / mL.

76. 76. The method of any one of claims 69 to 75, wherein the single cell suspension is cultured for at least 4 passages, days, or culture intervals.

77. The method of any one of claims 69 to 76, wherein the heterogeneous cell composition is further defined by a cell population that is both CD44 and CD326 positive.

78. 78. The method of claim 77, wherein the population of cells that are positive for both CD44 and CD326 is found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages.

79. The method of any one of claims 69 to 78, wherein the heterogeneous cell composition is a heterogeneous cell composition according to any one of claims 50 to 68.

80. 1. A method of treating, inhibiting or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in a canine or feline subject in need thereof, comprising: administering to said canine or feline subject at least one heterogeneous cell composition; the at least one heterogeneous cell composition comprises a cell population that is positive for both vimentin and cytokeratin-18; The method of treating, suppressing, or ameliorating, wherein the heterogeneous cell composition is primed with IFN-gamma.

81. 81. The method of claim 80, wherein the cell population that is positive for both vimentin and cytokeratin-18 is present at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages.

82. 82. The method of claim 80 or 81, wherein the heterogeneous cell composition is further defined by a cell population that is both CD44 and CD326 positive.

83. 83. The method of claim 82, wherein the population of cells that are positive for both CD44 and CD326 is found at a percentage of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% of the total number of cells in the heterogeneous cell composition, or any percentage within a range defined by any two of the foregoing percentages.

84. 84. The method of any one of claims 80-83, wherein said heterogeneous cell composition is autologous or allogeneic to said canine or feline subject.

85. 85. The method of any one of claims 80 to 84, wherein said at least one heterogeneous cell composition is a heterogeneous cell composition of any one of claims 50 to 68 or is produced by a method of any one of claims 69 to 79.

86. 86. The method of any one of claims 80-85, wherein the at least one heterogeneous cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

87. 87. The method of any one of claims 80-86, wherein the at least one heterogeneous cell composition is administered after being thawed from cryopreservation and transferred into a delivery device or container, such as a syringe, containing an appropriate buffer, diluent or fluid, such as phosphate buffered saline or lactated Ringer's solution.

88. 88. The method of claim 87, wherein thawing the at least one heterogeneous cell composition from the frozen storage state comprises diluting the at least one heterogeneous cell composition by 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x.

89. 69. The heterogeneous cell composition of any one of claims 50 to 68 for use in treating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

90. 70. The heterogeneous cell composition of any one of claims 50 to 68 for use as a medicament for the treatment or inhibition of chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

91. A primed cell composition comprising canine or feline cells, preferably uterine cells, that are positive for both vimentin and cytokeratin-18.

92. The cell composition of claim 91, further comprising mesenchymal progenitor cells and / or epithelial progenitor cells.

93. The cell composition of claim 91 or 92, further comprising fibroblast growth factor 2 (FGF-2).

94. The cell composition of claim 93, wherein said FGF-2 is recombinant human FGF-2.

95. The cell composition of claim 93 or 94, wherein the FGF-2 is present at a concentration of 8 ng / mL.

96. 96. The cell composition of any one of claims 91-95, wherein the cell composition is cultured in at least one tissue culture vessel that has not been pretreated with a biological or synthetic coating agent that enhances cell attachment and / or cell proliferation, including, but not limited to, a cell-based feeder layer, a polymer, a protein, a polypeptide, a peptide, an antibody, a nucleic acid, DNA, RNA, a saccharide, a polysaccharide, a carbohydrate, a lipid, polylysine, polyornithine, collagen, gelatin, fibronectin, vitronectin, laminin, elastin, tenascin, heparan sulfate, entactin, nidogen, osteopontin, extracellular matrix, basement membrane, Matrigel, hydrogel, PEI, WGA, hyaluronic acid, or any combination thereof.

97. The cell composition of any one of claims 91 to 96, wherein the uterine tissue is obtained by oophorectomy.

98. 98. The cell composition of any one of claims 91-97, further comprising additives, supplements, antibiotics, vitamins, growth factors, cryoprotectants, buffers, salts, proteins, polypeptides, peptides, sugars, polysaccharides, or carbohydrates, or any combination thereof, including, but not limited to, trehalose, DMSO, or albumin.

99. The cell composition of any one of claims 91 to 98, further comprising a cryopreservation medium.

100. The cryopreservation medium may contain: (a) CryoStor CS5 and / or BioLife Solutions CS10; (b) 98% Hespan and 2% DMSO; (c) about 98% Hespan and about 2% DMSO; (d) 2-10% DMSO and 2-20% FCS in growth medium, or The cell composition of claim 99, comprising: (e) about 2-10% DMSO and about 2-20% FCS in the growth medium.

101. 1. A method of treating, inhibiting or ameliorating chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in a canine or feline subject in need thereof, comprising administering to said subject The method of treatment, suppression or amelioration comprising administering to said canine or feline subject a cell composition of any one of claims 91-100.

102. 102. The method of claim 101, wherein the cell composition is administered intravenously, intraarterially, subcutaneously, intramuscularly, intradermally, intrathecally, intraperitoneally, intraportally, intraarticularly, intraocularly or intrarenally, or any combination thereof.

103. The method of claim 101 or 102, wherein the cell composition is administered after being thawed from frozen storage and transferred to a delivery device or container, such as a syringe, containing an appropriate buffer, diluent or fluid, such as phosphate buffered saline or lactated Ringer's solution.

104. 104. The method of claim 103, wherein thawing the at least one heterogeneous cell composition from the frozen storage state comprises diluting the at least one heterogeneous cell composition by 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, or at least 1.5x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, or 10x.

105. The cell composition of any one of claims 91 to 100 for use in treating or inhibiting chronic kidney disease, atopic dermatitis, immune-mediated arthritis, hepatitis, liver disease, inflammatory bowel disease, osteoarthritis, intravertebral disease, keratoconjunctivitis sicca (dry eye), pancreatitis, fibrosis, sclerosis, amyloidosis, immune-mediated polyarthritis, chronic gingivostomatitis or wounds in dogs or cats.

106. A composition according to any one of claims 91 to 100 for use as a medicament.

Citation Information

Patent Citations

  • Human cervical stem cell population and uses thereof

    JP2016509834A